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Preface
The fifth book in the Ethical eye series focuses on biomedical
research, a field involving a number of fundamental rights. On
the one hand, there is the right to freedom of research, estab-
lished in the Convention on Human Rights and Biomedicine,
as well as in other international instruments and a number of
national constitutions. The freedom of science has helped to
produce and promises to produce great advances in knowl-
edge, which translate into practical applications in the field of
healthcare, for instance. 
On the other hand, there are the rights of individuals: protection
of their dignity, identity and integrity. The Council of Europe
has always emphasised the primacy of the interests and wel-
fare of the human being over the sole interest of science or
society. 
Thus, biomedical research is a sphere in which it is necessary to
find an equilibrium between these different rights. There cannot
be unrestrained freedom of research without regard to other
fundamental rights, just as one cannot ignore the interests of
society or science in our European culture based on solidarity.
Researchers, medical professionals, ethicists, philosophers,
lawyers and policy makers must undertake a multidisciplinary
dialogue in order to find this equilibrium. This dialogue takes
place in research settings, hearings, ethics committees, parlia-
ments and international fora, such as the Council of Europe. 
Science is, by its very nature, international and is not isolated
within the borders of any single state. Research projects are
often undertaken in a number of countries at the same time
and researchers regularly go abroad to undertake research.
This very mobility can give rise to ethical concerns. In any
case, modern communications speed news of discoveries to all
corners of the globe. It is therefore important that ethical rules are
identified, endorsed and applied by all the scientific community
and subject to public debate. International instruments and
fora contribute to reaching these goals.
The Council of Europe has adopted an Additional Protocol to the
Convention on Human Rights and Biomedicine on Biomedical
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Research. This protocol addresses both basic and clinical
research. Based on the Convention, it develops rules for the
protection of individuals, especially by giving guidance to the
research ethics committees. It also provides additional protec-
tion for those who are unable to consent and those who are in
a vulnerable position such as prisoners. As the Parliamentary
Assembly highlighted, the protocol also contains rules for
transnational research, to ensure that its principles also apply to
research projects undertaken by European firms or researchers
that will be carried out abroad.
Elaborating ethical and legal norms on research is just a first
step. The next one is to have those norms applied. For this pur-
pose, it is important that researchers and other stakeholders
take part in a constructive debate. The creation of a European
Bioethics Forum in Strasbourg would no doubt contribute to
obtaining a high quality debate. This project is being devel-
oped by the European Democracy Forum and supported by the
City of Strasbourg and the Council of Europe. It would create
an environment for dialogue open to the largest possible number
of actors and where ethical issues would be approached in a
multidisciplinary and pluralist way.
This edition in the Ethical eye series is another part of this dia-
logue, bringing together just such a multidisciplinary group of
authors from different countries in Europe to discuss different
approaches, issues, achievements and problems in this field of
science and human rights. 
The importance of biomedical research is clear, and it is to be
hoped that this book will contribute to both the support for
science and specifically for biomedical research in Europe and
to the protection of those persons who participate in research
projects.
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The Debra co-opera-
tion project, set up in
1997 ,  fos te r s  the
development of inde-
pendent and multidis-
ciplinary ethics com-
mittees for review of
biomedical research in
central and eastern
European countries.
Introduction
by Claude Huriet
The background
The Act of 20 December 1988 on the Protection of Human
Subjects of Biomedical Research, which was – if it need be
pointed out – the first piece of legislation on clinical research,
had scarcely been passed by the French Parliament when com-
plaints rang out in many quarters about lawmakers interfering
in areas they should keep out of.
The same prophets of doom predicted that the act would be a
severe blow to biomedical research in France, with the pro-
moters of clinical trials moving their activities to other coun-
tries to escape the constraints of the new legislation.
While the act was largely based on ethical principles that had
already been proclaimed, it was clear that these established
principles – set out forcefully in Article 1 of the 1947 Nurem-
berg Declaration, which described voluntary consent as being
absolutely essential, and in subsequent international declara-
tions, before being taken up in one of the first opinions issued
by the French National Advisory Committee on Ethics in 1984
– had not really been taken account of, unless, of course, peo-
ple had immediately realised that the discrepancy was the
result of the difference between ethical recommendations,
which do not involve obligations, and legislative provisions,
contravention of which is subject to penalties.
Fortunately, as reasoned optimism had suggested would hap-
pen, neighbouring countries soon recognised the risk of ques-
tionable or unacceptable biomedical research practices, of the
kind banned under the French legislation, developing within
their own borders. The Council of Europe responded very
speedily with Recommendation R(90)3 concerning medical
research on human beings, the fundamental principles of
which were clarified in the Convention on Human Rights and
Biomedicine (see chapter by Zilgalvis). I saw this for myself at a
meeting of the Debra1 co-operation programme in Vilnius.
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The speed of this response, even though it did not involve
binding texts and even though it took almost ten years for the
joint declarations to be finalised, clearly sent out a strong sig-
nal that discouraged the introduction of unethical practices in
a particularly sensitive area.
The fact that Council of Europe Publishing is now bringing out
a publication on human rights and biomedical research fits in
logically with the work first started fifteen years ago.
The book highlights the ethical challenges of research and
provides an overview of biomedical research in Europe, before
setting out the legal instruments of the Council of Europe,
whose contribution in this area has been considerable, as well
as those of other European institutions in the biomedical
research field.
Three key points emerge from the various chapters written by
different authors, of different nationalities:
• medical research on human beings is based on shared values;
• efforts need to be made to agree shared definitions or give
shared concepts identical meanings;
• although the publication is made up of European contributions,
many of the authors place their views in the broader context
of the globalisation of research.
Shared values
Any discussion of research on human beings draws on the
Nuremberg Code, which formed part of the judgment by the
international tribunal that tried and sentenced Nazi criminals
for the human experiments carried out in the concentration
camps.
The following preconditions apply to biomedical research:
• it is absolutely essential for the persons concerned to give
their voluntary consent after being properly informed about
the research;
• the experiments must yield fruitful results for the good of
society;
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• it is essential for certain scientific prerequisites to be met:
for the scientists involved to be properly qualified, for the
risk–benefit balance to be assessed and for all unnecessary
physical and mental suffering and injury to be avoided.
These fundamental values are set out in human rights texts (see
chapter by Solbakk) such as the United Nations International
Covenant on Civil and Political Rights (Article 7).
However, having set forth these principles, it has to be admitted
that it is not always easy to put them into practice. Obtaining
consent for participation in clinical trials is impossible in cer-
tain circumstances; for example, in certain serious situations
such as emergencies or even in cases of Alzheimer’s disease.
Even preserving medical confidentiality, a widely held deonto-
logical obligation can sometimes, in the field of research, be at
odds with methodological rigour and public health issues. A
clear case in point is the contradictory situation in the case of
cancer registers (see chapter by Harpwood and Coleman).
Thus it has to be recognised that despite repeated assertions
that the patient’s interests are of paramount importance above
and beyond those of science and society, sometimes the benefit
to the greatest number wins the day. In such situations ethical
considerations are all the more necessary and nuanced, and
the term “ethical tensions” all the more apposite.
Apart from the possible pitfalls of the inappropriate translation
of abstract concepts, the mere use of the same terms does not
mean that the thinking or the content concerned are identical.
This is illustrated by two examples: ethics and ethics committees.
Shared definitions
Focusing an ethical eye on biomedical research is inconceivable
without first defining “ethics”. This is all the more essential
since there is a whole range of definitions, a fact which is a
source of confusion and, in some cases, of contradictions.
Confusion between the deontology and ethics of research may
be surprising. Even so, before considering individuality ethics or
collectivity ethics (see chapter by Riis) or making a distinction
13
Introduction
14
between the ethics of clinical research and the ethics of clinical
care (see chapter by Górski), I would suggest that we need
agreement on the following characteristics of ethics in the
biomedical field.
It is an evolving process that does not claim to be universal.
Being pluralist in essence, it aims to achieve an acceptable bal-
ance at both individual and collective levels between the pro-
tection of individual dignity and freedom and the expectations
of society.
The non-universal nature of ethics stems from the fact that,
although ethical perspectives are based on universal values of
a spiritual, religious and/or metaphysical character, they also
take account of historical and cultural references, and even the
economic environment.
While the principle of prior consent to any biomedical research
is generally accepted, the conditions for obtaining it, which
ethics is supposed to govern, are variable. This was brought
home to me by a visit to Mali where I had gone to talk about
the ethics of research. “Consent” there is given by the village
headman, who receives the compensation granted for the con-
straints the research imposes on the village population. This
practice is regarded as “unethical” in our part of the world …
and yet !
In central and eastern Europe (see chapter by Gefenas), partici-
pation in clinical trials can enable the individuals concerned to
receive treatment to which they would not otherwise have
access.
Another way of obtaining consent is illustrated by the national
genome project in Estonia, with reference to unconditional
overall consent rightly being regarded as unethical.
The questioning that characterises the ethics process and the
non-universality of ethics should be seen alongside the very
object and purpose of the process. After all, ethics bodies draw
up recommendations – not rules or laws. They issue opinions
but do not produce whole sets of rules that apply to everyone
and involve penalties if they are broken. From this point of
view, I fear that the references sometimes made to “non-binding
rules” may be a source of confusion.
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In their diversity, ethics committees, whether public entities or
private-law bodies (see chapter by Taupitz), also reflect the
non-universal nature of ethics. Apart from the fact that,
although they vary in composition, there are no countries
where they are democratically elected (for which they are
sometimes criticised), some are purely advisory, while others
do have decision-making powers (see chapter by Gallacher and
Sreeharan). Reference may be made here to the study conducted
by the Lithuanian bioethics committee (see chapter by Gefenas)
on obtaining informed consent.
The discussions about the use of placebos* clearly demonstrate
the wide range of opinions and arguments based on an ethical
approach and how the public can actually be involved, provided
a little effort is made.
One cannot but agree with the interpretation that giving up
placebo-controlled clinical trials* is just as unethical as using
them inappropriately, which Jean Bernard summed up in the
phrase “everything that is unscientific is unethical”.
In contrast, we are bound to be surprised by the National
Placebo Initiative organised in Canada (see chapter by Górski),
which, to my knowledge, is the first attempt to involve the
public in ethical choices.
The wide range of situations, the great differences in cultural
and economic environments, the large number of texts of vary-
ing legal force and the difficulties that can arise in imposing
penalties on researchers who violate human rights in the name
of medical research (inappropriate research, inappropriate data
acquisition or usage, inappropriate incentives, and so on ; see
Gallacher and Sreeharan), have led to calls in some quarters for
the establishment of an international tribunal based on an
international forum that could help harmonise practices and
prompt measures for overcoming the terrible inequality that
affects poorer nations (see chapter by Solbakk).
Globalisation of research
Although this is a European publication, the globalisation of
research is mentioned in various chapters.
15
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Placebo:
an inactive pill, liq-
uid, or powder that
has no treatment
value. In clinical tri-
als ,  experimental
treatments are often
compared wi th
placebos to assess
the  t reatment ’ s
effectiveness.
Placebo-controlled
clinical trials:
a method of investi-
gation of drugs in
which an inactive
substance  ( the
placebo) is given to
one group of partici-
pants ,  whi le  the
drug being tested is
g iven to  another
group. The results
obtained in the two
groups  are  then
compared to see if
the investigational
treatment is more
effective in treating
the condition.
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Reference to the “globalisation of research” actually involves two
separate trends (see chapter by Riis): increasingly frequent,
international multi-centre studies to recruit more easily and in
short periods cohorts for the clinical study of rare diseases,
among other examples, and co-operation between developed
and developing countries.
For people in developing countries, there is a significant risk of
developed countries “exporting ethical problems and importing
research findings”. The terrible global inequality (see chapter by
Solbakk) is illustrated by the following statistics. In 1996, 90%
of the US$56 billion spent on medical research concerned the
needs of the richest 10% of the population and the illnesses that
affect them.
Apart from respect for the particular cultural, religious, eco-
nomic and sociological features of developing countries, special
attention must be paid to such questions as to the way
informed consent is obtained among illiterate populations, the
determination of control groups, the reference treatments or
placebos, the diseases studied (malaria, tuberculosis, parasitic
diseases and Aids, among others) and the continuation of the
treatments after the completion of the trials.
The complexity of these situations – and the overriding need to
reverse or prevent the implementation of ethically unaccept-
able practices – led the Council of Europe to supplement the
Convention on Human Rights and Biomedicine, adopted on 19
November 1996, with an additional protocol on biomedical
research. Research conducted outside the member states is
covered in Article 29. Under its provisions, researchers may not
act “as they see fit” in countries where standards for the pro-
tection of human beings in the research field are low or non-
existent (see chapter by Zilgalvis).
A phrase that preface writers and literary critics are wont to use
– and overuse – is that a work is very timely. That certainly is
true of this book by Council of Europe Publishing, made up of
contributions from recognised experts.
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In spite of its noble aims, biomedical research, which is a
source of progress in understanding the human being and
improving individual and public health, must not be allowed
to develop without any account being taken of ethical consid-
erations or legal rules, as if “the end justified the means”.
Such noble aims must also not be pursued for the sole benefit of
only a part of the world’s population. Biomedical research must
involve a socially committed approach based on respect for
human rights, to which the Council of Europe is contributing
through this publication, as that is its raison d’être.
17
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History and definitions
by Povl Riis
The history of human rights and ethics relating to research on
human beings is fairly long, but limited in scope, if we take into
account only research based on evidence and not prejudices
and religious beliefs.
Well-known figures such as Ambroise Paré (1510-90), who
ended the treatment of gunshot wounds with boiling oil,
replacing it with the use of ointment, James Lind (1716-94),
who described the effect of lemon juice in the prevention of
scurvy, Johannes Fibiger (1867-1928), who made a systematic
comparison of serum treatment of diphtheria and treatment
without serum, and Austin Bradford Hill (1898-1991), who was
in charge of the controlled trial demonstrating the effect of
streptomycin on pulmonary tuberculosis, to mention just a few
forerunners of modern scientific methodology, were primarily
inspired by the need to discover the truth about the potential
effects of known or new biomedical practices, an additional
motivation being to help the soldiers, sailors, children and
tuberculosis patients concerned.
However, despite any optimism that may prevail concerning
human and societal developments, it is the transgression of
ethical boundaries that has been the key incentive for devising
and applying ethical concepts and standards relating to bio-
medical research, codes of good practice in this field and con-
trol systems based on the establishment of research ethics
committees.
In other words, the development of high ethical standards has
historically been less a progression phenomenon, bound up
with greater prosperity and general political progress, but more
a transgression phenomenon, as a reaction to severe disregard
for fundamental human rights. As a consequence of the shift
from transgression to progression, the primary focus today is
the key figure of biomedical research ethics, the patient or the
healthy volunteer, whose safety and right to respect and
autonomy must be guaranteed.
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The need for definitions
Ethics as a term in itself – that is, unrelated to research – has a
much longer history than research ethics. “Biomedical
research ethics” is accordingly a new expression, which has
been part of scientific terminology for only the last four to five
decades. As a recent addition to scientific language, this
expression has caused much conceptual confusion and a cor-
respondingly strong need to define the term or, at least for its
users, to clarify the meaning they attach to it. In order to
reduce the scope for confusion, the key terms of research
ethics are defined below.
To leave etymology behind and focus instead on semantics,
ethics – in the sense I accept for it – can be defined as follows:
An overall term for the immaterial values, norms and attitudes
prevalent in a country or culture, which underlie that coun-
try’s or culture’s concept of humankind and the laws and
codes based thereon and shape citizens’ personal existence
and relations with each other and with the legal and private
institutions of society. From a global perspective, ethics also
includes responsibility for the ecological balance of planet
Earth, its soil, water and air and its biological diversity.
After the Second World War and the large-scale serious violations
of human rights, even in research, perpetrated in the concen-
tration camps, prisons and ghettos, the main focus of ethical
codes and supervisory measures was the human being as an
individual, with strong emphasis on rights. I call this part of
ethics “individuality ethics”. It is still a fundamental, inescapable
part of ethics. 
However, it often overshadows our important responsibility
for our fellow human beings, sometimes known as distribu-
tional ethics, but which I call “collectivity ethics”, to use a less
technical term. Even if the starting point for codes and for
research ethics committees is the safety of and respect for indi-
vidual trial participants, they also need to consider the societal
aspects of solidarity and altruism, where these are based on
genuine informed consent. There could be no scientific
progress if the population of Europe did not have a latent sense
of collectivity ethics, not only among healthy volunteers but
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also among participants in randomised drug trials,* in phase-
one and phase-two drug trials, in epidemiological projects, in
genetic family studies and in many other research areas. 
The ethics of research, as an overall term for all ethical aspects
of biomedical science, has until recently been taken to mean
research ethics concerned with the safety of and respect for
research subjects. Research ethics is, however, a toto pro parte
term (an overall term applied to a part), which from a linguistic
standpoint excludes another important branch of the ethics of
research: researchers’ ethics, that is, good-practice standards
concerning the reliability of harvested variables, interpretation
of data, trustworthiness of publications and respect for other
scientists’ intellectual property.
This second part of the ethics of research will not be discussed
at length here, although ethical good conduct and reliability
are conditions for obtaining genuine informed consent. In
Europe, experience has shown that codes and supervisory
agencies with fraud-prevention aims are best established inde-
pendently of those dealing with research ethics, yet with some
sort of co-ordinating link between the two, and this argues
against discussing that branch of ethics here.
Biomedicine comprises all the disciplines related to the health
services and their educational institutions. As we will see later,
the ethics of biomedicine also covers projects carried out by
non-health professionals, if they obtain access to patients and
make their diagnoses via the health system, its case records
and other data.
The term “intervention” is used here to mean any planned
measurable influence on a person’s mind or body. It comprises
interviews, cognitive tests, diagnostic tests, surgery, drug ther-
apy, preventive arrangements, information about serious life
conditions and events, and so on. Use of the term “intervention”
makes it possible to avoid the usual excessive reliance on the
narrower term “therapy”.
Research subjects can be healthy volunteers, participating
patients or, in some countries, fertilised human eggs, foetuses
and even deceased persons.
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Randomised
drug trials:
these consist of a
study in which par-
t icipants are ran-
domly  ( i . e . ,  by
chance) assigned to
one of two or more
treatment arms of a
clinical trial. Occa-
sionally placebos
are used.
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The term “human rights” in a contemporary context, as used here,
refers to the international (including European) declarations,
directives, conventions and similar codes.
Ethical codes, apart from those mentioned above, include a
large number of United Nations declarations and professional
bodies’ declarations, guidelines and the like, in addition to
national law on research ethics. There are now a very large
number of codes worldwide, which can sometimes be confusing
for biomedical scientists, as some of these codes even contra-
dict each other. The final section of this chapter suggests a
hierarchical order for these many codes.
Ethical committees, in the accepted sense used here, mean eth-
ical research committees dealing with biomedical research
involving human beings, excluding such committees’ advisory
functions not related to research, for instance giving advice on
therapeutic dilemmas.
The scope of biomedical research
During the last three to four decades the scope of biomedical
research has widened considerably, with a proportional broad-
ening of the ways in which research ethics must be applied.
Even if the starting point for any research ethics approach is
the individual patient in a clinical setting, the scope is very
extensive.
It ranges from molecular biological studies of pathogenesis,*
to clinical and genetic studies and to epidemiological projects,
covering individual nations (regions) or more than one country.
Research ethics form part of the ethical aspects of a project not
only where live patients participate in a project, but also where
the source of variables is biological material from former
patients. The same may apply where the intention is to use
existing confidential data or new personal information of a
sensitive nature, to be obtained via questionnaires.
The globalisation of biomedical research
During the last two to three decades, not only has the scope of
biomedical research been extended as a result of the ever-broader
spectrum of methods and methodologies, but the universe of
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Pathogenesis:
the manner of devel-
opment of a disease.
scientists of many types – disciplinary globalisation – and the
number of nations collaborating in research and implementing
the results – geographical globalisation – have also grown con-
siderably. This development has brought about a corresponding
increase in demand for ethical codes and supervisory committees,
whereas even significant post-Second World War codes
remained centred on the medical practitioner, a clinician, and
his or her patient.
Today, many disciplines are grouped together in a growing
number of multidisciplinary teams : pharmacists, dentists,
nurses, biochemists, biological geneticists, midwives, social
workers, sociologists, psychologists and others, in addition to
physicians. If all such disciplines devise their own professional
codes (and some have shown signs of doing so), valuable multi-
disciplinary projects will be jeopardised by delays and sheer
bureaucracy. Conversely, multidisciplinary research will gain
from the emergence of national and European common codes,
and, at the same time, the fundamental human rights behind
each discipline’s ethics will remain unchanged.
Geographical globalisation covers both international multi-
centre studies and developed countries’ cooperation with
developing countries. International multi-centre studies,
implemented by equal partners, are necessary to identify quite
small but significant therapeutic benefits in the treatment of
common diseases, such as cardiovascular diseases, because the
groups compared have to be very large. Similar international
co-operation is also necessary for clinical study of rare genetic
diseases.
The second type of geographical globalisation, co-operation
between developing and developed countries, raises special
research ethics issues, which existing codes until recently
failed to address. Projects of this kind will in future have to
afford the populations of developing countries better protection
against exploitation – in the form of the “export of ethical
problems and import of results” – in connection with interven-
tions important to the developed countries. There is an obvious
need to involve anthropological advisers in the planning phase,
in order to respect and take into account national religious,
cultural and political norms (while naturally ensuring full
respect for fundamental human rights).
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Other major research ethics problems, not answered by the
“Just do as we do” attitude of affluent research partners,
include:
• obtaining genuine informed consent in illiterate groups
and/or those with a gender imbalance; 
• the interventions offered to control groups, whether a
placebo or an alternative, hitherto-used intervention, in
order to comply with the ideal, but unrealistic, rule that control
groups must receive the best intervention known worldwide,
irrespective of cost and local accessibility; 
• what to do when the research is finished, as a fixed item on
the agenda of planning meetings; 
• competence building and co-authorship for participating
professionals from the developing country, instead of “the
flying scientist” from the developed country gathering the
necessary results and then leaving on the first outward-
bound plane, making away with the loot for his or her own
benefit; 
• and, probably the most important ethical rule, to ensure that
both developing and developed countries’ ethical commit-
tees have approved the project with a mutual right of veto.1
Following the preparatory work done by the Nuffield Founda-
tion,2 it is to be hoped that a European protocol governing this
area of research ethics will be drawn up in future.
Research ethics committees
Some countries, including the new European democracies,
have still not established research ethics committees with
structures and functions that facilitate inter-European and
more wide-ranging international cooperation. The positive side
of this is that they can make the most of their thirty to forty
years’ experience with existing committee systems, but the
downside is that these existing committees constitute an
obstacle to the implementation of valuable inter-European
projects.
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Countries wishing to establish a committee system or to revise
an existing system have to answer a number of key questions
before deciding on the structure to be adopted.
Do they want a semi-official system or a law-based system? If
policy makers consider a law-based system acceptable, it will
probably facilitate international co-operation. Moreover, this
implicitly answers the next question: Should there be a nation-
wide system of regional committees or a network of mutually
independent institutional committees ? The latter solution may
appear to be the easiest but will, at the same time, also prove
the least satisfactory, according to the well-known adage that
what is next to best is the best’s worst enemy. Will the system
be single- or two-tiered (either a number of committees with
authority to take final decisions or a system of regional com-
mittees with a central committee whose role consists in hearing
appeals, co-ordinating matters and advising the government,
parliament, ministries and so on)?
Given the importance of geographical globalisation, the next
question is : Will our national system be geared to deal not
only with national projects but also with co-operative projects
with other developing countries?
Probably the most challenging question is: Will lay persons sit
on the committees and, if so, how many? And how will such
members be elected? One possibility is for lay members to be
elected/nominated through a representative democratic
process, and for scientific members to be chosen under a similar
procedure within scientific fora (academies, scientific societies,
research councils). 
How will the costs be met? In a two-tiered system, will local
committees be financed via the regional authorities, and the
central committee via the relevant ministries (health, research
and/or education)? And will members be salaried? Will appli-
cants have to pay a fee? 
Research ethics committees should in any case be established
in accordance with the requirements and conditions set forth
in the Council of Europe’s Convention on Human Rights and
Biomedicine and its explanatory report, the protocols thereto
and their explanatory reports, and the EU directives.
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Research ethics and its anchoring in society
One important aspect of research ethics committees’ work is the
contribution they make to public understanding of the need
for biomedical research and of the fact that participation by
patients and healthy volunteers is inevitable, if the population
at large and specific patient groups are to benefit.
Terms such as evidence-based medicine, trials, randomisation,*
blinding,* placebo, bias and many others are foreign to many –
even well-educated – citizens and, because the media usually
fail to bridge this language gap, it is necessary for chairs and
members of committees to reach out to the public via the spo-
ken or printed word. It takes time to counter the popular myth,
sometimes sustained by the media, that doctors do research
only because it will advance their careers (which is part of the
reason, but certainly not the full explanation). This can be
achieved by explaining how personal impressions or unsys-
tematic experience have sometimes resulted in prolonged use
of ineffective or even dangerous interventions. In other words,
research based on good scientific methodology, evaluated by
independent research ethics committees, must be considered a
public benefit. From the globalisation standpoint, it allows
individual countries to contribute to human well-being, while
at the same time reaping considerable benefits from other
countries’ research. The examples of this global exchange are
legion, but its benefits have yet to be demonstrated to the public.
The diversity of codes and Europe’s role
Since the Second World War the number of international and
national codes of research ethics has grown tremendously,
reflecting a virtual explosion of interest in and commitment to
ethics, and the sub-group of research ethics. Many of these
codes are intended to raise scientists’ and scientific societies’
awareness of the issues at stake and to provide them with
guidelines. On the one hand, this is a positive phenomenon
but, on the other hand, it sends a confusing cacophony of sig-
nals to planning and project researchers. Even in the case of
monocentre, national projects it can be confusing if national,
regional or international codes fail to adopt the same viewpoints
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or to set the same ethical standards, but this more frequently
poses a dilemma where biomedical research is based on inter-
European or more wide-ranging international multicentre
studies, not to mention interdisciplinary projects, which are
often combined with international studies.
It is accordingly appropriate and necessary for scientists to be
familiar with the multitude of codes, but also to be able to rank
them by order of importance and binding authority. A brief
hierarchical ranking, based on a number of principles, is set out
below as guidance for European biomedical scientists. The aim
is also to encourage European scientific societies and policy
agencies to extend European initiatives towards the adoption
of additional codes, in the form of conventions and directives,
so that Europe speaks with a single voice in global debate and
decision-making on research ethics.
Historically, the World Medical Association’s Declaration of
Helsinki (see Appendix III) strongly influenced post-Second
World War interest in and respect for biomedical research ethics.
The latest (fifth) version unfortunately fails to take account of
the huge expansion of the research sector’s scope, its changing
methodologies and its disciplinary and geographical globalisa-
tion (see the references at the end of this chapter). This applies
in particular to the paragraphs dealing with what should happen
when research is over and the considerations to be borne in
mind when deciding the interventions for a randomised control
group. Making it an ethical standard that in a controlled trial
the best intervention known must be offered to the control
group, irrespective of costs and national accessibility – and
imposing a similar idealistic, but sometimes unrealistic, condi-
tion for treating all participants once the research is over – can
have the paradoxical effect, despite good intentions, of blocking
much needed co-operative biomedical research in the poorest
developing countries. Despite these shortcomings, the declaration
is still an inspiring document, although it has now been over-
taken by, for instance, the European Convention on Human
Rights and Biomedicine and its protocols and the EU directives. 
On the international and global scene, the UN codes are also
important for European researchers. Unesco’s Universal Decla-
ration on the Human Genome and Human Rights deals with
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genetic research, as the title suggests, and cannot but have a
strong advisory influence on European scientists (see the bibli-
ography at the end of this chapter).
The same can be said of WHO’s work on research ethics, espe-
cially that done by the Council of International Organizations
of Medical Sciences (CIOMS), which recently published its
Guidelines for Biomedical Research involving Human Subjects.
An example of a special code is UNAIDS’ “Ethical considerations
in HIV preventive vaccine research”.
The United States, through the National Institute for Health,
has issued Guidelines for the Conduct of Research Involving
Human Subjects at the NIH, which are applicable to both US
research and other countries’ research sponsored by the USA.
As mentioned earlier, the most important code outside the
United States, dealing with biomedical research in developing
countries supported or performed by developed countries, is
the book issued by the Nuffield Council of Bioethics Working
Party,1 which exerts a strong influence on European biomedical
scientists.
In Europe the most influential initiatives in the area of research
ethics have been taken by the EU, with the directives on data
protection and drug research, and by the Council of Europe
through its above mentioned bioethics convention and addi-
tional protocols with their corresponding explanatory reports. 
For European biomedical scientists, the following approach to
ranking the many codes of research ethics can be advocated :
• Be familiar with your national legislation, if any, on biomed-
ical research ethics. If your country has ratified the Council
of Europe instruments and/or is an EU member state, the
codes and directives issued by these two organisations will
be consistent with your national legislation.
• If your country has not ratified the Council of Europe con-
vention and related protocols (although it may be on the way
to doing so), read the codes and follow the principles set out
therein.
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• Know the United Nations codes and guidelines and use them
as advisory documents.
• Be familiar with the professional guidelines and declarations,
such as the Declaration of Helsinki and let them guide you,
but at the same time be aware of their shortcomings and
inconsistencies with national law and with the European
conventions and directives. 
• When planning co-operative projects with developing coun-
tries, refer to the Nuffield Council of Bioethics Working
Party’s publications for guidance and advice.
From a global perspective, Europe has much to offer the world
in the field of biomedical research ethics. Its cultural potential
and its diversity of old and new democracies constitute an
inspiring complexity, which can provide non-European coun-
tries with a range of values and democratic solutions that may
be transposable to other countries wishing to create their own
control systems, while ensuring respect for fundamental
human rights as implemented in Europe, maintaining a balance
between diversity and unity.
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Ethical dilemmas
in research

Uses and abuses
of biomedical research
by Jan Helge Solbakk
What are the norms and values underlying and guiding bio-
medical research? What is their nature? From where do they
originate? To what extent can biomedical research be of help
in protecting and promoting basic human rights? In what ways
may biomedical research inadvertently violate humans or
abuse human rights (Boyd et al. 1997)? These are some of the
questions that will be addressed in the present chapter.
There are several possible ways of dealing with these ques-
tions. One way would be to focus attention on different forms
of abusive biomedical research that have actually taken place
throughout history and try to understand in what ways these
dark events have influenced the shaping of ethical codes of
medical research, in particular the emergence of human rights
concepts and language relating to them. A prominent example
of such a study is The Nazi doctors and the Nuremberg Code:
human rights in human experimentation (Annas and Grodin
1992a).1
An alternative path would be to start with a definition of the
purpose of biomedical research and try to identify situations
where the attempt at achieving the legitimate aims of biomed-
ical research could lead to abusive research and violation of
human rights. The fruitfulness of this approach is evidenced in
a report on medicine and human rights published by the British
Medical Association (BMA 2001). According to the authors of
this report, biomedical research is driven by two aims or
desires (BMA 2001):
• scientific curiosity;
• the desire “... to benefit society by the systematic acquisition
of useful, empirical knowledge”.
“Research”, the report continues, “is driven by a desire to
understand the causes of disease or dysfunction and find effec-
tive methods of prevention and treatment. In extreme cases,
however, even such humanitarian aims can be risky. The very
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potential for achieving tangible benefits can feed the tempta-
tion to press on beyond acceptable boundaries”. In the report
nine risk-factors for abusive research are identified (BMA
2001).
Factors that might lead to abusive research and violation of
human rights :
• the power and influence of the researcher ;
• the dependent situation of populations chosen as research
subjects ; 
• the perception of a national necessity or government pressure
to conduct research ;
• the perception of an urgent and overriding scientific need ; 
• extreme detachment and lack of any sense of sympathy
with the fate of research subjects ;
• the perception that some people are expendable or already
“terminal”;
• the perception that some populations should be excluded
from social concern ; and
• secrecy.
We shall return to the issue of abusive biomedical research
later in the chapter, but first it is necessary to get a clearer pic-
ture of the system of norms and values underlying and actu-
ally guiding biomedical research as well as a view of how this
normative system relates to the framework of values witnessed
in human rights documents.
The normative system of biomedical research
From a science-ethics point of view, medical research – as a
representative form of scientific inquiry – may be defined as a
systematic and socially organised :
1. search for;
2. acquisition of;
3. use or application of medical knowledge and insight
brought forth by acts and activities involved in 1. and 2.1
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This action-theoretical conception of medical research pictures
biomedical research as a “normative system”, that is, as a finite
and ordered set of norms and values for groups of people
doing medical research. Furthermore, it broadens the scope to
include not only the product and/or purpose of scientific
inquiry but also the acts and activities – in sum the processes
– that generate medical knowledge. Finally, it advocates a dis-
tinction between three different phases of scientific medical
inquiry, the phases of :
• planning and search;
• acquisition;
• communication and use.
Before turning to an analysis of the different phases of scientific
medical inquiry and of the possible forms of abuse and human
rights violations that may emerge, a closer look at relevant
core values in human rights documents seems justified.
Relevant core values in human rights documents
The first formulation of “an individual’s right to health” within the
framework of an “international human rights document” dates
back to 1946 and the preamble to the constitution of the World
Health Organization (BMA 2001). In subsequent human rights
documents, this right to health is reiterated in various ways.
For example, in Article 12 of the United Nations International
Covenant on Social, Economic and Cultural Rights it is stated that
“the enjoyment of the highest attainable standard of physical
and mental health” is a right ascribed to everyone. 
Furthermore, in Article 2 of the same covenant it is required of
each state to take steps “to the maximum of its available
resources, with a view to achieving progressively the full reali-
sation of the rights” and Article 11 of the Council of Europe’s
Social Charter requires the parties to take measures to ensure the
effective exercise of the right to protection of health, while in
Article 3 of the Convention on Human Rights and Biomedicine
of the Council of Europe, the parties’ duty to provide within
their own jurisdiction “equitable access to health care of appro-
priate quality” is underlined.
Another relevant article, and notably with explicit reference to
biomedical research, is found in the second covenant generated
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from the Universal Declaration of Human Rights, that is, in the
International Covenant on Civil and Political Rights. In Article 7
of this covenant, the core principle laid down in the Nuremberg
Code – the principle of consent – figures prominently:
No one shall be subjected to torture or to cruel, inhuman or
degrading treatment or punishment. In particular, no one shall
be subjected without his free consent to medical or scientific
experimentation.
Among the many questions that are the subjects of extensive
treatment and debate in the human rights literature, two seem
to be of particular relevance within the present context of bio-
medical research. First of all, the question of whether some
human rights matter more than others. For example, should
social and economic rights take priority over civil and political
rights ? And what about the right to development, which has
been suggested as a third generation of human rights, besides
the first generation rights of non-interference or “negative free-
dom” laid down in the UN Covenant on Civil and Political
Rights and the second generation of “positive liberty” wit-
nessed in the International Covenant on Social, Economic and
Cultural Rights ? (BMA 2001). 
The prudent stand advocated in the BMA report is that these
rights should not be treated hierarchically, but according to
their manifestation in the fabric of life, as rights which are
interdependent and intertwined. The importance with respect
to biomedical research of viewing the different categories of
human rights as extensively interconnected will become evi-
dent in subsequent paragraphs. 
The second question that deserves attention within the present
context is whether there is a need to establish an international
tribunal to deal with researchers who have committed human
rights violations in the name of biomedical research. According
to the advocates of this proposal, international ethical codes
and guidelines are necessary but not sufficient to deal with the
problem of abusive research, because ethical guidelines lack
the “... authority to judge and punish violators of international
norms of human experimentation” (Annas and Grodin 1992b).
We shall return to this question at the end of the chapter.
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Norms and values underlying and guiding biomedical
research
The search phase of biomedical research consists of two different
kinds of systematic and socially organised searches for truth,
each guided by different norms and values. First, there is the
search in the science policy sense of the word. Second, there is
the search in the sense of the design of individual research
projects. While the latter kind of search “can only be organised
and implemented by qualified researchers” (Tranøy 1996)
under the guidance of the internal norms of science (Tranøy,
1988a)1 the policy kind of search takes place under the guid-
ance of external welfare norms and values such as utility,
beneficence and equity, and linkage norms between the profes-
sional community of researchers and the community at large,
such as fruitfulness and relevance. Consequently, this kind of
search represents a shared responsibility between researchers
and political decision-makers (Tranøy 1988b).
Also in the second and third phases of medical research – in the
phases of acquisition and of communication and use of find-
ings – the system of internal or methodological norms plays a
paramount role. However, for obvious humanitarian reasons
these methodological norms and values do not provide sufficient
guidance with respect to the researchers’ modes of behaviour
towards their objects of research and towards subjects making
use of their research findings (Jonas 1980):
Experimentation was originally sanctioned by natural science.
There it is performed on inanimate objects, and this raises no
moral problems. But as soon as animate, feeling beings became
the subjects of experiment, as they do in life sciences and espe-
cially in medical research, this innocence of the search for
knowledge is lost and questions of conscience arise ...
...
Human experimentation ... involves ultimate questions of
personal dignity and sacrosanctity.
From these principal observations on moral conscience, moral
concern and personal dignity, we shall now turn to a more
concrete investigation of possible forms of abuse and human
rights violations in the different phases of scientific medical
inquiry.
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Possible forms of abusive planning and search for medical
data and knowledge
As to the question whether there exist forms of search or plan-
ning of research that deserve the label of “abusive search”, the
norm of  freedom of inquiry favours a negative answer, in the
sense that any prohibition in this early stage of planning and
design of a research project seems unjustifiable. A tendency
therefore, is to relegate the issue of forbidden knowledge to
the second phase of research, the acquisition phase of scien-
tific inquiry.1 The observation made in the BMA report about
the monstrous inequity in the world with respect to
which/whose diseases are favoured in ongoing or planned
research programmes hints, however, at the need for a different
answer (BMA 2001):
In 1996, ... it was estimated that approximately 56 billion US
dollars was being spent annually on medical research and that
at least 90% of this sum was devoted to the health needs of the
richest 10% of the world’s population. Therefore, the needs of
90% of the world’s population have to be met from 10% of
research funding. Infectious diseases, such as malaria, are
responsible for more than half of the premature deaths among
the poorest 20% of the world’s population but only 7% of
deaths among the richest 20%, who are more likely to suffer
from conditions such as cerebro-vascular disease and
ischaemic heart disease.
In the recently published WHO Report on Macroeconomics
and Health : Investing in Health for Economic Development
(World Health Organization 2001) this problem is dealt with
in considerable detail, and a research strategy intended to
reduce the gross inequity with respect to health and economic
development is also proposed. 
The underlying argument permeating the report gives support
to the interdependency of human rights, previously argued in
this chapter. Investment in health and essential health services
in poor countries and in countries with low levels of income
will not only reduce the disease burden in these countries, it
will also generate economic growth and human flourishing. In
turn, economic development will enable these countries to
cope better themselves with their health problems. 
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Such a “global strategy for health” will, however, not be possible
without a global medical science policy and research strategy
that takes into account the particular research needs of these
countries (WHO 2001). Four such research needs are identified
in the report (WHO 2001) :
• “operational research at the local level” to learn “what actually
works, and why or why not”;
• “a significant scaling up of financing for global R&D on the
heavy disease burdens of the poor”, such as HIV/Aids, malaria,
tuberculosis, childhood infectious diseases and micronutrient
deficiencies;
• “reproductive health”, including research to block perinatal
transmission of HIV;
• epidemiological research.
If these arguments prove to be valid, then it seems reasonable
to draw the conclusion that countries not willing to contribute
to this global research strategy for health and economic devel-
opment should be held accountable for lending support to
gross human rights violations in the name of biomedical
research. 
Possible forms of abusive acquisition of medical data and
knowledge
“The fact that new information might be gained by an experi-
ment”, says W.K. Mariner, “does not, by itself, make the exper-
iment ethically desirable or even justifiable. The Doctors’ Trial
at Nuremberg made abundantly clear, if it was not already
obvious, that experiments can hurt people” (Mariner 1992). It
thus also became clear why search for knowledge cannot be
considered “the supreme value” in biomedical research
(Mariner 1992) as well as making it clear why – in all interna-
tional ethical guidelines and human rights documents
addressing the issue of biomedical research – it is stated that
the safety and welfare of human subjects should be the
researcher’s primary concern and take precedence over the
interests of science and society. 
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From this it seems to follow that :
• biomedical research projects which involve a modest to high
risk of serious harm to the research subject’s life, health, privacy
or dignity should be carefully monitored to prevent abusive
forms of acquisition of medical knowledge slipping through.
One possible exception may be projects aimed at studying
seriously untreatable conditions, such as advanced cancer ; 
• research projects justified solely by reference to arguments
about “national necessity” or “an urgent and over-riding sci-
entific need” should be carefully monitored because of their
potential for abuse and human rights violations.1
From the above-mentioned examples we shall move to
research involving “vulnerable” persons as research subjects,
namely people who due to “insufficient power, intelligence,
education, resources, strength or other needed attributes” are
in special need of attention to their situation of vulnerability
which may necessitate, in some cases, protection of their
interests by an ethics committee reviewing a research project
for instance (CIOMS 2002). Examples of such groups are
patients in emergency rooms, patients with incurable diseases,
persons suffering from mental or behavioural disorders, resi-
dents of nursing homes, children, pregnant women, persons
living in populations or communities with limited resources,
ethnic and racial minority groups, unemployed or homeless
people, members of the armed forces or police, refugees or dis-
placed persons, and prisoners.2
To illustrate the potential for abusive research and human
rights violations with respect to such groups of people, chil-
dren and HIV-positive pregnant women living in developing
countries will be used as examples.
A prevalent view in international ethical codes and guidelines
regulating biomedical research, the Council of Europe’s Con-
vention on Human Rights and Biomedicine included,3 is that
children and other persons without the capacity to consent
should be protected from being involved in research of no real
and direct benefit to them, if it carries a risk that is greater than
minimal. In spite of the good intentions behind such a safety
measure, there are reasons to believe that it inadvertently may
lead to situations where children in need of treatment will be
exposed to greater therapeutic risks and dangers than necessary. 
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This problem arises from the practice in non-therapeutic
research of selecting adults instead of children as research par-
ticipants and of developing new standards for approving paed-
iatric use on the basis of extrapolation of data from studies in
adults. This practice, the critics argue, has led to the paradoxical
situation that children are often exposed to clinical decisions
“without appropriate guidance from research” (Brody 1998).
Consequently, diseased children are in danger of becoming
“therapeutic orphans” (Brody 1998).
The “starting-with-children” approach that has been proposed,
as an alternative to the classical “protectionist view” of extrap-
olation (Brody 1998), signals that although there may be
morally relevant differences between children and adults, as
subjects of medical research they should be treated as method-
ological equals. Therefore, in situations where the safety
option of using adults is not available, children should not be
systematically protected from participating in non-therapeutic
research with a risk level that is greater than minimal, as such
restrictions could lead to an infringement of their right to equi-
table access to health care of appropriate quality. This right is
explicitly stated in Article 3 of the Convention on Human Rights
and Biomedicine.
In 1997 a fierce standard of care debate broke out about the
ethical acceptability of using placebo* as a comparative alter-
native to established effective treatment in trials conducted in
developing countries for the purpose of preventing perinatal
HIV-transmission.1 The intervention, given the privileged
status of “standard of care” in 1994, was the first randomised,
controlled trial that successfully proved to be effective in
reducing the incidence of human immunodeficiency virus
(HIV) infection in pregnant women and their babies. 
The drug employed in the trial with the complex name, Aids
Clinical Trials Group (ACTG) Study 076 (Connor et al. 1994),
was zidovudine. Its mode of administration was complex as well :
oral administration to the pregnant women prior to giving birth,
intravenous administration during labour and, after delivery,
administration to the newborn infants as well. The intervention
reduced the incidence of HIV infection by two thirds (Sperling
et al. 1996).
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Placebo:
a placebo is an inac-
tive pill, liquid, or
powder that has no
treatment value. In
clinical trials, experi-
mental treatments
are often compared
with placebos to
assess  the treat -
ment’s effectiveness.
In some studies, the
participants in the
control group will
receive a placebo
instead of an active
drug or treatment.
1.
For an updated version
of this controversy, see
Solbakk, J.H. 2004.
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The main critique against the placebo-controlled trials* was
that they were intentionally withholding a well-documented
superior treatment (the “standard of care” regimen) from one
group of pregnant women involved in the trials, namely, the
control groups (Lurie et al. 1997; Angell 1997). The defenders
of the use of placebo-controls, on the other hand, argued that
the only way to proceed – in order to find a treatment that
would be efficient as well as affordable for HIV-infected
women living in these countries – would be to employ a
placebo-controlled research design, since the answer to the
question: “What reduction in rate of transmission would be of
value to a developing country ?, cannot be decided without
reliable knowledge about the actual in vivo rate of perinatal
transmission.1
The advocates of using a placebo-controlled study design also
claimed that the main counterargument employed against the
placebo controls – the immorality of withholding a well-docu-
mented superior treatment (the “standard of care” regimen)
from the women in the control group – could be used to inval-
idate the use of “standard of care” as an ethically appropriate
control regimen, as this would imply that the women in the
intervention group were deliberately precluded from access to
the best treatment option (Lie 1998 ; Lie 2002).
Furthermore, a trial using “standard of care” as control regimen
not only suffers from the same sort – though not necessarily
comparable in size – of ethical weakness identified in the trials
using placebo controls, but it also violates the epistemological
precondition deemed indispensable by all parties for conduct-
ing an ethical trial : the state of clinical equipoise (Lie 1998 ;
Lie 2002).
Finally, while the trials employing placebo could be acquitted
of the usual charge of exploiting resource-poor countries, this
is not the case with a trial using the “standard of care” regimen
as an active control (Lie 1998 ; Lie 2002).
This controversy, which has not yet been fully settled,2 provides
a vivid illustration of the ethical complexities involved in
acquiring scientifically sound knowledge of treatment options
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1.
Quotation is from Lie
1998 ; p. 308. 
See also Varmus, H.,
et Satcher, D. 1997,
337 : 1003-5.
2.
For details about the
kind of consensus that
has been reached so
far, see Solbakk 2004.
Placebo-controlled
trial:
a method of investi-
gation of drugs in
which an inactive
substance  ( the
placebo) is given to
one group of partici-
pants ,  whi le  the
drug being tested is
g iven to  another
group. The results
obtained in the two
groups  are  then
compared to see if
the investigational
treatment is more
effective in treating
the condition. 
responsive to the medical needs and economic capabilities of
people living in developing countries. On the other hand, the
empirical evidence available so far lends little support to the
view that the populations from which research subjects have
been drawn, have actually benefited much from the results of
the contested trials (Steinbrook 2002a ; Steinbrook 2002b). 
From a human rights perspective this represents a disturbing
example of lack of implementation and use of research find-
ings that are vital to the health needs of those communities
that have hosted the trials. Consequently, it may also be
argued that these communities have become victims of
therapeutic neglect and abuse, in the sense that their rights
to access to treatment of appropriate quality have not been
met.
Possible forms of abusive communication and use of medical
data and knowledge
A final form of abuse belongs to the phase of communication
and application (or use) of biomedical research findings, and it
deserves attention within the present context of human rights.
This is abuse related to the notion of secrecy. “There is neither
a legal nor a moral obligation to state, publish or communicate
whatever we know simply for the reason that we know it.”
(Tranøy 1996).
In research, on the other hand, the situation is quite different.
That is, regardless of what field of research we are dealing with,
scientific statements should not be concealed; they should be
made public, so that their scientific validity can be tested and
checked by other scientists. Only in this way can a researcher
comply with the norms and values of good scientific conduct.
That is also the reason why a sponsor’s wish to keep secret the
results of a research project – or to introduce certain restrictions
on the researcher’s right to publish results from the project –
represents one of the great moral challenges on the use or
application-level of biomedical research (Tranøy 1996).
Lack of transparency and secrecy should therefore always be
carefully monitored by the responsible health authorities,
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because these are factors that have proved to be present in all
forms of abuse and human rights violations in the name of bio-
medical research (BMA 2001).
A question previously posed, but not yet answered, will now
finally be addressed, viz. whether there is a need for establish-
ing an international tribunal to deal with researchers who have
committed human rights violations in the name of biomedical
research. 
An underlying argument throughout this chapter has been
that there is a need for some sort of international instrument or
forum to bring evidence to the global community about the gross
inequity in the world with respect to which/whose diseases are
favoured in ongoing or planned research programmes and
with the responsibility of developing a medical science policy
and research strategies aimed at meeting the particular
research needs of poor and low-income countries. Such a
forum could also serve as an instrument to monitor ongoing
research, in order to safeguard communities and populations
in those countries from being exploited in the name of bio-
medical research and medical treatment. 
Personally, I believe a forum aimed at uncovering the political
and structural deficiencies generating inequities in the world
with respect to health-related research and treatment would be
more necessary than an international tribunal aimed at targeting
human rights violations committed by individual researchers.
For such a forum to be able to function in a proactive way, close
collaboration with national health authorities – as well as with
international bodies such as the UN, WHO and the World Bank
– would be important. 
In the WHO report on macroeconomics and health previously
referred to (WHO 2001), two proposals are put forward that
seem to prefigure the idea of creating such a forum – first, the
establishment of National Commissions on Macroeconomics
and Health in developing countries, with the tasks of :
• assessing “national health priorities”;
• proposing strategies for the “coverage of essential health
services”;
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• preparing “an epidemiological baseline, quantified operational
targets, and a medium-term financing plan”.
and second, the creation of a Global Health Research Fund
(GHRF) to “... support basic and applied biomedical and health
sciences research on the health problems affecting the world’s
poor and on the health systems and policies needed to address
them” (WHO 2001).
An endorsement of those proposals by the international politi-
cal community and commitment on the part of those countries
capable of contributing resources to such a research fund
would be powerful signals to the world of biomedical research
that human rights matter. The creation of a global forum of
inequities in health-related research could make this message
come true.
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Selection and recruitment
of participants: European standards
by Herman Nys
The selection and recruitment of participants in biomedical
research has been the subject of many regulations at interna-
tional, European and national level. Internationally, the
Helsinki Declaration contains recommendations guiding
physicians involved in biomedical research on human subjects.
It was adopted and subsequently amended on various occasions
by the World Medical Association. In 1996, also at international
level, the International Conference on Harmonisation (ICH)
issued a set of Good Clinical Practices that provide a unified
standard for the European Union, Japan and the United States. 
Both the Helsinki Declaration and the ICH Good Clinical
Practices influenced European Parliament and Council Directive
2001/20/EC of 4 April 2001 on the approximation of the laws,
regulations and administrative provisions of the EU member
states relating to the implementation of good clinical practice
in the conduct of clinical trials on medicinal products for
human use. Recital 2 of the directive expressly refers to the
Helsinki Declaration as an accepted basis for the conduct of
clinical trials. It is, however, remarkable that reference should
be made to the 1996 version of the Helsinki Declaration and
not to the 2000 version. 
The same recital also refers to “the protection of human rights
and the dignity of the human being”. These words reflect the
title of the European Convention for the Protection of Human
Rights and Dignity of the Human Being with regard to the
Application of Biology and Medicine. One wonders why this
convention was not considered worthy of an explicit reference. 
The international and European regulations all contain rules
governing the protection of participants in biomedical
research. These rules not only offer protection but, for those
undertaking such research (sponsors, investigators and so on),
they provide guidance in the process of selecting and recruit-
ing participants. This chapter is mainly concerned with the
rules and standards governing the protection of participants in
biomedical research. 
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It is not my intention to provide a detailed analysis of these
rules and standards by comparing the texts and documents
that have already been mentioned. Rather, I want to indicate
the main points relating to the selection and recruitment of
participants in biological research in the EU directive on good
clinical practice in clinical trials. The references in brackets in
the text are to the directive. For a more detailed discussion of
the rules in the European Convention on Human Rights and
Biomedicine and the Additional Protocol on Biomedical
Research, I would refer you to the chapter by P-eteris Zilgalvis
in this publication. 
The protection of participants in biomedical research:
general rules
Scientific soundness
The first condition to be met, before starting to recruit and
select participants for biomedical research, is the scientific
soundness of the research project. This condition covers two
aspects: firstly, the research project itself and, secondly, the
staff, equipment, infrastructure and so on. Regarding the first
aspect, the so-called research protocol must describe the objec-
tive(s), design, methodology and organisation of the research
project, along with the statistical considerations. The protocol
itself must be based on reliable laboratory and animal
research. Furthermore, the research project must be feasible
and yield relevant information. Regarding the second aspect,
the investigator carrying out/supervising the research must be
a medical doctor, because of the scientific background and the
experience in patient care that the research requires. Each staff
member must have suitable educational qualifications, training
and experience. 
Risk/benefit ratio
The second condition is that an appropriate risk/benefit ratio
must be respected. This means that, before a research project
is initiated, the foreseeable risks (the term is tautologous,
because an event that is not foreseeable as medical science
stands is not a risk) and inconvenience should be weighed
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against the anticipated benefit for the individual participant,
other present and future patients and society at large (Article 3.2
(a)). A research project should be initiated and continued only
if the anticipated therapeutic and public health benefits justify
the risks. 
This evaluation is not a one-off risk assessment but an ongoing
process : newly available information must be considered. This
is the only way of ensuring that the investigator can end the
research project prematurely if its continuation will lead to
damage, death or other serious complications, that is, when
the risks exceed the benefits. If there is prior reason to suppose
that death or disability will occur, the research project must
not be carried out. Most international documents mention this
prohibition. 
Informed consent 
The “golden standard” of biomedical research is the free, volun-
tary, express and informed consent of the selected participant
(or his or her representative – see below). In a prior interview
with the investigator or a member of the investigating team,
potential participants must have had the opportunity to under-
stand the objectives and risks of the research project, the
inconvenience it entails and the conditions under which it is to
be conducted. They must also be informed of their right to
withdraw from the research project at any time (Article 3.2 (b)).
Participants must give their written consent after being informed
of the nature, significance, implications and risks of the
research project. If the participant is capable of giving his or her
consent but unable to write (because of a physical disability, for
instance), oral consent in the presence of at least one indepen-
dent witness may be given (Article 3.2 (d)). Participants may,
without any resulting detriment, withdraw from the research
project at any time by revoking the informed consent orally or in
writing (Article 3.2 (e)). Participants must be provided with a contact
point where they may obtain further information (Article 3.4). 
Medical care, insurance and indemnity
Any medical care given to, and medical decisions made on behalf
of, participants during the research project are the responsibility
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of an appropriately qualified doctor (Article 3.3). Provision
must be made for insurance or indemnity to cover the liability of
the investigator and the sponsor of the project (Article 3.2 (f)).
The protection of minor participants in biomedical research:
specific rules
Apart from the general rules that govern the protection of par-
ticipants in biomedical research, the following specific rules
must be observed when minors are recruited and selected for
such research.
Subsidiarity
A fundamental rule in biomedical research is the subsidiarity
rule. It means that, in principle, only persons who can give
their free and informed consent may be included in a research
project. If the project can take place with healthy, independent
subjects capable of giving their consent, no subjects belonging
to so-called “vulnerable persons”, such as minors, may be
included in the project. 
From this rule and the rule of scientific soundness, it follows that
research on minors has to be essential for the purposes of val-
idating data obtained in research projects on persons able to give
their informed consent or by other research methods (Article 4 (e)).
Subsidiarity also implies that research should either directly
relate to a clinical condition from which the minor concerned
suffers or be of such a nature that it can be carried out only on
minors. 
Direct benefit for the participant
Healthy persons capable of giving their informed consent may
participate in biomedical research without any anticipated
direct benefit to them (so-called “non-therapeutic biomedical
research”). This is not the case for minor participants : some
direct benefit has to be obtained from the research project for
the minors themselves or for the group to which they belong
by virtue of their age and/or illness (Article 4 (e)).
Informed consent of the parents
The informed consent of the parents of the minor or his or her
legal representative must be obtained. This consent may be
revoked at any time, without detriment to the minor (Article 4 (a)). 
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Considering the wishes of the minor
The explicit wish of a minor who is capable of forming an opinion
to refuse participation or to be withdrawn from the research
project at any time must be considered by the investigator
(Article 4 (c)).
Minimal risk and minimal discomfort
A research project in which minors are participating has to be
designed to minimise pain, discomfort, fear and any other foresee-
able risk. Both the risk threshold and the degree of distress have
to be specially defined and constantly monitored (Article 4 (g)).
The protection of incapacitated adults participating in
biomedical research: specific rules
In the case of adults incapable of giving their informed consent,
all the relevant requirements listed for persons capable of giving
such consent are applicable. In addition to these requirements,
inclusion in biomedical research of incapacitated adults is
allowed only if the following conditions are also met.
Subsidiarity
The research project is essential to validate data obtained in
research projects on persons able to give their informed consent
or by other research methods (Article 5 (e)).
Direct benefit for the participant
There are grounds for expecting the research project to produce
a direct benefit to the participant (Article 5 (i)). Moreover, the pro-
ject relates directly to a life-threatening or debilitating clinical
condition from which the incapacitated adult concerned suffers.
In other words, only research that is of direct benefit to the
participant, and the condition from which he or she is suffering,
is allowed (Article 5 (e)). A benefit for the group of patients that
the participant belongs to is not sufficient. However, there is no
consensus on this narrow viewpoint and, for instance, Article 17
of the Convention on Human Rights and Biomedicine allows
more leeway in this respect (see the chapter by Zilgalvis).
Informed consent
The informed consent of the legal representative must have
been obtained (Article 5 (a)). In many countries it is unclear who
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this representative is, because the large majority of incapaci-
tated adults do not come under a specific system of protection.
In practice, the next of kin are often considered as the repre-
sentatives of the incapacitated person, but from a strict legal
point of view this practice is disputed. A question that arises in
this respect is how binding an advance decision by an adult
who has since become incapable of giving his or her consent is. 
In theory, one may consent in advance to a research project.
But it is debatable whether such informed consent can ever be
specific enough to be valid. Was the person, at the time when
he or she consented in advance, really in a position to evaluate
all the risks? That may be so, but it would seem to be rather
exceptional for it to be the case. Such informed consent may of
course influence the decision of the legal representative, but it
cannot be considered as binding. 
The situation is different in the case of an informed refusal. One
has to accept that a competent adult may refuse in advance,
either in specific or in general terms, to participate in a partic-
ular research project or in any research project whatsoever.
This advance refusal has to be respected by the legal repre-
sentative and the investigators. Although from a moral point of
view one may defend an obligation to participate in biomedical
research, such an obligation does not exist in legal terms. 
The consent of the representative may be revoked at any time,
without detriment to the subject (Article 5 (a)). 
Considering the wishes of an incapacitated adult
A person not able to give his or her informed legal consent must
have received information according to his or her capacity of
understanding regarding the trial, the risks and the benefits.
The explicit wish of a subject who is capable of forming an
opinion and assessing this information to refuse participation in,
or to be withdrawn from, the medical research project at any time
must be considered by the investigator (Article 5 (b) and (c)).
Minimal risk and minimal discomfort
A research project in which incapacitated adults are participating
has to be designed to minimise pain, discomfort, fear and any
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foreseeable risks in relation to the disease and developmental
stage ; both the risk threshold and the degree of distress must
be specially defined and constantly monitored (Article 5 (f)).
A favourable opinion from an ethics committee
A most important step in the recruitment and selection of par-
ticipants for biomedical research is the evaluation of the
research protocol by an ethics committee. There is a broad
consensus in all international documents and declarations
regarding this requirement, although there may be differences
as to the membership of such committees, their competence
and so on.
Favourable opinion before the start of a research project
A biomedical research project in which human subjects are to
participate may not start until an ethics committee has issued
a favourable opinion (Article 6.2.).When the subjects involved
are minors or incapacitated adults, the ethics committee must
endorse the protocol (Article 4 (h) and Article 5 (g)). 
The favourable opinion requirement is legally binding in two
senses. Firstly, if the opinion is unfavourable a biomedical
research project cannot be started. Secondly, a protocol that
has received a favourable opinion may not be changed during
the research project. If, after the commencement of the project,
the sponsor of the project wants to make an amendment to the
protocol, the sponsor must inform the ethics committee, which
has to give its opinion on the proposed amendment. If that
opinion is unfavourable, the amendment to the protocol may
not be implemented (Article 10 (a)). 
Responsibilities of an ethics committee
It is the responsibility of an ethics committee to protect the rights,
safety and well-being of human subjects involved in the
research project and to provide public assurance of that protec-
tion (Article 2 (k)). To this end, the ethics committee has to consider
in particular the relevance of the research project and its design ;
whether the balance of the anticipated benefits and the risks is
satisfactory ; the research project protocol; the suitability of
the investigator and the supporting staff; the investigator’s
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information brochure and the quality of the facilities. It also
has to consider the adequacy and completeness of the written
information to be given to the participants and the justification
for research on persons incapable of giving informed consent. 
Further, it has to evaluate the provision made for indemnity or
compensation in the event of injury or death attributable to
the research project and insurance or indemnity to cover the
liability of the investigator or the sponsor. One particularly
important responsibility as regards the recruitment and selec-
tion of participants is that the ethics committee has to consider
the amounts and, where appropriate, the arrangements for
rewarding or compensating investigators and participants
(Article 6.3 (a) to (j)). With regard to minors and incapacitated
adults, no incentives or financial inducements may be given,
except compensation (Article 4 (d) and Article 5 (d)). Finally, an
ethics committee has to consider the arrangements for the
recruitment of subjects (Article 6.3. (k)).
Membership of an ethics committee
An ethics committee must consist of healthcare professionals
and non-medical members (Article 2 (k)). When minors are
involved as participants, the ethics committee should have
paediatric expertise or should seek advice on clinical, ethical and
psychosocial problems in the field of paediatrics (Article 4 (h)).
When incapacitated adults are involved, the ethics committee
should have expertise in the relevant disease and the patient
population concerned or seek advice on clinical, ethical and
psychosocial questions in the field of the relevant disease and
population concerned (Article 5 (g)).
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Placebo: its action and place in
health research
by Andrzej Górski
Ongoing progress in biomedical research and technology
promises to offer a substantial improvement in the quality of
people’s lives as well as generate important economic benefits.
However, those advances can also give rise to difficult ethical
questions (Gerold 2004 ; Koski and Nightingale 2001 ; Shapiro
and Meslin 2001). These problems are especially relevant in
clinical research with its inherent tensions between the ethical
values of pursuing rigorous science and of protecting partici-
pants from undue harm. 
In this context, it should be emphasised that the ethics of clinical
research is not tantamount to the ethics of clinical care : the
primary goal of clinical trials is to advance medical knowledge,
not to promote patients’ best medical interests (which may be
compromised by their exposure to risks not necessarily out-
weighed by known potential medical benefits (Emanuel et al.
2000 ; Horng and Miller 2002). Therefore, the biomedical
research community, international institutions and organisa-
tions, and the public have been engaged in a re-examination of
the ethical and responsible conduct of research involving
human participants for many years. 
Among the issues that have received great attention and have
been a matter of intense public controversy has been the role
and place of placebo in health research. The course of discus-
sion and the controversies surrounding the subject of placebo
are not unique in the history of bioethics. For example, the
world’s first laparoscopic appendectomy* was performed in
1980 by Kurt Semm in Kiel, Germany. The president of the
German Surgical Society called for his suspension, and the
relevant paper was rejected because the procedure was at that
time considered unethical (Tuffs 2003). Today laparoscopic
surgery is an accepted treatment.
Hippocrates (c.460-438 BC), regarded as the father of medi-
cine and author of the Hippocratic oath, was probably the first
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Appendectomy:
surgical removal of
the  vermi form
appendix. This pro-
cedure is normally
per formed as  an
emergency proce-
dure  when the
patient is suffering
from acute appen-
dicitis.
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to notice that medical attention itself can make a patient feel
better and induce an effect now referred to as placebo :
The patient, though conscious his condition is perilous, may
recover his health simply through his contentment with the
goodness of the physician. (Box 2004)
Placebo can be defined as “a dummy treatment administered to
the control group in a controlled clinical trial in order that the
specific and non-specific effects of the experimental treatment
can be distinguished” (see On-Line Medical Dictionary:
http ://cancerweb.ncl.ac.uk/omd).
A placebo can be pharmacological (a tablet), physical (a
manipulation), or psychological (a conversation, for example,
being a part of medical attention). An in-depth analysis by
Hrobjartsson et al. (Hrobjartsson and Gotzsche 2001) suggests
that there is little evidence that placebo has significant benefi-
cial effects ; therefore, there is no justification for its use outside
clinical trials. However, as pointed out by Emanuel and Miller
(2001), patients given “no treatment” (group in addition to a
placebo group) were in fact receiving clinical attention that
may have contributed to observed improvements. Thus, clini-
cal attention may be responsible for the placebo effect, and
clinical trials involving such attention in fact test whether the
experimental treatment is better than this attention, not
whether it is better than nothing. 
Furthermore, it has been recognised that a placebo can cause
the noxious or distressing effects referred to as the nocebo
phenomenon (Latin : I will harm, as opposed to placebo : I will
please). In fact, approximately a quarter of patients on placebo
report such adverse side-effects : drowsiness, nausea, fatigue
and insomnia, and their incidence may even exceed the inci-
dence of side-effects in patients taking the active drug (Barsky
et al. 2004).
Evidently, any treatment (pharmacological, physical or psy-
chological) may have a beneficial effect, since patients perceive
themselves as being treated. This in turn activates biochemical
mechanisms, which can lead to clinical improvement. There-
fore, the placebo effect is basically related to the expectation of
clinical benefit (a phenomenon that may explain placebo
responses obtained in treating pain, depression and Parkinson’s
disease).
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Recent studies indicate that placebo is related to the limbic
system of the brain and may be mediated by dopamine – a
chemical that transmits pleasure signals to the brain and is
therefore responsible for a placebo’s beneficial effects. On the
other hand, the ability of placebo to alleviate pain (placebo
analgesia) is mediated by endogenous opioids in the context of
a patient’s expectations. This results from the doctor–patient
interaction, but even the mere presence of medical staff may be
important. Aside from dopamine and opioids, other endogenous
mediators may also be involved, such as cholecystokinin (de la
Fuente-Fernandez and Stoessl 2004). 
Placebo-controlled clinical trials (PCT) have been criticised
since their initiation: in 1931, sanocrisin was compared with
distilled water in the treatment of tuberculosis (Emanuel and
Miller 2001). However, some scientists and doctors believe that
important negative consequences would result from uniformly
prohibiting PCT and allowing only active controls (a therapy
effective in treating a given condition) and suggest that it would
be difficult if not impossible to identify new treatments repre-
senting a major advance without studying them in such trials. 
The “active-control orthodoxy” group cites the Declaration of
Helsinki, which elevates concern for the health and rights of
individual patients above concern for society, for future
patients, and for science :
The benefits, risks, burdens, and effectiveness of a new method
should be tested against those of the best current prophylactic,
diagnostic and therapeutic methods. This does not exclude the
use of placebo, or no treatment, in studies where no proven pro-
phylactic, diagnostic or therapeutic method exists. (Declaration
of Helsinki, Provision 29)
If patients are assigned a placebo instead of a therapy effective
in treating their condition, placebo opponents argue that such
trials are in breach of the declaration, which – in their judge-
ment – proscribes the use of a placebo as a control, when a
proven therapeutic method exists. They also argue that the use
of a placebo allows for approval of drugs of undetermined effi-
cacy, as the scientific benefit of PCT is illusory (the effect of a
new drug appears large and may be statistically significant
even in a small study, so the evaluation of results is subject to
statistical errors).
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The 5th revision of the Declaration of Helsinki (October 2000),
containing the above-mentioned rigid standards in its placebo
control guidelines ignited much controversy and even criticism
(Forster et al. 2001). Consequently, in 2002 a note of clarification
was added that reads:
The WMA hereby reaffirms its position that extreme care must
be taken in making use of placebo-controlled trials and that in
general this methodology should only be used in the absence
of existing proven therapy. However, a placebo-controlled trial
may be ethically acceptable, even if proven therapy is available,
under the following circumstances :
• where, for compelling and scientifically sound methodological
reasons, its use is necessary to determine the efficacy or
safety of a prophylactic, diagnostic or therapeutic method; or
• where a prophylactic, diagnostic or therapeutic method is
being investigated for a minor condition and the patients
who receive placebo will not be subject to any additional risk
or serious irreversible harm.
Clear guidance on the matter of placebo is provided by the
Council for International Organizations of Medical Sciences
(CIOMS), which uses the term “established effective intervention”
instead of “best current therapeutic method” or “proven therapeu-
tic method” (Helsinki Declaration), as the active comparator that is
ethically preferred in controlled clinical trials. This avoids prob-
lems when there may be lack of agreement in the medical world
as to which method is the best (Idanpaan-Heikkila and Fluss 2004). 
CIOMS Guideline 11 (International Ethical Guidelines for
Biomedical Research Involving Human Subjects) states that :
As a general rule, research subjects in the control group of a trial
of a diagnostic, therapeutic, or preventive intervention should
receive an established effective intervention. In some circum-
stances, it may be ethically acceptable to use an alternative
comparator, such as placebo or “no treatment”.
Placebo may be used :
• when there is no established effective intervention ;
• when withholding an established effective intervention
would expose subjects to, at most, temporary discomfort or
delay in relief of symptoms ;
• when use of an established effective intervention as com-
parator would not yield scientifically reliable results and use
of placebo would not add any risk of serious or irreversible
harm to the subjects.
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The Council of Europe is recognised for its leading role in
bioethics and its focus on human rights. Therefore, it would be
important to present its views on placebo as expressed by the
Additional Protocol on Biomedical Research, supplementary to
the Convention on Human Rights and Biomedicine, adopted
by the Council of Europe’s Committee of Ministers in June
2004. It addresses such issues as consent, the protection of per-
sons not able to consent to research, and research ethics com-
mittees, and it is the first internationally binding legal instru-
ment covering the field of biomedical research.
Article 23 states : 
the use of placebo is permissible where there are no methods
of proven effectiveness, or where withdrawal or withholding of
such methods does not present unacceptable risk or burden.
Thus, as pointed out by Zilgalvis (Zilgalvis 2004), the protocol’s
definition represents a kind of “middle ground” proposing a real-
istic balance between the proponents and opponents of the use
of placebo.
In 2000 the European Parliament, the Council and the Commission
proclaimed the Charter of Fundamental Rights, whose Article 3
addresses important issues of medicine and biology, such as
free and informed consent, the prohibition of selling the
human body and its parts, and the prohibition of reproductive
cloning. 
Recently, the Commission has also formulated its stance on the
issue of placebo, as seen from the perspective of the European
Group on Ethics in Science and Technology (EGE). Established
in 1990, the EGE advises the President of the Commission on
questions related to bioethics and biotechnology. It has issued
its Opinion No. 17 (February 2003), stating that :
placebo-controlled trials may be acceptable when, for example,
the primary goal of the clinical trial is to try to simplify or
decrease the costs of treatment for countries where the standard
treatment is not available for logistic reasons or inaccessible
because of the cost. 
This opinion was not accepted unanimously, as two members
dissented from that conclusion, believing that it might allow for
double standards for research in wealthy and poorer countries.
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Furthermore, European Commission Directive 2001/83/EC
supports the Declaration of Helsinki :
All clinical trials shall be carried out in accordance with the
ethical principles laid down in the current revision of the
Declaration of Helsinki …
In general, clinical trials shall be done as controlled clinical trials,
and if possible, randomized … any other design shall be justified.
It also adds :
The control treatment of the trials vary from case to case and
also will depend on ethical considerations…
It may, in some instances, be more pertinent to compare the
efficacy of a new medicinal product with that of an established
medicinal product of proven therapeutic value rather than
with the effect of placebo.
In addition, the European Agency for the Evaluation of Medicinal
Products (EMEA) considers the issues of Good Clinical Practice
(GCP) – including ethical issues such as informed consent,
approval by ethics committees and the like – when granting
marketing authorisation. When problems are detected, the
EMEA can refuse or withdraw marketing authorisation and
advise the Commission. In June 2001, the EMEA adopted a
position statement on “The use of placebo in clinical trials with
regard to the revised Declaration of Helsinki”. Affirming that
the Declaration remains a vital expression of medical ethics
whose aims deserve unanimous support, it also states that :
Forbidding placebo-controlled trials in therapeutic areas where
there are proven prophylactic, diagnostic and therapeutic
methods would preclude obtaining reliable scientific evidence
for the evaluation of new medical products, and be contrary to
public health interest ... Provided that the conditions that ensure
the ethical nature of placebo-controlled trials are clearly
understood and implemented, it is the position of the EMEA that
continued availability of placebo-controlled trials is necessary
to satisfy public health needs. (www.wma.net/e/ethicsunit)
As summarised above, discussions about the use of placebo
have been particularly intense and polarised, and have perhaps
reached an impasse : while some approve of only a very limited
role for placebo and suggest that the need for them is over-
stated (Michels and Rothman 2003), others have endorsed more
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widespread use (Temple and Meyer 2003; Temple et al. 2000;
Ellenberg et al. 2000; Singer 2004). As recently pointed out by
Sugarman (2004) this debate has centred on rhetoric rather
than on analysing relevant empirical findings. 
Therefore, to assess whether PCT carry an increased risk of harm,
the results of eighty such trials in patients with mild to moder-
ate hypertension were evaluated. It appears that a short-term
PCT in those patients does not pose an elevated risk. Likewise,
an analysis of such trials involving more than 19 000 patients
with depression did not reveal differences between active
treatment and placebo (Sugarman 2004).
Obviously, physicians may be key players in the enrolment of
patients in clinical trials, and the attitude of the public may
also contribute to the place of placebo in health research
today. A nationwide mailed survey in the USA has revealed
that physicians preferred active-control trials and believed that
they are superior to placebo-controlled ones (on the basis that
they are more likely to lead to a patient benefit and public benefit
and are less likely to expose patients to risks). However, it is
unclear whether the respondents had a thorough understand-
ing and knowledge of the complexity of the problem; for
example, the number of currently used treatments that have
not been validated (Sugarman 2004).
To break the present impasse, national consultations were con-
ducted in Canada under the aegis of Health Canada and the
Canadian Institutes of Health Research (the National Placebo
Initiative). Potential participants were identified from five
major cities in Canada and the consultations were performed
using the process of deliberative dialogue (involving video ses-
sions presenting an overview of the current use of PCT, the
policies guiding its use, and the assessment of PCT by ethics
commissions (institutional review boards).
Participants supported the use of placebo as an important tool in
medical research and the advancement of science and thought
that it constitutes a necessary and valid part of developing and
testing new treatments. At the same time, they emphasised the
necessity of full informed consent and minimising potential
conflicts of interest as well as the fact that placebo use should
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be selective (believing its applicability should decrease when
there is an increasing risk for the trial patients). Some partici-
pants believed that patient autonomy should be the highest
priority and the first consideration: whenever possible, consid-
ering the patient as a partner and giving patients the choice to
participate in PCT.
Interestingly, the participants accepted that there might be
some risk involved in such trials, but valued the idea of their
country as a leader in medical research and wished to avoid
the negative effects of overly restrictive placebo policy. Even
though the total number of participants of the study was rela-
tively small, it should be emphasised that for the first time
public consultations were conducted nationally on such a key
bioethical issue as placebo (Huston 2004). 
The outcome of the Canadian National Placebo Initiative is
similar to the views expressed by Dr Temple, Director of the
Office of Medical Policy, Center for Drug Evaluation and
Research of the Federal Drug Administration (FDA) in the USA,
who believes that there is a continued need for placebo even
when there is effective therapy (Temple and Meyer 2003). In
his important paper published in 2000 he considers the ethical
concerns about the use of placebo controls and emphasises the
limited ability of active-control trials to establish efficacy of
new therapies. 
Temple and Ellenberg believe that in conditions in which for-
going therapy carries no important risk, the participation of
patients in PCT seems appropriate and ethical – as long as patients
are fully informed (Temple and Ellenberg 2000). Moreover, they
point out that not all placebo studies leave patients untreated,
as it is frequently possible to provide standard therapy while
carrying out a superiority study (intended to demonstrate an
advantage of a treatment regimen over the control – for exam-
ple using an “add-on” design in which all patients are given
standard therapy and are also randomly assigned to receive
either a new agent or a placebo). Also, it has to be kept in mind
that even FDA approval does not exclude the continuation of
PCT when drug efficacy or its side-effects are still in doubt. 
Furthermore, the authors emphasise a longer-range rationale for
patient participation in a PCT. The trial participants themselves
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may benefit in the future regardless of their assigned treatment
in the initial trial (active drug versus placebo). Thus, it could be
argued that forgoing active treatment for the short term may
improve long-term chances of successful treatment. In addition,
it must be recognised that a new treatment may represent a
major advance without being more effective than alternatives,
which is another argument for the negative consequences of
uniformly prohibiting PCT (Temple et al. 2000; Ellenberg et
al. 2000).
In the United Kingdom, PCT seem to be less popular than in
the USA. The UK Medical Research Council, which supports
high-quality research aimed at improving human health, is
currently funding 190 trials, and only 20 of them are PCT
(Box 2004 ) – the details are available on the website
http ://www.controlled-trials.com/. However, elsewhere in
Europe the opinions on PCT also vary. 
Thus, placebo is valued at the prestigious University of Vienna:
the head of its ethics commission believes that waiving the
PCT altogether may be as unethical as its unjustified use. In his
lecture during the placebo conference in April 2003 in Warsaw,
he presented examples of clinical trials which support the
importance of a placebo group, without which one might
never have learned about the uselessness of the suggested and
subsequently tested clinical treatment. This is another important
argument for the consideration of placebo, since scientifically
invalid research cannot be ethical, no matter how favourable
the risk/benefit ratio for the study participants may be. The
author rightly points out that placebo is not an ideal solution,
but clinical research cannot provide ideal solutions, only the
best possible ones (Singer 2004).
Within the subject of placebo, nothing could be more provoca-
tive and challenging than the use of placebo in surgery. It is
known that surgical procedures are sometimes introduced into
practice without rigorous evaluation, and it is likely that at
least some of them may be unjustified. Recently, Moseley et al.
reported that in a PCT of arthroscopic surgery for osteoarthritis
of the knee, the surgical intervention was no more effective
than placebo operations (Moseley et al. 2002).
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An in-depth analysis of this problem by ethicists from the
National Institutes of Health suggests that surgery may indeed
be associated with a strong placebo effect ; this and other rea-
sons discussed in this relevant and obviously very important
paper lead the authors to believe that a placebo control may be
required for a rigorous scientific evaluation of a surgical pro-
cedure – when the primary outcome is subjective (for example,
pain or quality of life), especially as no other sufficiently rigor-
ous study design poses less risk. The authors also emphasise
the consequences of not conducting rigorous trials of surgery,
in particular the exposure of patients to unjustified risk and
the high costs incurred by the health system (over $3 billion in
the USA alone, in the case discussed) without benefit to the
patients. They believe that such PCT should be considered and
conducted – following rigorous ethical assessment – before
the procedure becomes standard (Horng and Miller 2002).
Recently, experts have also defined conditions that would
permit the ethical use of placebo in osteoporosis : refusal of
approved therapies by well-informed patients, substantial dis-
agreement or lack of consensus about whether approved
treatments are better than placebo or subjects are refractory to
known effective agents (Brody et al. 2003). Those conditions
may also apply to other situations where placebo use might be
considered.
An international conference on placebo was held in Warsaw
in April 2003 under the auspices of the Secretary General of
the Council of Europe (http ://surfer.iitd.pan.wroc.pl/events/
Placebo.html).1
As already mentioned, Dr P. Zilgalvis, deputy head of the
Bioethics Department of the Council of Europe, highlighted
the “middle ground” approach (Zilgalvis 2004). The rationale
for this policy on placebo has been formulated and proposed
by Emanuel and Miller (Emanuel and Miller 2001). It appears
that the acceptance of this approach would allow for the opti-
misation of the ethical and scientific conduct of clinical
research.
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1.
The programmes of
other bioethical con-
ferences held in War-
saw are available on
the following web-
sites :
http ://surfer.iitd.pan.
wroc.pl/events/integr
ity.html
http ://surfer.iitd.pan.
wroc.pl/events/
misconduct.html
http ://surfer.iitd.pan.
wroc.pl/events/coi.ht
ml
http ://surfer.iitd.pan.
wroc.pl/events/paten
ts.html
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Cancer clinical trials
by Maxime Seligmann
The European Directive 2001/20/EC, which is about to be
incorporated into French law, states that
[t]he accepted basis for the conduct of clinical trials in humans
is founded in the protection of human rights and the dignity of
the human being with regard to the application of biology and
medicine” and that “[t]he clinical subject’s protection is safe-
guarded through risk assessment based on the results of toxi-
cological experiments prior to any clinical trial [and] screening
by ethics committees.
Article 1 states that “[g]ood clinical practice is a set of interna-
tionally recognised ethical and scientific quality requirements
[and that] compliance with this good practice provides assur-
ance that the rights, safety and well-being of trial subjects are
protected, and that the results of the clinical trials are credible”.
Ethical considerations are particularly important in oncology,
for two reasons : firstly, the patients are suffering from what is
often a very serious (and feared) disease and, secondly, most of
the methods used to treat it are highly cytotoxic* and have
side-effects that are sometimes serious. The ethical problems
are particularly acute in so-called phase I trials* which will be
considered at the end of this chapter. 
The various treatment methods 
Most of the drugs currently used are cytotoxic agents, and the
usual forms of chemotherapy combine, simultaneously or
alternately, several such substances. A bone marrow transplant
is increasingly indicated in many malignant blood disorders,
and this requires prior “conditioning” by radiation and/or
chemotherapy.
“Cytostatic” drugs are currently being developed on a large
scale and probably represent the treatment of the future. Most
of these drugs attack pharmacological targets that are essential
for the proliferation of cancer cells. A very large number of
drugs is involved, and they belong to two main categories :
there are those which modify the biological behaviour of the
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the quality of being
poisonous to cells.
This can be a chemi-
cal substance or an
immune cell.
Phase I trial:
a cl inical  tr ial  on
normal volunteers,
designed to deter-
mine the biological
activities and range
of toxicity or other
safety factors of a
given therapy.
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tumour (for example, by blocking growth factors, hormones or
signal pathways, or by inhibiting invasion), and those that alter
the body’s response (for example, immune-response modulators
and angiogenesis* inhibitors).
Care and therapeutic research
The role of the doctor administering the treatment is to care
for individual patients in what he or she considers the best
possible way. Care is therefore a therapeutic activity which
caters for the subjective needs of a particular person, whereas
research is designed to take an objective approach to a biologi-
cal individual. The former approach involves listening to
someone in a way that takes account of personal concerns,
whereas the latter is designed to update the impersonal laws
that apply to human beings (French Advisory Committee on
Ethics in the Life Sciences and Health Field [CCNE] 2003,
Opinion No. 79). It is the elimination of everything that is
purely subjective that allows knowledge of diseases to
progress. “We must therefore accept the fact that there is a real
divide between knowledge that takes account of subjective
concerns and scientific knowledge” (Bachelard 1938).
Clinical trials are designed to answer scientific questions and
check hypotheses, so as to expand our knowledge and improve
treatment for future patients, and thus provide collective ben-
efits. The divergence between the personal dimension of care
and the collective benefits of therapeutic research affects the
relationship between doctor and patient, which is built on
trust. It means that there is an absolute duty to protect people
who take part in clinical trials, and it raises ethical problems
that were analysed very recently (Miller and Rosenstein 2003).
What is unethical is not the fact of taking a collectivist
approach to investigations, but to lose sight of the patient’s
own interests and treat him or her simply as a research subject.
The tendency of patients to confuse personalised medical care
with participation in a clinical trial has been dubbed a “thera-
peutic misconception”. Investigators must counteract this by
informing patients as honestly as possible and in a way that is
as easy to understand as possible. They themselves must guard
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Angiogenesis:
the formation of new
blood vessels.
against this confusion and be aware of the potential conflict of
interests between scientific progress and the protection of
research subjects. Integrity requires that they rule out any
form of exploitation of a vulnerable subject. It is a moot point,
moreover, whether the clinical trial investigator should not be
separate from the doctor administering the treatment.
Assessment of the risk/benefit ratio
This is a key stage when a clinical trial protocol is devised and
drafted. An analysis of the risks necessitates recognition of all
the physical, psychological, social and financial implications.
The pros and cons of participation in the trial and the con-
straints entailed must be carefully weighed up. 
The benefit to the patient must be assessed in both quantitative
and qualitative terms. A benefit cannot be assessed solely in
terms of the number of months or years gained. The develop-
ment of a new molecule or a new form of treatment that makes
it possible to prolong the life of a patient suffering from an
incurable disease may not bring about any improvement in his
or her quality of life – an aspect we consider it essential to take
into account. There is some substance in the view that
“patients treated as part of a clinical trial do better than those
receiving routine treatment” (Hoerni 1991), because they are
more closely monitored. The concept of benefit must remain
sufficiently flexible to allow biomedical research to oscillate
between individual and collective concerns. 
The practice of setting up a data and safety monitoring board
comprising independent experts to oversee the trial should be
encouraged for most trials. 
Patient information and consent
European Directive 2001/20/EC states that the trial subject
must have “given his written consent after being informed of
the nature, significance, implications and risks of the clinical
trial [and] may … withdraw from the clinical trial at any time
by revoking his informed consent”. Consent is based on the
information leaflet prepared by the sponsor, which must be as
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explicit and objective as possible, and on the information
provided orally by the investigating doctor. The provision of
information must take the form of a dialogue and exchange of
views. 
The information must make it clear that what is involved is a
research project and that its benefits are uncertain, and the
alternatives to participation in the trial must be put forward.
The consent form must not be signed until several days after
the information leaflet is handed to the patient, so that the
latter may discuss the matter with his or her family and general
practitioner, and until the investigator has answered any new
or repeated questions.
In the case of paediatric oncology, the issue of minors deserves
special consideration. In addition to the consent of the parents
or legal representative, the investigator must expressly take
account of the personal consent of under-age children who are
able to make their wishes known and also take account of a
refusal or the revocation of consent on their part. It is an ethical
requirement to ascertain the wishes of the child.
The CCNE has issued an opinion (CCNE 1998, Opinion No. 58)
on the “informed consent of and provision of information to
persons taking part in treatment or research”. Numerous articles
on these issues have been published in connection with cancer
clinical trials (Daugherty 1999; Tattersall 2001), and question-
naires designed to assess the quality of informed consent have
been drafted (Joffe et al. 2001).
We consider it desirable that a European model information
leaflet and consent form, covering the information that must
be included, be drawn up to help investigators promote good
practice.
Ethics committees
Ethics committees play a key role in protecting people taking
part in research, for they provide a critical and ethical analysis
of the therapeutic research envisaged.
Under European Directive 2001/20/EC, in preparing their rea-
soned opinions, such committees must consider, in particular :
the relevance of the clinical trial and the trial design; whether
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the evaluation of the anticipated benefits and risks is satisfac-
tory and whether the conclusions are justified ; the suitability
of the investigator and supporting staff; the adequacy and
completeness of the written information to be given and the
procedure to be followed for the purpose of obtaining informed
consent ; and the arrangements for the recruitment of subjects.
Ethics committees must be multidisciplinary and include persons
with appropriate scientific expertise (doctors, scientists, phar-
macologists in the case of phase I trials, and statisticians in the
case of phase III* and IV* trials), but also nurses, legal experts,
psychologists or psychiatrists and other representatives of civil
society. To ensure independence and avoid the exercise of
pressure, it is desirable that the bodies concerned be separate
from the treatment centre where the principal investigator works.
Involvement of nursing teams and patients’ associations
Involvement in a trial confers special responsibility not only on
the doctor but also on the nursing team, all of whose members
should be involved in the conduct of the trial and ensure,
beforehand, that the patient has understood what is at stake.
The involvement of patients’ representatives is to be highly
recommended when the protocol is devised and particularly
when the information leaflet is drafted. It may also be desirable
when the ethics committee examines the protocol.
As the trial ends
It is essential that arrangements be made for the long-term
monitoring of subjects when they leave the trial, and for them
to receive the treatment that has proved the most effective.
The findings of a clinical trial should be made public within a
reasonable time. Even negative results should be published,
given the need for openness in research. Failure to comply
with these rules is unethical (Antes and Chalmers 2003). A
European register of cancer clinical trials and their results is
highly desirable.
Trials not involving medicinal products
The European directive concerns “clinical trials on medicinal
products for human use” and does not therefore concern
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physio-pathological and cognitive oncological research. The
provisions concerning information and consent should also
apply to such research. There is justification for subjecting
behavioural research to ethical scrutiny. Its consideration by
ethics committees requires the presence of researchers in
behavioural science. All research must be evaluated.
European multicentre trials
There are numerous financial, legal and administrative obstacles
to large-scale trials carried out at European level by public
institutions that are scientifically independent of the pharma-
ceutical industry (whose major objectives are to obtain product
licences and market its products) (Cornu et al. 1999). The
recent European directive, which is designed to simplify and
harmonise statutory and administrative rules in the various
member states, should make it possible to remove some of
these obstacles. For instance, it obliges each member state to
issue a single ethics committee opinion, and rightly states that
repetitive trials should not be carried out within the Community.
Until very recently, the European Commission had serious mis-
givings about financing clinical trials. Private and quasi-public
bodies, such as the European Organisation for Research and
Treatment of Cancer in the cancer field, have endeavoured to
remedy this situation.
Phase I trials
The CCNE recently published an opinion on the ethical issues
raised by phase I cancer trials (CCNE 2002, Opinion No. 73).
Phase I trials are defined as the first trials carried out on
human beings after animal and in vitro experiments. They are
an essential stage in the use of any new molecule, and their
main purpose is not to look for a therapeutic effect, but to
assess toxicity. They are therefore designed to reveal any side-
effects, their duration, whether or not they are reversible and
their relationship with pharmacokinetic data. The data
obtained are needed in order to carry out the initial studies on
the effectiveness of the drug.
Ethical eye – Biomedical research
As anti-cancer molecules are generally highly cytotoxic, phase
I trials cannot be carried out on healthy volunteers, and are
conducted on cancer patients for whom no further treatment
is available. In phase I trials, it is compulsory to administer
gradually increasing doses, on the grounds that the highest
dose tolerated is the one which is the most likely to be effec-
tive. This widely accepted hypothesis is by no means always
confirmed. The traditional method, whereby at least three
patients receive the molecule at each dose, is now rarely used. 
Other systems for increasing the doses, using new statistical
models and new pharmacokinetic methods, have been pro-
posed. The purpose of these changes is to determine the toxic
dose more quickly, avoid an excessive risk of toxicity and limit
the number of patients to whom a dose that is very low and
therefore, a priori, completely ineffective is administered.
Despite progress, however, it is difficult to achieve these three
objectives simultaneously (Eisenhauer et al. 2000). 
There is little point in determining the maximum dose toler-
ated in the case of the various cytostatic agents, which can be
most effectively administered by means of sub-acute exposure
or chronic exposure, whether continuous or weakly discontin-
uous. Instead, in the case of these molecules, the objective is to
determine the biologically effective dose, which is usually very
different from the toxic dose. The recent guidelines of the
European Agency for the Evaluation of Medicinal Products
(Emea 2003), which cover both cytotoxic and cytostatic agents,
continue, however, to state the need to determine the maximum
tolerated dose, even though this requirement has been criticised
by certain authors (Degos 2000).
Methodological and pharmacological progress should make it
possible for tolerance and effectiveness to coexist. At present,
however, the objective of these preliminary but necessary
phase I trials is to assess tolerance to the new molecule with-
out directly determining whether there is a therapeutic benefit
to the patient taking part. This shows how heavily weighted
the risk/benefit ratio is in favour of the risk. Such trials are
therefore at variance with the Declaration of Helsinki,
although the person drafting the protocol must indicate that
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he or she has complied with the declaration, which states that
“[i]n medical research on human subjects, considerations
related to the well-being of the human subject should take
precedence over the interests of science and society” (World
Medical Association Declaration of Helsinki 2000). 
Side-effects are frequent and sometimes serious, whereas the
clinical benefit is very small. Specialists differ over its frequency
and scale. Meta-analyses show that fewer than 6% of patients
derive a (minor or more substantial) benefit, whereas 0.5% of
them die because of the product’s toxicity (Horng et al. 2002).
The benefit is, of course, more substantial when the trial com-
bines a new molecule and a previously recognised medicinal
product. 
Pharmacological progress will make it possible to identify
patients who are unlikely to benefit from the new molecule or,
conversely, those whose tumours will be sensitive to the sub-
stance being tested. Moreover, it is desirable that, as far as pos-
sible, patients taking part in phase I trials should, secondarily,
be able to benefit as soon as possible from a phase II trial
designed to determine the effectiveness of the substance.
The choice of patients is an ethical issue of key importance. Such
trials are normally offered to patients for whom there is no
alternative treatment. It is, however, highly desirable that ter-
minally-ill patients should not take part, for both scientific and
ethical reasons. In terminally-ill patients, clinical and biological
tolerance and pharmacokinetic data on cytotoxic molecules
may be different from those in a less severely affected patient,
and this calls into question the actual scientific validity of the
proposed protocol. Besides, the inclusion of particularly vul-
nerable people, who are often prepared to submit to any phase
I trial without having properly understood its purpose and
scope, raises a real ethical problem. 
The eligibility criteria of the European Agency for the Evaluation
of Medicinal Products (Emea 2003) require that the survival
probability exceed eight to twelve weeks. It will probably
become possible to select patients likely to benefit from a new
molecule by identifying targets and by means of pharmaco-
genetic studies. This might mean that it would not be suggested
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that a patient be included in a phase I trial until a tumour sam-
ple has been taken in order for these parameters to be studied.
It is particularly important to inform patients to whom such tri-
als are suggested and obtain their informed consent, and these
procedures often cause many problems. There is a wealth of
literature on the subject in English: the main references are to
be found in the article by Horng et al. (2002). There is a major
conflict of interests between the need to find cancer patients in
order to explore, in phase I, tolerance to new molecules and
the duty to care for individual patients, and this presents the
doctor with a genuine moral dilemma (Miller 2000).
The doctor must indicate, in the information leaflet and at the
interview with the patient, that the main objective of the trial
is to determine tolerance to a new substance, and must avoid
the word “treatment”. He or she must specify the nature of the
toxic symptoms that will be looked for and their possible
effects on the patient’s quality of life. The doctor must refer to
a modest hope that there will be benefits, without concealing
the uncertainty surrounding this. He or she must also discuss
alternatives, such as continuing a standard form of treatment,
which will most probably be ineffective, stopping all treatment,
and palliative care. 
It is necessary to avoid any ambiguity that allows the problem
to be played down, deliberately or otherwise. The concept of
collective utility and of benefits to other patients must be
referred to. Each patient must understand that any new treat-
ment is invariably based on such trials. The patient’s main
motivation, however, is not generally altruism, but the hope of
a new form of treatment. The main problem is to avoid dashing
any hopes, without raising them unjustifiably. Such rigorous
openness must, however, take account of the patient’s capacity
for discernment. In its Opinion No. 58, the CCNE stressed that
“the duty to inform does not imply the right to do so bluntly or
abruptly”. 
It is always necessary to consider whether patients’ consent is
genuinely independent, as the independence of their judg-
ment is undermined by the vulnerable situation in which they
find themselves. The main ethical problem raised by phase I
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trials is therefore that of ensuring that the decision to include
a patient is the result of a genuine exchange between doctor
and patient in a relationship based on mutual trust. The factors
involved in the patient’s decision have been analysed in a
major centre in the United States (Gordon and Daugherty 2001).
The conditions under which trials are proposed and consent is
obtained naturally raise particularly serious issues in the case of
phase I paediatric oncology trials.
As regards European regulations, it is desirable that, in the case
of molecules that have already been tested and used abroad,
account be taken of prior phase I results so as not to repeat trials
unnecessarily in patients, who would thus be subjected to
administrative rather than scientific constraints.
The duty of solidarity must not be used as an argument for
undermining the rights of the individual. Society as a whole
must be aware that research needs may sometimes cause the
interests of the community to take precedence. This awareness
is never, however, a reason for ignoring the important require-
ment that full respect be shown for the individual who, by
virtue of his or her disease, may help humanity (CCNE 2002,
Opinion No. 73).
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Some ethical considerations in
industry-sponsored clinical trials
by Tom Gallacher and Sreeharan1
“Ethics and Science need to shake hands”
Richard Clarke Cabot (1868-1939)
This statement becomes truer with the passage of time. The
pharmaceutical industry perspective on biothics derives from
the constant need to integrate ethical principles with rapidly
evolving scientific and medical advances and hence new inves-
tigational paradigms.
The primary societal responsibility of the pharmaceutical
industry is to discover and develop new drugs, vaccines and
diagnostics. Biomedical research is an important element of
global strategies to improve health and healthcare. However,
taking account of patient needs in the context of research
ethics is also critical in determining industry research and
development (R&D) strategies. The time taken from initial
discovery to product launch can be several years and the esti-
mated average cost of development can be of the order of 800
million euros or more. 
As well as being a long, costly process, pharmaceutical R&D is
complex and risky. For each compound that is eventually
licensed for sale, several thousand will have been identified
and discarded along the way. In the course of a development
programme there are many check points, both in the pre-clin-
ical stage and once the potential product has progressed to
evaluation in humans. Throughout this lengthy process,
assessments of the risk/benefit profile are made at frequent
intervals, with the possibility of the project being terminated at
any stage if an unfavourable ratio is detected.
The development programme is conducted within a very
demanding nationally and internationally regulated framework.
The need for product safety to be paramount has produced a
regulatory environment for pharmaceuticals that is one of the
most demanding of any industry. In addition to the external
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scrutiny of government regulatory agencies during develop-
ment and following submission of an application for a product
licence, most research-based pharmaceutical companies have
some form of safety board charged with the overview of
human safety issues associated with the development of
potential new products. Typically this body will be chaired by
the chief medical officer and its membership will comprise
senior physicians with a facility to involve, either routinely or
as needed, independent, external experts. 
Innovative new medicines, by the very nature of their targets
being novel, may not deliver their full potential to healthcare
and patient needs at the time of introduction of the product.
This is one important reason why pharmaceutical companies
continue to sponsor clinical trials after products are initially
launched. In many instances, additional uses emerge from this
post-marketing stage of research; for example, the role of ACE
inhibitors in the treatment of heart failure, following their initial
introduction as anti-hypertensives. Hence industry sponsorship
of clinical research can often continue over the majority of the
product life cycle. 
In order to improve this prospect, the industry exercises a pre-
cautionary approach when conducting clinical trials, with a
high level of internal scrutiny and quality control in addition
to the scrutiny of external regulatory agencies. This paper pre-
sents a perspective on how industry approaches some of the
ethical issues associated with clinical trials which it sponsors. In
developed countries, industry-sponsored clinical trials account
for the majority of all clinical trial activity. 
The ethical justification of biomedical research involving
human subjects is the prospect of adding to scientific knowledge
which will enhance healthcare. Additionally, to be ethical, the
investigation must be designed in a scientifically robust manner
and conducted in a way that ensures respect for the dignity
and safety of participants as judged morally acceptable, relative
to international norms and by the locality/communities in which
it will be conducted. 
There are a number of international instruments on the ethics
of medical research of which the Nuremberg Code, the Belmont
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Report, the UN Declaration of Human Rights and the World
Medical Association’s Declaration of Helsinki in particular con-
tribute to the key principles that are widely accepted by medical
researchers including the pharmaceutical industry as research
sponsors. The key principles are complemented by other dec-
larations and several operational-level guidelines. From an
industry perspective, the ICH guidelines on Good Clinical
Practice (GCP) – together with relevant sections of the US Code
of Federal Regulations and other national or regional regulations
– have particular relevance, as they set standards with which
industry-sponsored research has to comply. 
Recognition of the need to respect the dignity of trial participants
and protect their safety are fundamental objectives for all clinical-
research sponsors (including industry) and investigators.
Ethics-related areas or issues that are reviewed in this paper
are :
• the role of ethics committees in overseeing clinical research;
• the informed consent process;
• conflict of interest and payments to investigators and trial
participants;
• research in populations/communities with limited resources.
Role of ethics committees
The mechanism that is universally used to assess adherence to
the fundamental ethical norms is that of independent ethics
committees (in some countries referred to as independent
review boards). Ethics committees have independent decision-
making authority and the responsibility to act in the interests
of research participants. Proposed clinical trial designs and
implementation plans (in the form of protocols) must be sub-
mitted to an ethics committee for review before clinical trials
can commence. The ethics committee has the right to endorse
a proposed clinical trial, or require changes, or disapprove it.
Confirmation of their favourable opinion is a required step
before clinical trials can commence. 
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There are well-defined considerations against which the ethics
committees evaluate the protocol and operational aspects of
the trial. Two key elements are:
• the information to be provided to the potential participants; and
• whether there could be inducements that might unduly
influence either the investigators or the potential participants. 
One of the obligations of ethics committees is to assess the
adequacy of the information to be provided during the informed
consent process. This needs to be done on a case-by-case basis,
relative to the nature of the drug and/or test procedures
involved. There is no “one size fits all” set of information for
informed consent statements, although some of the information
will be common to any trial situation. 
A number of international guidelines as well as national
laws/regulations provide details of what should be explained
in the information to be provided to potential participants.
Among the essential elements are :
• clear communication that the trial involves research (including
any aspects that are experimental);
• the purpose of the trial;
• whether and to what extent participants will be assigned to one
of several treatment regimens;
• reasonable foreseeable risks or inconveniences;
• reasonably expected benefits – if none, participants must be
made aware of this;
• alternative treatments that may be available;
• any anticipated reimbursement of expenses or payments for
participation;
• that participation is voluntary and refusal or withdrawal
from the study will not affect their future healthcare.
More extensive lists of elements to be considered for inclusion
can be found for example in ICH GCP, the US Code of Federal
Regulations and the CIOMS International Guidelines for
Biomedical Research Involving Human Subjects.
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Any proposed deviation from full disclosure of study procedures
must be explicitly identified to the ethics committee and be
endorsed; for example, the purpose of tests performed to mon-
itor participants’ compliance with the protocol. Similarly, if the
normal requirement that participants provide personal consent
might not be possible, as in emergency situations such as
stroke or head trauma, the proposed alternative process must
be brought to the ethics committee’s attention so that they can
consider whether it is justified and advise accordingly.
Given the critical role of ethics committees in the overview of
clinical trials, the pharmaceutical industry recognises the need
for sufficient, well-trained, well-resourced committees capable
of thorough protocol review. Whenever possible structured,
sustainable initiatives to develop increased review capacity
need to be encouraged.
Informed consent process 
The original concept of consent to medical care related to a
doctor’s obligations to obtain the patient’s permission before
intervening medically. “Consent” has evolved to “informed
consent”, reflecting the increasing emphasis on patients being
informed about risks. In the context of medical research,
informed consent takes on additional meaning and complexity
because the individual is invited to participate in a research
project which, to varying degrees, is experimental. In this setting,
it is considered necessary to ensure that potential participants
are adequately informed of potential risks and benefits of the
trial. 
In their role as clinical-trial sponsors, pharmaceutical compa-
nies accept that they have a duty to ensure that investigators
establish a process for obtaining individual, informed consent
from potential participants in a manner that is appropriate to
the trial circumstances, for example the medical condition
being treated, the patient population and any relevant cultural
factors. To meet these requirements the person obtaining consent
has to be sufficiently knowledgeable about the trial to be able
to deal with participants’ questions. To ensure that this will be
the case, industry sponsors will address this area within the
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overall training/briefing of investigational site staff that is under-
taken prior to the trial starting. This will extend to knowledge
about the trial protocol, product information and procedural
issues, including adherence to Good Clinical Practice (GCP)
requirements and safety monitoring and reporting obligations. 
Consent should be sought only once it is clear that the potential
participant has received and understood the information relating
to the trial (as endorsed by the ethics committee), and has consid-
ered the options. There must be no undue influence. Both
before and during the trial there should not be any obstacles
that could restrict the opportunity for participants to have
questions answered/clarified.
Individual, informed consent must be documented and, unless
there are circumstances that have been deemed justifiable by
the ethics committee, documentation will be by way of a consent
form personally signed by each participant. Circumstances in
which it might be justified to document consent in an alterna-
tive manner could be where a participant is unable to read. In
this scenario an impartial witness should be present during the
consent process in order to sign the consent form, thereby
attesting that the trial-related information was accurately
explained, that it was apparently understood by the participant
(or their legally acceptable representative) and that the partici-
pant (or legally acceptable representative) gave their consent
voluntarily.
In the case of trials involving children who by law are not able
to “consent”, agreement to participate must be by a parent/
guardian/legal representative of the child. Also, when age and
mental comprehension allows, the assent of the child should be
obtained following an explanation of the trial in terms relevant
to their comprehension.
Conflict of interest and payments to investigators and trial
participants
The issue of payments both to investigators and trial partici-
pants continues to be controversial. In the case of payments to
research participants, views range from “it is never ethical” to
“ethically acceptable provided the amounts do not constitute
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inducement”. Industry is increasingly sensitive to the possibility
that ethics committees and others may consider any payments
as potential inducements. This is therefore an area where the
ethics committee is in the best position to make an objective
assessment as to whether the level of proposed payment is
appropriate and unlikely to induce participation for economic
benefit. These are not always easy judgments to make and the
need for knowledge of local circumstances is another reason
why ethics committees are the appropriate forum to assess this.
With regard to financial and other influences on those involved
in clinical trials, different considerations apply in the case of
investigators/researchers – if they receive payment – and in the
case of participants.
Payments to investigators/researchers
When sponsor organisations agree with investigators that they
will participate in the conduct of a clinical trial, it is entirely
reasonable that they should be reimbursed for the services
that they contribute in conducting the study, including any
reasonable personal expenses such as travel, with the proviso
that any payments do not create a personal conflict of interest
and that they satisfy the criterion of being in accordance with
“fair market value”.
Payments to researchers and/or their institutions must be
formally agreed and documented. There should be a clear
understanding as to the purpose of the overall payment –
salaries of research workers, technicians and nurses, administra-
tive support, equipment purchase or hire, institutional overhead
costs, attendance of research staff at scientific meetings for
study related activities. 
Payments should be commensurate with the time and effort
which will be required, which means application of the concept
of “fair market value”. In the context of pre-enrolment assessment
of potential participants, payments should not exceed the cost
of assessing participant’s suitability plus any associated
expenses.
As already identified, this is an important aspect of the informa-
tion to be assessed by the ethics committee.
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Payments to the study participants
There is a long tradition that both patients and healthy volun-
teers for non-therapeutic studies are motivated by a sense of
altruism and a desire to help society at large by contributing to
the advance of knowledge. Despite this, it has been the prac-
tice to at least reimburse participants’ “out-of-pocket” expenses
and sometimes to pay for their participation. Different situations
justify different ways of dealing with the issue of payments to
participants. The assessment of what is appropriate in a given
situation is again within the remit of the ethics committee,
which must decide if the reimbursement and/or payment
offered constitutes an undue inducement.
In the case, for example, of pharmacology studies that will offer
no therapeutic benefit to participants, and which will some-
times involve intensive monitoring, it is accepted as reasonable
that participants should be paid for the inconvenience and
possible discomfort in addition to the reimbursement of any
expenses incurred, such as transport costs. These reimburse-
ments are designed to eliminate barriers to participation by
returning the economic circumstances of participants to what
they would otherwise have been. To avoid potential participants
volunteering against their better judgment, payment should
not be based on perceived exposure to risk. 
In the case of studies that involve patients who will have an
opportunity for therapeutic benefit, there are various poten-
tially motivating factors that need to be considered in order to
minimise the risk of undue inducement. For example, the
requirement to consent should only be discussed relative to a
specific trial protocol – not as consent to participate in research
in a generic sense, followed by enrolment into a specific study
that might provide access to a potentially beneficial treatment.
For some patients it is undoubtedly the case that the opportu-
nity to participate in a clinical trial will be seen as resulting in
more detailed medical monitoring and supervision. In present-
ing the opportunity to participate, it is important that the
prospect of improved care is not offered in a way that consti-
tutes an inducement.
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It is also important to minimise the effects of both the patient’s
loyalty to their doctor or the “power dynamics” of the doc-
tor/patient relationship as factors that could unduly influence
patients to decide to participate. There are two important assur-
ances that must be communicated to potential participants :
• the patient is entirely free to decline to participate – this is
their right ;
• a refusal to participate will be accepted, and medical care will
then continue in exactly the same way as though participation
in a trial had not been considered.
A related issue is that of advertisements for participants. In
countries where this is allowed, it is essential that applicable
stipulations are followed. The advertisements should be con-
structed as an information item, not as an encouragement to
participate. All proposed advertisements (print, audio or audio-
visual) must also be submitted to the ethics committee for
review prior to use, which provides a mechanism for indepen-
dent scrutiny of this aspect.
Both with respect to payments to investigators/institutions and
to trial participants, the role of the ethics committee is critical
in assessing whether or not either form of payments might
constitute inducement or conflict of interest. In doing so it
might be necessary to also consider (in the case of potential
participants) their likely medical and economic status together
with any relevant cultural issues. The multifactorial nature of
such an assessment for a particular trial means that it is not
possible to have a “one size fits all” set of payment levels for all
trials – even at a national level.
Clinical trials in populations with limited resources
In some instances it is claimed that pharmaceutical companies
(and other sponsor organisations) have exploited the vulnera-
bility of populations in resource-poor, developing countries in
order to expedite global development programmes for products
that will not become available to the populations of the
resource-poor countries, or carry out research that would not be
sanctioned in the country where the sponsor organisation is
based.
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There is now a high level of awareness that proposals to con-
duct clinical research in such settings have to take several key
factors into account from the earliest consideration, for example :
• Is the research programme compatible with and responsive
to the health needs and priorities of the population in which
it is proposed to be conducted?
• Will the outcome (product or information) become available
for the benefit of the host community/country?
• Is the research conducted to internationally accepted ethical
standards?
• Will the research contribute to local infrastructure or capa-
bility development?
When sponsors consider proposing that clinical research pro-
jects should be conducted in areas with limited healthcare
resources, it is therefore necessary to investigate the extent to
which the project aligns with local priorities, and the prospect
of meeting the factors such as those identified above. Local
health priorities will be centred on diseases of the developing
world and there is increased recognition within industry that
ways must be found to make full use of existing products as
well as develop relevant new products for these diseases. As
part of its social contract industry is increasingly involved,
either on its own or in partnership with the public sector, with
R&D into diseases of the developing world.
Proper assessment of the issues will often be difficult and time-
consuming, as it must involve relevant local stakeholders.
According to specific circumstances, this might need to
include relevant government agencies/departments, local
health authorities, representatives of the communities that
might be involved, potential investigators, representatives of
concerned scientific and ethics groups, and other non-govern-
mental agencies. Experience has shown that the most effective
way to achieve this is on a partnership basis, through engage-
ment of the sponsor(s) with the relevant parties.
Consultation needs to cover all aspects of the relevance of the
research, its feasibility relative to the local healthcare infrastruc-
ture and any interventions needed to make it viable, confirma-
tion that local ethics review capacity exists, what the healthcare
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provision for research participants will be after the trial and
which parties will be responsible for these healthcare provi-
sions. The general standards of conduct that should apply in
such projects will be the same as for clinical trials in developed
countries. This consultation process might identify opportunities
for capacity building associated with a clinical trial and, as in the
case of the trial itself, any specific capacity-building activities
that are to be pursued should be agreed with the relevant local
stakeholders.
The longer-term availability of the product (or information
generated) is also an important aspect of the early stage con-
sultation. This is a potentially complex issue and can only be
determined on a case-by-case basis. It needs to take account of
the projected costs of the product relative to the healthcare
system and its capacity to provide the product. At this stage,
cost projections may only be a provisional estimate due, for
example, to the early stage of development or the unknown
outcome of planned scale-up of manufacturing processes.
When, following initial consultation and feasibility assessments,
it is proposed to progress further, all the information from
these preliminary consultations should be made available to
the local ethics committee considering the proposed project so
that all relevant factors are considered. If it is clear that the
outcome of a successful programme is not going to be reason-
ably available to benefit the host country once the overall
development programme is completed, it is unlikely that there
is an ethical justification to conduct the research in such loca-
tions. If it is considered that in exceptional circumstances such
a proposal can be justified, its acceptability must be endorsed
by the local ethics committee.
It will be clear from what is involved in assessing the feasibility
of clinical research projects in developing countries that the
best prospect for success with such projects is for them to be
conducted on a partnership basis.
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Women in biomedical research
by Outi Leena L. Hovatta
Women as study subjects
Requirements for clinical studies
The ethical principles regarding all clinical studies are the
same for female and male study subjects. They are clear from
the Declaration of Helsinki. Human dignity has to be respected
in all medical research. The benefit to the individual is always
more important than that to society or science. All the possible
risks of a research project have to be avoided as much as pos-
sible. A study subject can only be exposed to procedures from
which the expected benefit is greater than the possible risk or
harm. The study subject has to be given information regarding
the aim of the research, how the procedure is to be carried out,
and the benefits and possible risks and harm associated with a
procedure.
The information has to be given in such a way that the study
subject understands it and is capable of giving her or his consent,
being aware of the benefits and risks. Documented consent
from the study subject is required. An exception can only be
made for authorising the participation of a person not able to
consent if the results of the research have the potential to pro-
duce real and direct benefit for her or his health.1 The study
subject always has the right to withdraw her/his consent.
Information regarding this right has to be given to her/him.
Women and pregnancy, and the effects of treatment on the
foetus
Clinical studies involving women as study subjects are very dif-
ferent from those involving only men, because women of fertile
age may be pregnant or could become so. 
Pregnancy is a very special period as regards medical treatment
and research. The possible effects of pharmaceutical and other
substances on the foetus are a major concern. Such concerns
became real after the disasters that happened with thalidomide
and diethylstilbestrol, both of which were used as medication
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for pregnant women. Animal experiments had not indicated
that these substances cause abnormalities during early human
development, and large numbers of malformed infants were
born before the causes were detected. That individuals
exposed to diethylstilbestrol during foetal life can develop can-
cers in later life was, indeed, a most unpleasant complication of
such treatment. 
These unfortunate events have resulted in strict national and
international regulations on how substances have to be stud-
ied before they can be used in clinical research and treatment,
and there are particular requirements for tests for the possible
harmful effects of substances on the foetus. In the European
Union, these requirements are presented on the EU website
and have been harmonised with corresponding requirements
in the USA and in Japan. There are detailed guidelines and
requirements regarding how to test the safety of a substance
before any clinical trials are proposed. There are also special tests
regarding reproductive toxicity that have to be performed.
The methods include certain numbers of tests on pregnant ani-
mals, and tests concerning the normality of the offspring.
Mouse embryos can be cultured in vitro, and the effects of sub-
stances studied in such circumstances. There are also tests that
can be performed in cell cultures.
In spite of the available tests, the possibility still remains that
cell culture and animal tests will not reveal the possible effects
on a human embryo and foetus. There are often differences
between species, and in some respects human development is
different from that in other species, including non-human pri-
mates. Human embryos cannot be used in toxicological tests,
and mouse embryos may react differently. Hence, the concern
remains that a pharmacological or chemical substance may
cause disturbances in human embryonic or foetal development
in spite of normal results in animal tests.
In addition to international requirements, each country has
national laws that have to be adhered to before the statutory
authority can give permission to carry out a clinical trial. In all
countries in the European Union and in most other countries,
ethics committee approval is needed before any study involving
Ethical eye – Biomedical research
human individuals can be initiated. International biomedical
journals do not publish articles based on studies that do not
have ethics approval. These requirements have to be met in all
studies involving human individuals, both women and men.
Concern regarding the possible effects on the foetus has
resulted in extreme care in giving any medicines during preg-
nancy. There are lists of medicines that are known to be safe,
and lists of medicines that are known to cause foetal abnor-
malities. These lists are available to medically and pharmaco-
logically trained personnel, and also for other people. However,
the list of medicines that have not been studied at all during
pregnancy is much longer than the two other lists.
The possible influences of the vast majority of pharmacological
substances on foetal development are unknown. Knowledge
only accumulates from situations in which a woman has taken
the medicine not knowing that she is pregnant, or in which the
nature of her disease has demanded treatment in spite of the
pregnancy. The general recommendation is to avoid medicines
during pregnancy.
This strategy appears to be wise. On the other hand, it means
that women often do not receive optimal treatment of their dis-
eases during pregnancy. In many cases this is harmful to the
woman’s health, and may cause unnecessary suffering. New
methods to study the effects of pharmaceuticals and chemicals
on embryonic development in humans are definitely needed.
There is one new option to study the effects of various substances
on early human development. Culture of human embryonic
stem cells has been possible since 1998, when Thomson et al.
reported their first permanent human embryonic stem cell
lines (Thomson et al. 1998). Such cell lines have their origin in
certain cells of human embryos five to seven days after in vitro
fertilisation, this being the most effective treatment for invol-
untary childlessness. Now and then there are embryos that
cannot be used in infertility treatment, usually because of poor
quality. There are also embryos that have been frozen after the
family has achieved the desired number of children after earlier
treatments. These embryos are normally discarded. 
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Cells can be taken from the inner cell mass of such embryos
before they are discarded. One fifth of these supernumerary
embryos* reach the so-called blastocyst* stage when cultured up
to the age of five to seven days. From 10-15% of such blastocysts,
the cells begin to grow in certain culture conditions, and they
form the so-called cell lines. The difference between these early
non-differentiated embryonic cells and more specialised cells
is that the embryonic cells can divide and form new similar
cells indefinitely, while specialised cells can only survive for
certain numbers of generations. This means that one embryonic
stem cell line can in optimal conditions form enormous numbers
of cells.
Because these cells are the progenitors of all the cell types and
tissues in the body, there are expectations that they can be
used in cell transplantation in order to cure many severe dis-
eases. However, being early human embryonic cells they
might also be used in testing the effects of various substances
on early human embryonic development. Such tests could be
carried out in cell cultures. The cultures might be much more
reliable than animal tests, and large numbers of animal exper-
iments might become obsolete. But above all, the use of
human embryonic stem cells would, in this respect, greatly
benefit women’s health. 
There are, however, differing opinions as regards the ethical
acceptability of the use of human embryonic stem cells. In
this field, there is real plurality in Europe. The European Group
on Ethics (EGE)1 for the European Parliament and European
Commission has prepared a thorough report regarding the
ethics of working with human embryonic stem cells.
Pregnant women as study subjects
Pregnancy can be regarded as a vulnerable situation for both
the foetus and the mother. Hence, more protection is neces-
sary for pregnant women than non-pregnant ones. This is also
reflected in laws regulating medical research. In Finland, for
instance, the law regarding medical research (9.4.1999/488,
www.finlex.fi) regulates studies in which pregnant women can
be subjects of medical research, and at the same time it regulates
the conditions under which children or mentally impaired
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individuals can be recruited to become study subjects. A preg-
nant or breast-feeding woman can be a study subject only if
the same scientific results cannot be obtained with non-preg-
nant subjects. The research project has to benefit the health of
the woman, or the infant to be born, or it has to benefit the
health of her relative(s) or other pregnant or breast-feeding
women, or foetuses or newborn infants.
It is extremely important for women that as much as possible is
known about the physiological and psychological events during
pregnancy. There are very many changes in the human body
during pregnancy, and they can only be measured during preg-
nancy. Pregnancy-related diseases can, of course, be studied
only in pregnant women. 
Numerous standard laboratory tests give different values during
normal pregnancy, and the values change during the course of
pregnancy. Many of them have been systematically studied by
taking samples from pregnant women. However, there are
some parameters that have still not been properly characterised,
and they can cause serious concern among pregnant women.
This is particularly the case with some rare diseases that may
occur during pregnancy. This is very unfortunate and can result
in poor treatment or unnecessary treatment of pregnant women.
Obstetric disorders, related to pregnancy itself, are well-known
and studied, and they have not been causing major concern. 
Differences between female and male study subjects 
The fear of embryonic effects also has other consequences on
women’s treatment. Differences between men and women in
the effects and metabolism of many pharmaceuticals are
poorly known, because it has been easier and safer to carry out
clinical trials on men only. Women aged between 15 and 50 have
often not been included because of the possibility of preg-
nancy, which is difficult to exclude completely. In addition,
contraceptive pills, for instance, may influence the metabolism of
other medicines. Women who are younger than 15 are children,
and they cannot represent adult women as study subjects.
Women over 50 are post-menopausal and their bodies again
behave differently in many respects. The present information
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regarding the way in which many pharmaceuticals behave in the
female body is based on extrapolation of what has happened in
male study subjects. However, there is existing information
that there are differences.
The hormonal variations during the menstrual cycle also make
women different from men as study subjects. Different concentra-
tions of many hormones, such as oestrogen and progesterone,
influence many other common test parameters. There is a vast
amount of literature in which this fact has not been taken into
account at all. In recent years most clinical scientists have been
aware of this fact, and they have been taking samples in both
the follicular phase (time before ovulation) and the luteal
phase (time after ovulation) of the cycle. When interpreting
research results one has to be careful in this respect.
The effects of contraceptive pills on the female body, and the
co-effects with other medicines, have been studied relatively
thoroughly because they are regulated pharmaceutical sub-
stances. The same holds true as regards hormonal replacement
therapy in post-menopausal women. For the time being there
remains much to be known, but there are large clinical and
epidemiological studies going on. These are of extreme impor-
tance for women’s health.
Pregnancy also offers some health benefits to women. The
probability of certain cancers arising is somewhat lower among
women who have been pregnant. Some protection is obtained,
for instance, against cancers of the ovary, uterus and the
breast. Epidemiologists, in their large studies, take into account
pregnancies as a contributing factor in various diseases. 
It is not possible to study women’s health and diseases, and to
develop optimal treatment, without having women as study
subjects. Pregnancies are an integral part of women’s life and
health, and it is of the uttermost importance to study pregnancy-
related diseases with pregnant women as study subjects. 
Women as scientists
Women are contributing to biomedical research not only as
study subjects. Their role as researchers is, of course, most
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important. It is a natural thought that 50% of biomedical sci-
entists would be women, if half the population are female. This
is not yet the reality in many European countries, but efforts
are being made to achieve it. Getting the female half of the
population actively involved in research has been mentioned
in European science reports (EU 2002 ; EU 2003).
Having female scientists in leading positions is important
when thinking of the problems that still exist in women’s
health, and equal treatment. Female scientists are more likely
to pay attention to these particular problems. 
The proportion of female university students has been growing
everywhere. In many countries, including Finland and Sweden,
there are now more female than male graduates from the uni-
versities in the fields of medicine and biology. Among students
and graduates in technical universities the proportion is still
low, but it is growing. This could mean that in the future the
proportions among leading scientists may be equal. Active fol-
low-up and intervention, however, are necessary because there
are other factors apart from the numbers of trained persons
who contribute to positions in the research community.
There are statistics regarding the proportion of female professors
in universities in different countries. In the countries of the
European Union, the proportion of women is still much lower
than that of men. There have been wide discussions about this
in Sweden, with attempts to actively increase the proportion,
which at present is 12%. In Finland, progress has been faster,
21% of professors being female. 
The main reason for the successful development in Finland has
probably been the very active education of biomedical scientists,
which was initiated in the mid-1990s (Academy of Finland
2003). The Finnish Ministry of Education decided to create a
graduate school system, and the first four-year schools started
in 1995. The amount of governmental spending on PhD edu-
cation was considerably increased, while additional funding
for the students also came from other sources, such as private
foundations and industry. 
During this programme, the proportion of PhD degrees
awarded to women rose to 46% (including technology). In
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medicine, half of the students achieving PhD degrees in 2003
have been female. In the public sector and in the universities,
women accounted for over 40% of the research staff in 2001,
but in business and industry the figure was only 20% (Academy
of Finland, 2003). Hence, governmental funding of education
and research appears to be a good way to increase the proportion
of female scientists.
Governmental funding does not alone guarantee that it is fairly
distributed. Wennerås and Wold (2000) analysed the propor-
tions of female and male recipients of grants from the Swedish
Research Council. They found significant under-representa-
tion of the female applicants among those who were awarded
grants. They analysed the scientific work on which the appli-
cations were based, and found that a female applicant had to
have a much higher total impact factor score in her preceding
publications than her male colleagues in order to obtain a grant.
The difference was comparable to the impact of one article in the
journal Nature. This appears to happen in other countries too
(Mavis and Katz 2003).
Since the study by Wennerås and Wold, the Swedish Research
Council has actively paid attention to equity and, as a conse-
quence, the proportion of new grants to women increased from
30% in 2000 to 45% in 2003 (www.vr.se). The proportion of
female members in the evaluating committees increased from
10% in 1996 to 40% in 2002. This certainly has had an impact
on female scientists’ work in Sweden. 
There are others factors to consider when thinking of optimal
working conditions for female scientists. High quality day-care
facilities should be available for families, hence allowing young
parents to be optimally educated in research. This would also
help women to have their children at the physiologically opti-
mal age. Optimal day-care would help young parents to be
employed without the threat of discrimination. When award-
ing research grants, the time spent on maternity or paternity
leave should be excluded from research time when scoring the
productivity of individuals. 
Discrimination against pregnant women when appointing
people to posts is already illegal in most European countries,
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but there are still hidden attitudes that influence the possibility
of a pregnant woman being appointed. Local, national and
international women’s networks are still of great importance
for women’s positions in science.
The ethical principles regarding study subjects are similar for
women and men. The main concern regarding women as study
subjects is the possibility of pregnancy and the effects of the
trials on foetal development. The risks of pharmaceuticals and
chemicals have been recognised, and there are harmonised
international regulations concerning how these substances
have to be tested before any trials. The concern over foetal
effects is why pregnant women particularly are a very specific
group of study subjects. 
There are clear restrictions, which, however, have impaired the
gathering of knowledge of certain aspects of women’s health. It
has been easier to have male study subjects. Female scientists
are more likely to promote the issues particularly important for
women. Women are under-represented in leading positions in
research. All possible ways to promote the careers of female
scientists are extremely important. 
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Biomedical research
in Europe

Germany: current legislation
by Jochen Taupitz
The following chapter describes the legal situation in Germany
as of August 2003. Since Germany has not yet acceded to the
Council of Europe’s European Convention on Human Rights
and Biomedicine (the Bioethics Convention), its provisions are
not considered in the following chapter, although significant
differences are noted.
Applicable rules of law
Germany has no comprehensive law on research or on the pro-
tection of patients or persons used in scientific research.
Rather, German law attempts to cover certain relatively easily
definable risks in biomedical research with special sets of rules
that supplement the general provisions of civil, criminal and
public law.
In Germany, legislative power is divided between the Federation
and the Länder, but most of the regulations on the dangers of
biomedical research are federal. The Land regulations, on the
other hand, relate principally to specific professions, due to the
fact that the Länder have exclusive competence to legislate on
the exercise of professions, especially the healing professions.
Special federal regulations on research on human beings
The following are the main areas regulated at federal level:
• the clinical examination of drugs (Sections 40ff. of the Drugs
Act, in the version of 11 December 1996);1
• the clinical examination of medical products (Sections 20ff. of
the Medical Products Act, in the version of 7 August 2002);2
• the hyper-immunisation of test subjects (Section 8 of the
Transfusion Act, in the version of 1 July 1998);3
• research with radioactive substances and ionising radiation
(Sections 33ff. of the Radiation Protection Order, in the version
of 20 July 2001);4
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• the import and use of human embryo stem cell lines in the
Stem Cell Act of 28 June 20021 – although the Protection of
Embryos Act of 13 December 1990,2 which protects the
embryo all but absolutely until its nidation in the uterus, also
imposes considerable restrictions on research on germ cells,
germ line cells, embryos and embryo cells.
Land regulations on exercise of the medical profession
The Länder also have legal regulations, particularly on the
exercise of the medical profession (including research), which
apply in cases where the above more specific regulations do not.
In some cases, they have separate laws on doctors, dentists,
pharmacists, etc. In other cases, they have laws on professional
associations, covering several health professions. All of these
Land laws give professional associations under public law
(membership of which is compulsory for persons exercising
the professions concerned) the competence to issue professional
codes in the form of public-law regulations. 
Some of these regulations also contain rules on biomedical
research. They stipulate, for example, that an ethics committee
must be consulted before an experiment begins (cf. Article 15 of
the Model Professional Code, produced by the Federal Medical
Association as a basis for the codes of the Land medical associ-
ations).
The World Medical Association’s Helsinki Declaration has also
had a powerful influence on the profession, although it has no
legal force, and compliance is voluntary. Moreover, provisions
concerning research on persons incapable of giving consent in
the new version (2000) have been severely criticised in Germany.
Finally, mention should be made of the law applied to univer-
sities, which imposes on their members public-law obligations
of varying scope in the matter of research on human beings.
General regulations 
Outside those areas of practice where special laws apply, it is
largely unclear how research should be assessed in German
law. It is often argued that these special laws merely express
general legal principles, and can thus be applied mutatis
mutandis in areas they do not specifically govern – but this does
not explain the reason why the legislature has simply enacted
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(non-uniform) rules on a few areas, instead of formulating gen-
eral legal rules on research on human beings, or at least rules
applying to all the specialised areas concerned. A better
approach would be to try to lay down legal principles for med-
ical research on human beings (which might also have been
embodied – at least partially – in the special laws).
Nonetheless, research conducted outside the purview of the
special laws does not take place in a legal vacuum. The legal text
that outranks all others is the Basic Law (Grundgesetz, the
German Constitution) – especially where the fundamental rights
of patients and research subjects, and of researchers, are con-
cerned. Most legal experts take the view that the fundamental
rights protected by the Basic Law are not directly applicable to
research conducted by non-state authorities, since the Basic
Law is concerned with the individual’s rights vis-à-vis the state
(and not vis-à-vis other individuals).
However, those fundamental rights also shape and influence
the rules of civil law, and so have an indirect effect on legal
relations between private individuals. In addition to protection of
human dignity (Article 1, paragraph 1 of the Basic Law), the basic
rights most relevant to patients and research subjects are the right
to free development of personality, including general personality
rights (Article 2, paragraph 1), the right to life and physical
integrity (Article 1, paragraph 2.2) and the right to self-determi-
nation derived from the others (Article 2, paragraph 2.1 in con-
junction with Article 1, paragraph 1). The rights most relevant
to researchers are freedom of research (Article 5, paragraph 3),
which can be limited only by the basic rights of others or by other
constitutionally protected interests, freedom to exercise a pro-
fession (Article 12, paragraph 1) and general freedom of action
(Article 2, paragraph 1).
As for ordinary law, the general law of contract and tort, and
general criminal and administrative law, also apply to biomed-
ical research. Specifically, this means that offences involving
bodily harm, as defined in Article 823(1) of the Civil Code and
Articles 223ff. of the Criminal Code, are relevant – as is the
protection of general personality rights (included under “other
rights” in Article 823(1) of the Civil Code) in civil law. Also
relevant is liability for violations of protective laws, under
Article 823(2) of the Civil Code.
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Other applicable provisions include the rules on doctors’ oblig-
ation to maintain secrecy and the data-protection regulations
of the Federation and the Länder, some of which have regulations
which make it easier to use data for research than for other
purposes.
Research institution guidelines
The guidelines of the major German research institutions (for
example, the German Research Foundation) also do much to
ensure that the research they fund respects certain quality
standards, and that patients and research subjects are protected.
For example, the German Research Foundation will not fund
research on human beings without the consent of of an ethics
committee.
Requirements for biomedical research on human beings
Separation from clinical practice
Biomedical research and clinical (medical) practice must be
separated. Clinical practice, in which the doctor–patient rela-
tionship is regulated partly by medical association statutes, but
mainly by judge-made law, comprises standard and individual
treatment. Both are exclusively focused on the individual
patient’s well-being, but one is newer than the other. On the
other hand, biomedical research – as well as being innovative –
involves systematic, research-orientated planning and systematic
evaluation of results. 
In other words, it also sets out to extend medical knowledge
beyond the individual case, that is, to serve the common good.
Since patients (people who are actually suffering from the dis-
ease on which research is being done) and research subjects
(people who are not suffering from that disease) are partly sub-
jected to measures during the research that do not benefit
them directly, and are often exposed to certain risks in the
process, it is recognised that they need special protection.
Basic types of biomedical research
Biomedical research includes both therapeutic research and
scientific experiments. As well as the advancement of scientific
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knowledge, therapeutic research is designed and intended to
improve the health of the participating patient. It is thus both
possible and necessary to make an assessment, including not
only the gains in scientific knowledge, but also – and above all
– the ratio of benefits (expected) to risks (feared) for the
patient. Scientific experiments, on the other hand, seek merely
to add to scientific knowledge, and this means comparing two
things – general gains and individual risks – which are not
really comparable.
The (admittedly fluid) distinction between therapeutic
research and scientific experiment is important in several
areas, of which the chief are :
• Risk/benefit analysis: In the case of a measure taken in the
patient’s direct interest, a very high level of risk may be
acceptable (for example, life-threatening cardiac surgery,
when this is the patient’s only hope). On the other hand, a
measure that mainly or solely benefits the community
should be attended by minor risks only.
• Presumed consent: Consent may indisputably be presumed in
the case of measures which are objectively in the patient’s
interest, but not in the case of experiments that simply con-
tribute to scientific knowledge. This is why some authors
take the view that scientific experiments cannot be based on
presumed consent. However, this is probably going too far.
The most that can be said is : the less clearly a measure is in
the patient’s objective interests, the stronger must be the
reasons for presuming consent. 
• Research with people incapable of giving consent: There is con-
siderable disagreement as to whether scientific experiments
with people incapable of giving consent should be totally
banned, or whether experiments of merely possible benefit to
the person concerned, and experiments that do not benefit
him/her, but will – it is hoped – benefit others in the same group,
may sometimes be permitted. The Drugs Act (Arzeimittelgesetz)
and the Medical Products Act (Medizinproduktegesetz) permit
research (only) with diagnostic and prophylactic drugs and
medical products, including research on healthy minors
(that is, research with possible benefits only for the person
concerned), but not on adults incapable of giving consent.
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Freedom of research: protection of patients and test subjects
In principle, Article 5, paragraph 3 of the Basic Law guarantees
freedom of research, and thus of biomedical research as well. In
other words, research requires no special legal permission.
However, it is clear from the rules outlined above that there are
– in the interests of patients and research subjects – numerous
restrictions on research. However, because there are, as we
have said, so many regulations, there is no fixed catalogue of
protection criteria, applying equally to all research projects.
Moreover, the content of the various regulations sometimes
differs considerably. The following is thus a mere overview.
Protection criteria can be roughly divided into three groups :
objective criteria, criteria designed to protect the individual’s
right of self-determination, and procedural safeguards. Objective
criteria include risk/benefit analysis and requirements con-
cerning the qualifications of the researcher. The main criterion
concerned with the individual’s right of self-determination is
the requirement that his/her consent (or that of his/her legal
representative) must be obtained. Finally, procedural safe-
guards include the involvement of independent outsiders
(especially ethics committees) or the obligation to submit the
details to a public authority.
Overview of protection criteria
Informed consent
It is generally agreed that research involving human beings is
permissible only with the consent of the person concerned. To
be valid, consent must be informed – that is, the person con-
cerned must be given a clear picture of the nature, significance
and consequences of the measure, including any risks. Consent
may be revoked at any time with future effect. This is expressly
stated in various special laws, but the Transfusion Act probably
takes this point for granted and so does not mention it explicitly.
All the special regulations we have mentioned call for written
consent – advisable in any case for purposes of proof.
For consent to be valid, the person concerned must also be
capable of giving it. A person is capable of giving consent if
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he/she can at least roughly understand the nature, significance
and consequences of the measure, weigh up the pros and cons
and reach an informed decision on this basis. Individual cir-
cumstances must be considered here. The predominant view is
that the age qualifications which determine the capacity of
minors to enter into legal transactions (limited capacity from
the age of 7, full capacity from the age of 18), are not applicable.
In practice, this is a source of considerable uncertainty. 
If the person concerned is unable to give consent, the decision
is taken (once they have been duly informed) by their legal
representative (normally the parents for a minor, the statutory
guardian for an adult). Under ordinary family law, the legal
representative is required to consider the protected person’s
“welfare”. There is considerable disagreement regarding the
scope of this term, although the prevailing view is that at any
rate, it must not be taken to mean “physical well-being” only.
A person may also be represented by an authorised agent,
meaning someone to whom they have granted the right to
handle their affairs. However, this has rarely happened in the
field of medical research.
In the special laws, the situation of adults unable to give consent,
and of minors able or unable to give consent, is regulated in
various ways :
• All the laws allow therapeutic research but, in the case of
minors legally unable to give consent, in addition to the con-
sent of their legal representative, their own must nonetheless
be obtained.
• Both the Drugs Act and the Medical Products Act prohibit
scientific experiments with adults unable to give consent.
Their legal representative’s consent makes no difference. 
• As already stated, the Drugs Act and the Medical Products
Act allow diagnostic and prophylactic drugs, and medical
products to be tested on minors, if these drugs/medical prod-
ucts are used to detect or prevent children’s diseases, and
their use is justified, according to medical knowledge, in
order either to detect diseases in the minor concerned or to
protect him/her against them. In the case of minors legally
capable of giving consent, both the consent of their legal rep-
resentative and their own is again required.
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Informed consent is not required if, according to medical
knowledge, the research in question is justified to save the
patient’s life, restore their health or alleviate their suffering;
provided that informing them would jeopardise the treat-
ment’s success, and that no objections are discernible. Some of
the special laws cover this point expressly, but the Radiation
Protection Order and the Transfusion Act do not mention it.
Risk/benefit analysis
Consent does not always legitimise research. Rather, the risks
involved for the person concerned must be medically justifi-
able when set against the likely benefits. Unlike the Council of
Europe’s Convention on Human Rights and Biomedicine, German
law does not generally require more stringent risk/benefit
analysis in the case of research carried out for the benefit of others.
Official procedure
All the special laws provide for an official procedure for conduct-
ing research, but only the Radiation Protection Order and the
Stem Cells Act insist on prior authorisation. Under the other
laws, it is sufficient to submit the relevant documents to the
authorities or to give them notice of the project – thus allow-
ing them to prohibit it, if necessary.
Ethics committees
Under all the special laws and the law on the medical profession,
research projects must first be examined by an independent
and interdisciplinary ethics committee. However, there are
differences as to:
• whether the examination must be carried out by an ethics
committee under public law (Drugs Act, Transfusion Act, the
law on the medical profession), or whether consulting a
(registered) ethics committee is enough (Medical Products
Act, Radiation Protection Order);
• whether consultation in itself is sufficient, for example even an
advisory verdict rejecting the proposal, (Radiation Protection
Order, the law on the medical profession), or whether a positive
approval is required (Drugs Act, Medical Products Act, Trans-
fusion Act). However, under the Drugs Act and the Medical
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Products Act, research can even begin without a positive
approval from the ethics committee, if the supreme federal
authority concerned does not object to the project within
sixty days of receiving the documents;
• whether one verdict is sufficient for multicentre projects
(Medical Products Act) or whether local ethics committees in
all the areas where the project takes place must be consulted
(Drugs Act, Radiation Protection Order, Transfusion Act, the
law on the medical profession).
The Stem Cells Act established a special Central Ethics Committee
for Stem Cell Research, which is the only ethics committee
operating at federal level. In other fields, there are no central
(that is, national) ethics committees.
At present, there are no uniform procedural rules or guidelines
on the composition of ethics committees, and standardisation
is therefore badly needed.
Assessment plan
Under all the special laws, the research before the authority or
ethics committee concerned must be based on a scientific
assessment plan.
Obligation to notify unexpected occurrences
Under the Drugs Act and the Transfusion Act, the ethics com-
mittee must be informed of unexpected events.
Qualifications of clinical trial directors 
The Drugs Act, the Medical Products Act, the Radiation Pro-
tection Order and the Transfusion Act all lay down special
requirements for the qualifications of clinical trial directors :
• Drugs Act: a doctor with at least two years’ experience in
clinical testing of drugs;
• Medical Products Act: a specialised doctor with appropriate
qualifications. In the case of medical products for use in dental
treatment, there must also be a dentist or some other suitably
qualified and authorised person with at least two years’ expe-
rience in clinical testing of medical products;
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• Radiation Protection Order: a doctor who has at least two
years’ experience of using radioactive substances or ionising
radiation on human subjects, has the necessary radiation
protection expertise and can be reached at any time during
the research. An expert on medical physics must also be
involved in the planning and implementation phase ;
• Transfusion Act: a registered physician familiar with the latest
developments in this field.
Necessity or quality of research
The Radiation Protection Order, the Transfusion Act and the
Stem Cells Act lay down certain requirements concerning the
necessity or quality of research.
Under the Radiation Protection Order, there must be a com-
pelling need for the project because previous research findings
and medical knowledge are insufficient. It must also be impos-
sible to replace the use of radioactive substances or ionising
radiation with a type of examination or treatment which does
not expose the subject to radiation. Moreover, the radioactive
substances or ionising radiation used in the research must
match their purpose. It must be impossible to replace them
with other substances or applications that involve less expo-
sure for the research subject. Finally, it must not be possible, in
the present state of medical knowledge, to reduce exposure to
radiation or the activity of the substances used any further
without jeopardising the purpose of the project. 
Under the Transfusion Act, the donor immunisation needed to
obtain plasma for the production of special immunoglobulins
may be carried out only when, and for as long as, this is necessary
to ensure adequate stocks of these products, and in accordance
with the latest medical knowledge and technology.
Under the Stem Cells Act, research using embryonic stem cells
may be carried out only if it has been scientifically shown that:
• its findings will make an important contribution to scientific
knowledge and be usable either in basic research or in devel-
oping new diagnostic, preventive or therapeutic methods for
use on humans;
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• in the present state of science and technology, the questions
to be studied have already been investigated, as far as this is
possible, with the help of in vitro models using animal cells,
or animal experiments;
• the scientific knowledge hoped for from the project can fore-
seeably be obtained only by using embryonic stem cells.
Unlike the Bioethics Convention, none of the special laws stip-
ulates that there must be no alternative to research on human
beings, or expressly states that the interests of the individual
must always take precedence over the common good.
Prior safety tests 
All the special laws require the carrying-out of certain safety tests
(for instance, pharmacological and toxicological tests) before
research is conducted.
Provision for injury
Under the Drugs Act, the Medical Products Act and the Radiation
Protection Order, patients and test subjects must be compen-
sated for any injuries, regardless of whether fault is involved.
Some of those involved in the politico-legal debate insist on
compensation regardless of fault, for research out of the appli-
cation area of the special laws mentioned above.
Specific groups 
Under the Drugs Act, the Medical Products Act and the Radiation
Protection Order, research may not be carried out on persons
detained in an institution by order of a court or public authority. 
The Medical Products Act and the Radiation Protection Order
contain special protective rules on research during pregnancy
and lactation.
When research using persons unable to give consent is permit-
ted by the special laws (see page 113) or is generally considered
to be acceptable, there is still a requirement that research
using persons able to give consent must be thought unlikely to
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yield adequate results. Research with the latter must always be
preferred to research with the former.
There is no general ban on improper attempts to influence
research subjects.
The following are the main issues currently under discussion
in Germany:
• Expansion of research with persons unable to give their
consent.
• Expansion of research with embryos and embryonic stem
cells.
• Limits on human genetic research, including research with
human body parts.
• Greater financial involvement of public health insurance
bodies in research.
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Central and eastern Europe:
research-related problems
for transition countries
by Eugenijus Gefenas
It is a challenge to talk about central and eastern Europe (CEE) as
a whole without lapsing into oversimplified generalisations or
neglecting the peculiarities of individual states. The main reason
for making this reservation is the diversity of socio-economic
conditions and cultural backgrounds in the various transition
countries in the region. For example, some of the CEE countries
are still taking their very first steps towards democracy and, in
addition, have to cope with an extremely difficult economic
situation. That is why my observations will be mainly based on
the Baltic countries’ experience, which will, I hope, also cover
common problems arising in the course of ethically sensitive
biomedical research in other European transition societies. 
Establishing research ethics committees in central and
eastern Europe
Let me first make a few observations about the motives for set-
ting up research ethics committees (RECs) and meeting the
requirements of research ethics in the CEE countries, and the
incentives to do so. It could be argued that the initial incentive
– to meet the formal requirements of an ethical review of bio-
medical research comparable to that in western countries –
was introduced in many central and eastern European countries
by foreign pharmaceutical companies (Simek et al. 2000).
It was most probably because of the willingness of CEE
researchers to take part in multi-centre clinical trials that the
intensive process of establishing RECs started in the most sci-
entifically active healthcare research institutions in the late
1980s and early 1990s. It also explains why research ethics
committees have been predominantly based in teaching hospi-
tals and therefore came to resemble the institutional review
boards operating in the USA (Trontelj 2000) rather than the
regional RECs of the Scandinavian countries. Poland is a good
example of this tendency, because in this country each medical
school has its committee for research involving human subjects
(Górski and Zalewski 2000).
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It is worth pointing out that the procedural requirement to
apply for and obtain approval from the local REC before starting
any biomedical research project has been recognised in almost
all the countries of central and eastern Europe. More impor-
tantly, however, in order not only to follow the procedural
rules of ethical review but also to implement the substantive
principles of research ethics in practice, it is necessary to be
sensitive to those cultural and socio-economic features of a
particular society that have a negative impact on the freedom
of choice of the subjects who are to participate in biomedical
research. 
That is why I shall concentrate on two main features that tend
to increase the vulnerability of the research population in central
and eastern Europe. These features have been linked with the
scarcity of resources in the healthcare sector as well as with a
somewhat insufficient culture of respect for personal auton-
omy as regards health care.
Financial incentives and the vulnerability of research partici-
pants
A traditional list of vulnerable research subjects includes,
among others, children and adults with behavioural disorders,
as well as those whose voluntary choice as regards participation
may be restricted by their dependency on particular institu-
tions or persons. The concept of vulnerability might also be
extended to cover participants from less developed and less
affluent societies, who may be vulnerable because of their lack
of sophistication when it comes to modern scientific medicine
and because their financial status may be exploited by
researchers (Brody 1998).
Research as a means of obtaining treatment
Let us therefore first analyse the economic context of the ethical
review of biomedical research in central and eastern Europe.
We need to be aware that, in the majority of the former Eastern
Bloc countries, annual per capita healthcare expenditure is on
average five to ten times lower than in many welfare-state soci-
eties. For example, it amounts to US$250 in Lithuania, which
might be regarded as a medium-income country in the wide
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spectrum of CEE states, as compared with US$ 1 700 in Sweden
(Brody and Lie 1993). Sophisticated biomedical technology and
expensive drugs available in the more affluent country would
not therefore normally be accessible in many transition soci-
eties, not to mention the fact that the poorest CEE states face a
shortage of quite basic biomedical material, such as disposable
syringes and antibiotics. 
That is why the argument that a clinical trial provides an
opportunity for the research participants (or some of them at
least) to receive treatment not otherwise available will receive
strong support in these circumstances. This state of affairs
might also lead to a situation whereby a trial that had not been
approved in a Western country would be regarded as acceptable
in the transition society.
To illustrate the problem, it is worth recalling the well-known
example of the AZT* placebo-controlled trial on pregnant
woman conducted in Africa in the 1990s. The trial was
designed to establish the effectiveness of a smaller dosage of
AZT in preventing HIV in newborns and involved two groups
of pregnant women, the first receiving the active medication,
the second one being a control group given a placebo. At that
time, such a trial would not have been approved by the ethics
committees in any developed country in the world because the
effectiveness of AZT had already been established. 
This trial revealed the double standards of research ethics in
the developed and the developing world. However, its propo-
nents argued that it was justified in Africa, where the drug was
not available at all and nobody was therefore worse off as a
result of the trial, while at the same time the research was ben-
eficial to the group of participants receiving the medication.
It is important to note, in this connection, that a few international
instruments have recently addressed the issue of protection of
research subjects in societies with limited resources. For example,
CIOMS Guideline 10 expressly states that, before research is
transferred from affluent countries to populations with limited
resources, the investigator and sponsor should be responsive
to the health needs and priorities of the communities or popu-
lations concerned and, furthermore, should try to make the
results of the research “reasonably available” to them (CIOMS
Guidelines 2002).
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AZT:
an ant ivira l  drug
(trade name Retro-
vir) used in the treat-
ment of  Aids ;
adverse side-effects
include liver damage
and suppression of
the bone marrow.
124
Research as a source of income
Another important aspect of the shortage of financial
resources conducive to the vulnerability of the research popu-
lation is related to low salaries in the healthcare sector.
Researchers in the region have a relatively stronger incentive
to conduct clinical trials proposed by pharmaceutical compa-
nies because the benefits offered in the transition societies are
relatively much higher than in Western countries. 
For example, the payments received by the researchers in
remuneration for conducting a clinical trial could very well
exceed their regular salaries, especially if we add such hidden
types of remuneration as the reimbursement of expenses for
overseas conferences and the like. This argument carries the
most weight in the CEE countries with the largest difference
between the income of healthcare practitioners and the remu-
neration offered by the pharmaceutical industry. Consider, for
example, certain former Soviet republics where the doctor’s
official monthly salary hardly exceeds US$50, while the fee for
the recruitment of the research subject amounts to a few hun-
dred US dollars. 
Combined with the tradition of medical paternalism, the finan-
cial incentive to enrol research participants makes it very likely
that some of the basic principles of research ethics may not be
followed in the circumstances. At European level this issue has
recently been addressed by the Council of Europe’s Protocol on
Biomedical Research to the Convention on Human Rights and
Biomedicine. Article 12 of the protocol stresses the need to pro-
tect vulnerable and dependent persons against “undue influ-
ence”, which might be exerted on persons to participate in
research (Additional Protocol on Biomedical Research to the
Convention on Human Rights and Biomedicine, 2004).
The paternalistic tradition and the vulnerability of research
subjects
The paternalistic doctor–patient relationship prevalent in post-
communist societies is another important issue for research
ethics. It leads to a situation whereby patients simply do not
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ask the questions that are essential if they are to give their free
and informed consent and, in addition, are not able to resist the
proposals made by the doctor/researcher. In other words, a
biased researcher might easily exploit a paternalistic attitude
and consequently mislead a patient, creating false expectations
as to the main purposes of the clinical trial in which he or she
is participating. 
To explore all these important issues and evaluate the practical
implications of informed consent, the Lithuanian Bioethics
Committee conducted an anonymous postal survey of
participants in clinical trials carried out in the country during
the year 2001. Of 1106 questionnaires sent to the research par-
ticipants, 438 completed questionnaires were returned to the
committee, revealing a number of problems related to the
practical implementation of the principle of informed consent
(Lukauskaite 2003). 
Let us now concentrate on one particular aspect of the study,
which I would consider a test case as regards informed consent,
and which entailed checking whether research subjects partic-
ipating in the placebo-controlled double-blind* (PCDB)
research project had understood the design and essential fea-
tures of such a trial.
Placebo-controlled double-blind clinical trial: a “test case”
for informed consent
About 100 anonymous questionnaires were received from the
participants in PCDB clinical trials. The evaluation of the quality
of informed consent to this type of trial was based on checking
the participant’s understanding of three essential features:
• the main goal of the trial;
• the use of a placebo;
• the double-blind design.
The PCDB trials could hardly be regarded as being conducted
with the intention of benefiting individual patients. However,
the question “What do you think is the main goal of the doctor
conducting this clinical trial?” revealed that almost a half of
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Double-blind
study:
a clinical trial design
in which neither the
participating indi-
v iduals  nor  the
study staff knows
which participants
are receiving the
experimental drug
and which are
receiving a placebo
(or  another ther-
apy). Double-blind
trials are thought to
produce objective
results ,  s ince the
expectations of the
doctor and the par-
ticipant about the
experimental drug
do not  a f fect  the
outcome ; also called
double-masked
study.
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the participants had a “therapeutic misconception” about the
research as they thought that the aim of the trial was to
improve their – or their child’s – health. 
The fact that some of the participants in the PCDB trial receive
a new drug while others receive a substance without any
pharmaceutical activity (a placebo) was understood by only
one-third of the research participants. Finally, the question “Do
you think your doctor has been aware of what exactly is being
administered to you?” was answered positively by almost 40%
of participants, who evidently misunderstood the double-blind
character of the trial. 
The results of the survey give cause for concern about respect
for the principle of informed consent as well as for the safety of
the patients. Such an impression, however, needs to be quali-
fied. Firstly, the survey covered only international, multi-centre
clinical trials conducted simultaneously in many different
European countries. The placebo group was a justified feature
of these trials as it was only used where no effective treatment
was available and/or where giving a placebo resulted in mini-
mal risk and burden. Secondly, the misunderstanding of the
way in which the PCDB trial was designed could also be
related to the fact that some research subjects would find it dif-
ficult to follow relevant information even if this information
were presented in a completely adequate way by the researcher. 
The national genome project
By turning to molecular biology and genetics, modern medi-
cine has held out greater promise of “personalised” medicine
and pharmacogenetics. In Estonia and some other countries,
this process has even sparked off national population-based
genome projects. The Estonian project is probably one of the
most developed and well-known in the Baltic region and
Europe generally. Because information about the project
(including the information given to potential participants) has
been made available on the Internet, it might serve as a good
“test case” for research ethics, with particular reference to its
features in the transition societies.
The Estonian project has been praised as having the potential
to become Estonia’s Nokia – the most promising facilitator of
Ethical eye – Biomedical research
scientific and even economic development in the country. At the
same time, because of the lack of informed public debate about
it and the potential for future abuse, the project has been
called “an ethical time bomb” not only by some local commen-
tators but also by international commentators (Gross 2000).
Even though this might be regarded as going too far, we have
to be aware that genetic research is a highly controversial field.
It seems that the ethical controversies revealed by the Lithuanian
survey of informed consent to pharmaceutical trials are also
applicable to the genome project. Let us first consider its financial
context, in particular the incentives for the general practitioners
who are supposed to serve as recruiters of the participants in the
genome research. One of the leaders of the Estonian Genome
Project was quite eloquent in commenting on the economic
advantages of conducting the project in Estonia. He estimated
that Estonian general practitioners would be willing to work
for US$10-15 per patient, whereas in a country such as the USA
that amount of money would not even allow one “to walk
through the door” of the doctor’s surgery (Mapping Estonia,
www.internationalspecialreports.com/europe/01/estonia/edu-
cation).
This argument, however, can be viewed from a different angle.
Even though the same US$15 might indeed be regarded as a
sufficient incentive to work for the project, this sum could also
be seen as having the potential to elicit abuse. Recruiting two
or three patients per day would almost double the income of
the Estonian doctor. This might also strengthen our misgivings
as to how free to choose and how well informed those who
sign the genome project participation documents in their GP’s
clinic actually are, given the “therapeutic promises” made in the
gene-donor consent form.
The problem is that the “non-therapeutic” features of the project
do not seem to be clearly explained to the research participants.
Describing possible benefits, the information accompanying
the gene-donor consent form merely says that “The Gene Bank
provides a gene donor with an opportunity to assess his or her
health risks and diagnose illnesses more precisely, prevent
falling ill and receive more effective treatment in the future.”
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(Gene donor consent form, 2001). How distant this “future”
might be, and how uncertain the process of finding effective
treatment for genetic disorders still is, remain unexplained in
the written information documents given to the patient. Perhaps
it is no coincidence that the gene-donor consent form lists the
right not to know one’s genetic data before the right to know
one’s own genetic data.  
Besides the criticisms of the features of the genome project
mentioned above, there are some more complicated problems
to be highlighted in this context. Is it at all possible to run an
Estonian genome project on the same model of informed consent
as is applied in case of an ordinary PCDB pharmaceutical trial?
The problem is that this project has a very broad and ambitious
aim, namely “genetic and medical research to be carried out in
order to find genes that influence the development of illnesses”
(Gene donor consent form, 2001). 
Such a broad goal could hardly be consistent with the funda-
mental criterion of informed consent, namely, that sufficiently
specific and explicit information is provided about its future
relevance to the individual concerned. However, it is important
to note that even if the future research use of human genetic
material and personal data cannot be precisely anticipated,
“unconditional blanket consent” should be avoided as it can-
not be seen as a valid form of informed consent (Paragraph 64
of the Draft explanatory report to the draft instrument on the use
of archived human biological material in biomedical research,
2002).
Future measures
What are the ways of coping with the situation when people
are enrolled for different types of biomedical research without
actually being aware of what kind of procedures are being
offered to them and what potential benefits, if any, they might
realistically hope for?
One suggestion might be more active monitoring of biomed-
ical research activities. The anonymous survey of respect for
the principle of informed consent to pharmaceutical trials
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could serve as an example of a means of establishing feedback
from research participants to researchers. For example, the
results of the anonymous Lithuanian survey of informed con-
sent were presented to the researchers at a special conference,
and triggered significant interest among the biomedical com-
munity. 
This example of an anonymous survey might also be interesting
from an international perspective. Even though the difficulties
related to the practice of informed consent are greater in the
countries with a relatively short history of research ethics, it
might also be useful to compare compliance with the funda-
mental principles of research ethics in different sociocultural
contexts, for example, not only in CEE countries but also in
southern, western and northern Europe. The globalisation of
biomedical research and the increasing number of multi-centre
clinical trials make this idea quite feasible. We should, however,
be very careful to prevent such monitoring being transformed
into policing.
The controversy surrounding the genome studies might prompt
us to direct our efforts to somewhat broader research ethics
issues. These projects reveal more systematic difficulties in
conforming to the standards of informed consent applied in
traditional clinical trials and might therefore also prompt us to
think about alternative research ethics paradigms. For exam-
ple, some bioethics experts would argue that it might not
always be feasible to obtain informed consent, even from indi-
viduals who are competent to give it and understand the
issues, because it is not possible to foresee the full range of
uses to which genetic information might be put. According to
the proponents of this point of view, the strict requirement of
informed consent evolved as a reaction to Nazi experiments,
whereas the context has changed in contemporary research.
An alternative principle of solidarity might be proposed in the
case of research with so-called “minimal risk” (Chadwick and
Berg 2001).
Both researchers and those responsible for ethical review
therefore find themselves in a rather difficult situation, where
the established rules of biomedical research cannot be directly
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applied and there is an urgent need to look for alternatives or
exceptions in the case of genetic research or research on
archived human biological material and personal data. The
situation is more confusing in the CEE countries, where not
even the standard rules of research ethics have yet been fully
established.
In spite of the critical spirit of my observations, I have to stress
that, since the collapse of the Eastern bloc in the late 1980s,
many post-Soviet European countries have made remarkable
progress in the field of biomedical research ethics. The major-
ity of countries have already established research ethics bodies
and are on their way to introducing an efficient system for the
ethical review of biomedical research. 
This paper should not, therefore, be seen as a pessimistic eval-
uation of the processes taking place in the European countries
in a state of transition. It should, rather, be regarded as a sign
of increasing transparency and openness to positive changes.
The very fact that information about ongoing research activities
and surveys of these activities are becoming accessible to the
public is the main guarantee of successful future developments.
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Italy: some shortcomings
of biomedical research
by Stéphane Bauzon
The legal situation of biomedical research in Italy is ambiguous.
On the one hand, Article 32 of the constitution (concerning the
individual’s fundamental right to health), which stipulates that
no one may be obliged to take part in biomedical research,
seems to be fully complied with: Italy has legal rules that
strictly protect biomedical research subjects. On the other hand,
Article 9 of the Constitution, which states that “[t]he Republic
shall promote the development … of scientific research” has by
no means been translated into practice. The high degree of
protection afforded to all biomedical research subjects therefore
contrasts with the small amount of medical research.
Italy obviously endorses the World Medical Association’s 1964
Declaration of Helsinki (which concerns the ethical principles
applicable to medical research on human subjects). The Decla-
ration has been amended at the World Medical Association’s
various general assemblies, one of which (the 35th) took place
in Venice, Italy in 1983. Italy recognises the universal importance
of the Declaration of Helsinki and its fundamental principles,
for example:
• The principle of respect for the individual, which covers the
capacity and right of all individuals to make their own
choices and decisions. It concerns respect for the independence
and self-determination of all human beings, whose dignity
and freedom are acknowledged. One important aspect of
this principle is the special protection that needs to be
afforded to vulnerable people.
• The principle that benefits must be derived from the
research, which requires that researchers assume responsi-
bility for the physical, mental and social well-being of the
research subject in all areas connected with the research. 
• There is also the principle of doing no harm. The risks
incurred by research subjects must be assessed in the light
of the benefits that they may derive from the research and
the importance of the knowledge likely to be obtained. In
any event, the risk to the research subject must always be
reduced to a minimum.
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To this end, a legislative decree (No. 211) was passed on 24 June
2003, in order to incorporate into Italian law EU Directive
2001/20/EC on the implementation of good clinical practice in
the conduct of clinical trials on medicinal products for human
use. The decree prohibits private-law companies from offering
patients remuneration for agreeing to test a medicinal product
(Article 1.5). The fine for doing so ranges from 50 000 to 150 000
euros (Article 22.1).
The decree also prohibits violation of the principle that there
must be benefits (Articles 3.1.a, 4.1.d and 5.1.b) and requires
that the person concerned (or his or her guardian) be informed
of the aims of the trial and the risks and constraints involved
(Articles 3.1.b, 4.1.d), that research subjects should not be sub-
jected to physical or psychological duress (Article 3.1.c), that
their consent (or that of their guardian) be obtained, on the
understanding that it may be withdrawn at any time (Articles
3.1.d, 3.1.e, 4.1.a and 5.1.a), and that subjects be given the contact
details of a person with the authority to provide further infor-
mation (Article 3.1.g). Fines range from 20 000 to 60 000 euros
(Article 22.2).
In the case of minors, the decree requires that they be received
by someone specialising in dealing with young people, who
will explain the nature of the trial to them (Article 4.1.b). In
addition, the person in charge of the trial must take into con-
sideration a refusal on the part of a minor (Article 4.1.c) or an
adult incapable of giving legal consent (Article 5.1.c). The per-
son in charge may therefore override such a refusal if he or she
has obtained the consent of the parents or guardian. It should
be noted that there is no penalty for failure to comply with
these provisions.
Furthermore, there is no express provision to the effect that
the parents (or guardian) of a minor or adult incapable of giving
legal consent must receive the contact details of a person with
the authority to provide further information. As there is a
penalty for failure to comply with this requirement in the case
of a person capable of giving legal consent, it is likely that the
same will apply by analogy to the legal representatives of a minor. 
The clinical trials must have been authorised by the competent
ethics committee, failing which a fine of 100 000 to 500 000
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euros is incurred (Article 22.5). The ethics committee is an
independent body that includes members of the health profes-
sions, among others. In its (written) opinion, the ethics com-
mittee must assess (Article 6) the relevance and advantages of
the clinical trial, the risk/benefit ratio, the protocol, the impor-
tance of those in charge of the trial, the biomedical research
subjects’ files, the quality of the healthcare institution and
whether the research subjects (or their legal representatives)
have been properly informed. It is also responsible for address-
ing, and covering in its opinion, such matters as the existence
of insurance, any remuneration given to healthy subjects taking
part in the trial and the way in which the subjects are contacted
in connection with the biomedical research project. 
The ethics committee responsible is the one attached to the
healthcare institution in which the research is taking place. The
ethics committee has thirty days in which to draft an opinion,
which it must forward to the Ministry of Health (Article 7). In
the absence of an opinion, the biomedical research cannot
start, at any rate if it is connected in any way with gene therapy.
In any event, biomedical research that modifies the individual’s
germ-line genetic identity (Article 9.6) is prohibited. 
During the biomedical research, the person in charge of the
trial may amend the protocol, but is required to inform the
Ministry of Health and the ethics committee. It is also specified
that the manufacture (or import) of medicinal products for use
in biomedical research is subject to the prior approval of the
Ministry of Health (Article 13). Inspectors from the Ministry of
Health may investigate the nature of the biomedical research
undertaken.
In respect of points not covered by the legislative decree (No. 211)
on the implementation of good clinical practice in the conduct of
clinical trials on medicinal products for human use, biomedical
research is governed by Ministry of Health Circular No. 6 of 2
September 2002. This covers, in particular, all research involv-
ing the use of medicinal products already on the market with a
view to ascertaining their effects. 
Such observational clinical trials must also be endorsed by an
ethics committee, whose opinion, like all ethics committee
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opinions on biological research, must be made public through its
transmission to the Ministry of Health’s Directorate General for
the Assessment of Medicinal Products and Pharmacovigilance,
National Clinical Trials Observatory (http ://oss-sper-clin.sanita.it).
Furthermore, a decree of 26 April 2002 issued by the Istituto
Superiore di Sanità (Health Institute) indicates the tests that
must first be carried out to ensure that medicinal products
used for biomedical research on human beings are harmless.
These guidelines are based on the standards of the European
Agency for the Evaluation of Medicinal Products (Emea).
The “Guidelines for ethics committees in Italy” (Orientamenti per
i comitati etici in Italia) of 13 July 2001, issued by Italy’s National
Bioethics Committee (Comitato Nazionale per la Bioetica),
specify the membership of ethics committees and how they
should operate. The key feature is the recommendation that a
distinction be drawn in ethics committees between people
responsible for monitoring biomedical research and those
responsible for trials of new medicinal products. 
Although it by no means wants to set up a team of bioethics
specialists, Italy’s National Bioethics Committee stresses the
importance of providing all medical and paramedical staff with
training in bioethics. The committee considers it appropriate
that those responsible for deciding on the ethics of biomedical
research should, by this means, have a sound knowledge of
the subject. In addition, by making this distinction, the
National Bioethics Committee wanted to avoid the tendency
for opinions issued by the members of ethics committees
(which usually have an excessive workload) to become
“bureaucratic”. The suggestion that a Bioethics Committee and
a Biomedical Research Commission be set up side by side was
not acted on when legislation was introduced.
Like many European countries, Italy has had lengthy and acri-
monious bioethical debates about whether or not it should be
possible to carry out biomedical research on embryos and stem
cells. Italy’s National Bioethics Committee has issued three
opinions on the subject. The first, dated 22 June 1996, is entitled
Identità et statuto dell’embrione umano (Identity and status of the
human embryo). The second, dated 27 October 2000, is entitled
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Sull’impiego terapeutico delle cellule staminali (The therapeutic
use of stem cells), while the third, dated 11 April 2003, is entitled
Su ricerche utilizzanti embrioni umani et cellule staminali
(Research using human embryos and stem cells). The third
opinion did not elicit a unanimous vote on the issue. 
In response to a request from the Minister for Research, the
National Bioethics Committee expressed a view (in connection
with the European Union’s Sixth Framework Programme for
Research) as to whether it was ethical to carry out research in
Italy using stem cells from human embryos – particularly sur-
plus embryos destined to be destroyed. A majority of the mem-
bers endorsed the spirit of the first two opinions and rejected
any kind of research on embryos or stem cells (except “adult”
stem cells and those from the umbilical cord or a miscarriage). 
The majority of members of the National Bioethics Committee
took the view that “human embryos are complete human
beings” and that “the Nice Treaty recognises the dignity of all
human beings” and therefore condemned “all public funding
in this area which reinforces the view that an embryo is simply
a mass of cells”. They added that there was “no logical reason”
for using stem cells from surplus embryos “except occasionally,
for pragmatic reasons” and that “this would, in particular
encourage the production of embryos for research purposes”. 
A minority of members of Italy’s National Bioethics Committee,
on the other hand, took the view that “taking stem cells from
an embryo that is not destined to be implanted in no way
reflects a lack of respect for the embryo, but may be considered,
if not a contribution from the donor couple, at least as an act
of solidarity that enables researchers to devise methods of
treating diseases that are difficult to cure”. Lastly, a small
minority rejected the idea of using stem cells from human
embryos except in the case of embryos that were already surplus
to requirements, and then only within very restricted limits.
A recent law (passed early in 2004) on medically assisted pro-
creation reflected the opinion of the majority of the members
of the National Bioethics Committee. Section 1 states that “in
order to facilitate a solution to reproductive problems stem-
ming from human sterility or infertility, it is permissible to resort
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to medically assisted procreation under the conditions laid
down in this law, which safeguards the rights of all the subjects
concerned, including the unborn child”. The law talks of the
“concepito”, which may be translated as “unborn child” or “child
conceived”. In any event, under the law the embryo is a person
recognised by law. 
Section 13 of the law, entitled “Experiments on human embryos”,
prohibits “all research on human embryos” (E’ vietata qualsiasi
sperimentazione su ciascun embrione umano) in paragraph 1.
Paragraph 2 adds that research may be carried out on a human
embryo solely for the benefit of “the health and development of
the embryo”. Paragraph 3 adds that, in all cases, “the production of
human embryos for research purposes … and the selection of
embryos for eugenic purposes shall be prohibited” (Sono,
comunque, vietati la produzione di embrioni umani a fini di ricerca
… e ogni forma di selezione a scopo eugenetico degli embrioni).
This paragraph also prohibits human cloning for reproductive or
research purposes (clonazione dell’embrione sia a fini procreativi
sia di ricerca). Incidentally, the statements by Dr Antinori on his
attempts to create clones have made public opinion much more
aware of this issue. In an opinion dated 17 October 1997, Italy’s
National Bioethics Committee had already condemned human
cloning. It rejected it again in a motion dated 17 January 2003.
Because it has not been fully ratified by Italy, I have not referred
to the Oviedo Convention for the Protection of Human Rights
and Dignity of the Human Being with regard to the Application
of Biology and Medicine. Despite numerous requests from the
National Bioethics Committee, no legislative initiative in this area
is in the offing.
With regard to biomedical research on animals, Legislative
Decree No. 116 of 27 January 1992 states that biomedical
research on animals “may be carried out only to obtain results that
cannot be obtained by other scientifically valid and applicable
methods that do not involve the use of animals”. Furthermore,
Law 413/93 allows researchers who have a conscientious objection
to so doing to avoid using animals in their biomedical research.
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Animals used in biomedical research in Italy, 2000
In 2000, 95% of the animals used were mice, rats or other
rodents.
Source : Official Gazette, General Series (Serie Generale) No. 297-
30.11.2001.
Financially speaking, biomedical research in Italy is not in a very
favourable situation. According to information from ISRDS-CNR
(Scientific Documentation and Research Institute – National
Research Council), total expenditure on biomedical research
(by private-law and public-law institutions) in 2001 accounted
for 1 540 million euros, or barely more than 0.1% of the gross
domestic product. It should be added that 95% of this sum is
financed either by the public sector (nearly 48%) or the phar-
maceutical industry (nearly 48%). The overall contribution made
by funds raised by charities (such as Telethon) accounts for
roughly 5% of the total expenditure on biomedical research.
In 2001 public spending on biomedical research amounted to
770 million euros. The main sources of public funding were:
• the Ministry of Health and the Ministry of Research: 370 million
euros;
• major research institutions – CNR (National Research Council),
ENEA (Organisation for New Technologies, Energy and the
Environment) : 266 million euros;
• the Health Institute (Istituto Superiore di Sanità): 93 million
euros.
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Purpose of research activity No. %
pure research 274 673 30.0
research & development, production and quality control:
products and apparatus for medicine and dentistry 518 025 57.0
research & development: products and apparatus
for veterinary medicine 14 248 1.6
toxicity tests 64 233 7.0
diagnosis of diseases 25 670 2.8
education 2 835 0.3
other 5 919 0.7
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In 2001 the Italian pharmaceutical industry spent 769 million
euros, or 0.063% of the GDP – less than half the European
average (0.190%), and less than Japan (0.153%) and the United
States (0.235%).
The lack of investment in biomedical research has caused
numerous Italian researchers to go abroad. The 2004 Budget Act
has, however, provided for financial assistance to reverse this
“brain drain”. A survey conducted in 2002 by Censis (Centre
for Social Studies and Policies) revealed that the reasons that
prompted Italian researchers to go abroad were the higher
funding for research (59.6%), financial incentives (56%) and
faster career development (50.9%). 
Biomedical research in Italy has, however, produced some out-
standing achievements. For instance, in October 2002 the MIA
(Microscopy and Image Analysis centre) was set up in Monza.
It is a European centre of excellence for the analysis of micro-
scope images for biomedical research. The initiative is the result
of a partnership between the University of Milan-Bicocca, the
Mario Negri Pharmacological Institute and the M. Tettamanti
Foundation. In 2003, in southern Italy (the poor relation in
regional terms in Italy), a similar initiative (in Ariano Irpino-
Campania) made it possible to set up a centre of excellence for
genetic research, one of the aims of which is to encourage
Italian researchers to return to Italy.
The thirteenth Italian scientific and technological culture week
was held in Naples in March 2003. The title of the gathering
was “From DNA to the human genome: 50 years of progress in
elucidating the mystery of life”. The occasion elicited an appeal
from Renato Dulbecco (Nobel Prize for medicine), who said:
“Italy is second to none, but the lack of research facilities and
funds for research has significantly hampered results. There is
no shortage of scientific discoveries in Italian laboratories, but
it is necessary to make the most of the professional skills that
exist and create conditions conducive to the steady progress of
Italian biomedical research”.
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United Kingdom: data protection
and confidentiality
by Vivienne Harpwood and Michel Coleman 
Medical confidentiality has been recognised as fundamental to
codes of medical ethics for centuries,1 and it is widely regarded
as an essential practical component in the successful treatment
of patients.2 In the United Kingdom, the National Health Service
(NHS) Code of Practice 2003 states:3
Patients entrust us with and allow us to gather sensitive informa-
tion relating to their health as part of their seeking treatment.
They do so in confidence and they have the legitimate expec-
tation that staff will respect their privacy and act accordingly.
Despite the many commitments to respect for the secrecy and
security of identifiable medical information, it is recognised
that absolute confidentiality – only the patient and his or her
doctor having access to the information – cannot be achieved
in the modern world, where patients’ records are regularly cir-
culated even outside what are strictly regarded as the medical
professions.4
It is also accepted that unless information about patients suf-
fering from certain categories of diseases is collected on a large
scale, it is impossible to predict trends and other vital develop-
ments in the public health arena.5 The Department of Health
acknowledges that public health surveillance must be both
reliable and sufficiently comprehensive so that changes can be
tracked over time, noting that “if significant levels of patients did
opt out of … surveys, this would call into question their valid-
ity, with possible adverse implications over time for public
health itself”.6
In the UK, the desirable balance between confidentiality and the
permissible uses of identifiable health information has become
confused, mainly as a result of the Data Protection Act 1998
(DPA), the implementation of the Human Rights Act 1998
(HRA) in the year 2002, and professional guidance issued by the
General Medical Council in 2000. This chapter examines the
status of medical confidentiality in the UK in the context of health
surveillance, with particular reference to cancer research and
the information collected and held by the cancer registries.
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Information and health surveillance
Health surveillance systems facilitate research on trends in
various diseases, in their management and in their impact on
the public health. Health surveillance can be described as “the
ongoing collection, collation and analysis of data and the
prompt dissemination of the resulting information to those
who need to know so that action can result”.1 Cancer registries
are an integral part of this process. 
“Cancer” describes a group of diseases that affect about one in
three persons in developed countries, that kill one in four, and
which have huge economic and social costs : the importance of
cancer in public health is unchallenged. Cancer registries collect
and hold long-term identifiable information about the person,
the cancer, the treatment and the outcome for all persons diag-
nosed with cancer among the resident population of the terri-
tory they cover. They handle clinical requests for information
relating to particular patients, and for counselling healthy per-
sons about genetic risks. 
The information they generate is used for public health sur-
veillance and for epidemiological research into the causes,
trends and management of disease. This is invaluable in
improving the diagnosis and treatment of patients and in the
management and control of the disease in the entire commu-
nity. The UK Department of Health lists a range of cancer reg-
istry functions on its website ; it also sets out why identifiable
data are required, and some of the purposes for which they are
used.2
Central to the principle that it is acceptable for identifiable
information to be divulged by a doctor to others is the notion
that the patient’s consent will legitimate departures from strict
medical confidentiality. This notion is present in ethical guid-
ance,3 at common law4 and in legislation.5 In the UK, the
emphasis on this position has increased:6
Requirements for patients to consent to processing of their
identifiable healthcare information have increased since the
1990s. The pendulum has swung away from implied consent,
the basis of medical research for decades.
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However, as will be seen, in the UK in certain circumstances it
is not unlawful for information about patients to be divulged
and collected, even without their consent. This limitation of
the need for patient consent has prompted some concern. The
fears are magnified because in the field of consent to medical
treatment and research more generally, UK law is increasingly
prepared to maximise patient autonomy, and government policy
and the prevailing culture in healthcare demands that patients
be “put at the centre”.1 This approach indicates that the UK
courts are moving closer to the position in North America2 and
Australia.3
The legal framework
The legal framework dealing with medical confidentiality is
complex. It derives from contractual obligations, from common
law and from statutes. The position at common law was stated
in Hunter v. Mann4 as follows :
The doctor is under a duty not to disclose, without the consent
of the patient, information which he, the doctor has gained in
his professional capacity.
Exceptions have been developed to this basic proposition over
the years, and the common law now recognises that the
patient’s consent is not necessary if, for example, as a result of
a balancing exercise, it would be considered in the overriding
public interest to divulge the information,5 or if the identity of
the patients concerned is protected by anonymisation, even if
the information is divulged to further the commercial interests
of a third party.6
The common law and the exceptions that it recognises are
relatively straightforward, but the position under the Data
Protection Act 1998 (DPA) – which must be read in the light of
the Human Rights Act 1998 (HRA) – is not.
The DPA was enacted to bring the UK into compliance with
the European directive,7 which aims to harmonise the law on
the processing of personal data in member states. The act is a
complex and convoluted piece of legislation, and a full discus-
sion is beyond the scope of this chapter. Suffice it to note that
recent confusion about the scope and application of the UK
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Data Protection Act – outside the medical context – has led to
several deaths, and forced the UK Government to consider an
expert review of some of its provisions.1
The DPA 1998 updates earlier data protection legislation in the
UK. It provides additional protection for medical information,
over and above that which is recognised by the common law.
It applies only to identifiable living individuals, and covers all
information held or processed in any way about data subjects
– for our purposes, patients. It prohibits processing unless the
data controller is registered under the act, and it creates the
post of Information Commissioner to supervise the operation of
the law and to guide data users and the public on its operation. 
The act places specific duties on data controllers, permits
access by individuals to data held about them, and creates spe-
cific offences and remedies. There is special protection under
the act for personal data, defined as “Any information relating
to an identified or identifiable natural person”. An identifiable
person is “one who can be identified directly or indirectly, in
particular by reference to an identification number or to one or
more factors specific to his physical, physiological, mental, eco-
nomic, cultural or social identity”.2
An important feature of the act lies in its reference to a set of
eight data protection principles, within which the law regulates
the processing of data. Among the principles of particular rele-
vance for medical data are the following:
• Personal data shall be processed fairly and lawfully and, in
particular, shall not be processed unless (a) at least one of the
conditions in Schedule 2 is met, and (b) in the case of sensi-
tive personal data [the category to which health records
belong], at least one of the conditions in Schedule 3 is met
[see below];
• Personal data shall be obtained only for one or more specified
and lawful purposes, and shall not be further processed in any
manner incompatible with that purpose or those purposes;
• Personal data shall be adequate, relevant and not excessive
in relation to the purposes for which they are processed;
• Personal data shall be accurate and, where necessary, kept up
to date;
• Personal data processed for any purpose or purposes shall not
be kept for longer than is necessary for that purpose or those
purposes.
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Because health records fall into the category of “sensitive per-
sonal data” defined in the act,1 they are given additional pro-
tection under Schedule 3, and can normally be processed only
if at least one of the conditions in Schedule 1 is met and at least
one of the conditions in Schedule 2 is met. In effect, this means
that health data can only be processed either with the explicit
consent of the patient or, in special circumstances, without
consent. The special circumstances under which explicit con-
sent is not required include when:2
The processing is necessary
(a) in order to protect the vital interests of the data subject or
another person in a case where –
(i) the consent cannot be given by or on behalf of the data
subject, or
(ii) the data controller cannot reasonably be expected to
obtain the consent of the data subject, or
(b) in order to protect the vital interests of another person, in a
case where consent by or on behalf of the data protection
subject has been unreasonably withheld.
The processing is necessary for “medical purposes”3 and is
undertaken by – 
(a) a health professional, or
(b) a person who in the circumstances owes a duty of confi-
dentiality which is equivalent to that which would arise if
that person were a health professional.
“Medical purposes” is defined as including the purposes of pre-
ventative medicine, medical diagnosis, medical research, the
provision of care and treatment, and the management of
healthcare services.
A need for legislative intervention?
This wide range of exceptions to the requirement for patient
consent for processing of health data to be legitimate under
the act, in addition to exceptions recognised by common law,
would suggest that there is no obstacle to the collection and
processing of data for the purposes of health surveillance even
without consent, and that cancer registries could safely operate
without further legislative or other intervention.
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However, considerable confusion and uncertainty remain as to
whether this is in fact the case,1 and the weight of opinion
favoured the need for legislation to clarify the issue. We take
issue with that view later in this chapter.
Both the Data Protection Act – which requires processing to be
both “fair” and “lawful”2 – and the common law must comply with
the Human Rights Act 1998, and therefore with the ECHR.
According to Department of Health guidance, the principle of
“fairness” under the first data protection principle would sug-
gest that before their data are collected or used, patients must
be informed of who will have access to the data (that is, the
identity of the data controller),3 and the purposes for which the
data are to be processed.4 They must also be given any further
information required to enable the processing to be fair5 –
apparently this means the information that the Department of
Health considers is required at common law to support choice
as to how their data might be used – and they must be told of
their right to impose restrictions upon its use.
For processing to be “lawful”, the act requires information to be
processed in accordance both with the provisions of the act
itself, and with common law.6 Again, according to the Depart-
ment of Health, this requires that patients be provided with
sufficient information to support their decisions.7 Since imple-
mentation of the Human Rights Act, lawful processing also
requires the information to be processed in compliance with
the patient’s ECHR rights – of which more later in this chapter.
The DPA does include specific exemptions relating to the
rights of patients to give consent to the processing of their
data,8 but it does not contain specific exemption from any com-
mon-law requirement that patients be given sufficient infor-
mation about potential uses of their data to support their
choices concerning consent to such uses. The Department of
Health advice9 appears to be based on a vague assumption that
there is indeed such a common-law requirement, not
exempted by the act, to give patients adequate information to
enable them to make considered choices concerning the use of
their data, and to impose restrictions upon how their data may
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be used. However, the cases decided so far at common law
relate only to consent to medical treatment: they have not
been extended by the courts to consent to the confidential use
in research of identifiable information obtained in the course
of such treatment. 
The most recent advice issued by the General Medical Council
(GMC)1 to doctors on confidentiality,2 which in the past has
been accepted without question, and endorsed by UK courts,3
states:
Seeking patients’ consent to disclosure is part of good commu-
nication between doctors and patients and is an essential part
of respect for patients’ autonomy. When seeking express consent
you should make sure that patients are given enough informa-
tion on which to base their decision, the reasons for the disclo-
sure and the likely consequences of the disclosure.
Nevertheless, on this precise issue the courts have yet to pro-
nounce. It would seem, therefore, that in its advice on confiden-
tiality, the Department of Health is taking an understandably
cautious approach, and on the basis of the general drive
towards greater respect for patients’ autonomy, includes consent
to the use of confidential information within the legal framework
that is currently developing in relation to consent to treatment. 
Under the common law on consent to treatment, the competent
patient must give voluntary and continuing permission to the
medical treatment proposed, though in some circumstances a
patient may be taken to have given implied consent. It must be
emphasised, however, that although the Department of
Health’s general guidance on consent to medical treatment4
seeks to promote patient autonomy, the law in this area is as
yet by no means fixed. It is even possible to find contradictory
statements at the Court of Appeal on the information required
for a patient to consent to medical treatment. For example, in
Pearce v. United Bristol Healthcare Trust,5 Lord Woolf stated
the position as follows:
If there is a significant risk which would affect the judgement of
a reasonable patient, then in the normal course of events it is the
responsibility of the doctor to inform the patient of that risk.
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By contrast, in Burke v. Leeds Health Authority,1 a differently
constituted Court of Appeal took the view that what a doctor
had to tell a patient, at what point and with what force, were
matters for the clinical judgment of the doctor. 
It follows from this discussion that legislative intervention in
the UK to create further exceptions to the Data Protection Act
and the common law may never have been necessary. This
view received authoritative support from the responsible cabinet
minister in the House of Lords who said, when discussing an
amendment to the Freedom of Information Bill,2
the concern … is … that the Data Protection Act 1998 does not
prevent the medical data of individuals being used for certain
medical research purposes, notably, but not solely, in relation
to cancer registries […]. I assure your Lordships that the Act
does not have that effect. At present, the 1998 Act allows med-
ical data to be used for any medical research purpose without
the need for the consent of individuals. It is not necessary to
define the term “medical research”, nor to make specific provi-
sion for it to include the monitoring of public health, which for
these purposes is regarded as medical research.
Additional support comes from the European directive itself,
which exempts from its provisions any data
required for the purposes of preventive medicine, medical
diagnosis, the provision of care or treatment or the management
of health-care services, and where those data are processed by a
health professional subject under national law or rules established
by national competent bodies to the obligation of professional
secrecy or by another person also subject to an equivalent
obligation of secrecy.
Such broad categories of exemption would certainly cover
health surveillance and the work of organisations such as the
cancer registries, although of course the UK as a member state
of the European Union was entitled to draft the legislation
more tightly, so as to offer more stringent safeguards for the
confidentiality of its citizens than those provided under the
European directive. The problem arises when the interpretation
of those extra safeguards compromises medical research and
public health surveillance, because their consequences have
not been adequately taken into account.
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Soon after the Data Protection Act became law, grave concerns
were expressed by the scientific community about the perceived
threat to the prospects for health research. Numerous letters in
scientific journals and the media expressed fears about the
future of research,1 and in particular cancer research, with its
emotive connotations for the general public. Attention was
drawn in the medical press2 to the uncertainties of healthcare
workers faced with interpreting the DPA. The concerns appear
to have been aggravated by the GMC, which issued guidance
indicating that, by October 2001, cancer registries had to cre-
ate new mechanisms for seeking and recording consent for
processing their data from every cancer patient about whom
they held information.3
The House of Commons Select Committee on Science and
Technology considered the issue of confidentiality in its
inquiry into cancer research. Professor Bruce Ponder argued in
his evidence that if it were indeed the case that explicit con-
sent of patients was necessary for the processing of their data,
“it would make both cancer registration and almost all cancer
epidemiological research effectively impossible”.4 The committee
heard substantial evidence on those lines, and recommended
that “as a matter of urgency the Advisory Group on Patient
Confidentiality should address the concerns posed by the
1998 DPA regarding the registration of cancer”.5 It also recom-
mended that cancer registration should become a statutory
requirement, in part to resolve the issue of requiring consent,
but the government rejected this proposal.
Support for cancer registries created momentum for clarifica-
tion of the law, so as to allow cancer and communicable dis-
ease registries to conduct their valuable work in a way that was
visibly legal. The GMC agreed to suspend its guidance relating
to cancer registration until October 2001, to allow time for the
Department of Health to find a solution.
Is Section 60 of the Health and Social Care Act 2001 the
solution?
The government response to these widespread concerns about
confusion surrounding the DPA, the common law and the
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GMC’s guidance, was to insert a special provision into a bill
focused primarily on other healthcare matters. Section 60 of the
Health and Social Care Act 2001 (HSCA), as it became, provided
a mechanism for certain classes of identifiable health data to be
legally processed without the patient’s consent, thus modifying
the common law :1
The Secretary of State may by regulations make such provision
for and in connection with requiring or regulating the process-
ing of prescribed patient information for medical purposes as
he considers necessary or expedient – 
(a) in the interests of improving patient care
(b) in the public interest
“Medical purposes” are defined here as any of the following :
(a) preventative medicine, medical diagnosis, medical
research, the provision of care and treatment and the
management of health and social services, and
(b) informing individuals about their physical or mental
health or condition, the diagnosis of their condition or
their care or treatment.2
It also created a new statutory body, the Patient Information
and Advisory Group (PIAG), under Section 61 of the Act, to
provide safeguards to control the operation of Section 60 and
regulations made under it. 
But the Government views Section 60 support for the confiden-
tial use of identifiable information for research as “transi-
tional”, until such time as anonymisation obviates the need for
patient identifiers, or adequate measures for obtaining patient
consent can be instituted. The Health Minister expressed it
very simply in Parliamentary debate:3 “as soon as we can, we will
take away that support”.
Even Section 60 did not receive an unqualified welcome in its
passage through Parliament, and the wide discretion it gave to
the Secretary of State was criticised in several quarters.4 The
introduction of such far-reaching powers gave rise to concerns
about compliance with the European Convention on Human
Rights.
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The Human Rights Act requires all public bodies – including
government bodies and ministers, local authorities, courts,
NHS Trusts and disease registries – to act in accordance with
the rights identified in the European Convention on Human
Rights. When interpreting legislation, and when human rights
issues are raised before them, UK courts are required to take
into account the jurisprudence of the European Court of
Human Rights.1 If a higher court in the UK considers that any
statutory provision infringes a Convention right, it may issue a
declaration of incompatibility for Parliament to deal with as
appropriate. 
In the context of confidentiality, Article 8 is the relevant article
of the European Convention on Human Rights, which deals
with the right to privacy and family life.2 The European Court of
Human Rights has ruled that medical records are covered by
this article.3 Article 8 rights are not absolute, and derogations
are permitted in certain circumstances stated in Article 8 (2) :
There shall be no interference by a public authority with the
exercise of this right except such as is in accordance with law
and is necessary in a democratic society in the interests of
national security, public safety or the economic well-being of
the country, for the prevention of disorder or crime, for the
protection of health or morals, or the protection of the rights
and freedoms of others.
Although measures taken by member states for the protection of
health, such as those legitimated by the DPA and by Section 60
of the HSCA and regulations made under it, are clearly covered
by the permitted exceptions to Article 8, a ruling of the European
Court of Human Rights4 indicates that:
Any state measures compelling communications or disclosure
of such [confidential] information without the consent of the
patient call for the most careful scrutiny.
In particular, in the spirit of Article 8 (2), any departures from
the rights in Article 8, including those specified in the UK leg-
islation and regulations considered here, must pursue a legiti-
mate aim; must be necessary in a democratic society, and must
be proportionate to the end to be achieved by them. In other
words, the means by which the aim is to be secured must not
be excessive, taking into account the political, cultural and
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social traditions of the UK, for which a margin of appreciation
is permitted.1 A fair balance must be struck between the
demands of the interests of the community and the need to
protect the rights of the individual.2
The concept of proportionality requires that appropriate safe-
guards be established by member states when enacting mea-
sures that derogate from Convention rights. The legislation
under discussion here does contain such safeguards, though
in the case of the DPA and the common law in the UK, these
are drafted in such a way as to confuse rather than clarify. 
The safeguards introduced by the Health and Social Care
Act 2001 include the setting-up of the Patient Information
Advisory Group, the remit of which is to comment upon any
regulations proposed under Section 60 by the Secretary of
State for Health. The safeguards also include the caveats that
regulations be reviewed each year,3 that relevant interest groups
be consulted,4 and that regulations may not provide for the
processing of confidential patient information for any purpose
if it would be reasonably practicable to achieve that purpose in
some other way having regard to the cost and technology
available.5 This means that if PIAG’s annual review concludes
that technical progress since the previous year makes it
unnecessary to hold identifiable data without consent for a par-
ticular purpose, the relevant regulation must be revoked and
the power to use data in that way withdrawn.
Despite the inclusion of such safeguards, numerous objections
were raised to Section 60. Earl Howe commented in the House
of Lords :6
The dignity and privacy of the individual is being subordinated
to the administrative convenience of the NHS …. That extends
to giving the Secretary of State power to instruct any health
professional to divulge individual patient data even against the
express wishes of the patient.
Baroness Finlay countered with the point that research is crucial
in the long-term interests of the community, and that cancer
registries play a vital part in providing essential data for
research.
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The impact of the regulations
Regulations made by the Secretary of State under Section 60 came
into force in June 2002. Regulation 2 exempts data collection
by the cancer registries from the common-law requirement to
obtain the patient’s consent. The practical consequences of the
new legislative safeguards on cancer registries, in terms of the
additional workload required to prepare documentation in
order to gain PIAG approval for their health surveillance and
research activities, and that involved in anonymisation of
patients, cannot be underestimated. Although the regulations
provided new legal protection for data collection activities by
cancer registries, continuing reluctance by some data
providers forced the Department of Health to remind all NHS
Chief Executives in September 2002 : “All organisations are
asked to continue submitting information to cancer registries
and can be assured that it is legitimate to do so.”1
It remains to be seen whether the present legislative safe-
guards are adequate, since no court has yet pronounced on
them. The Department of Health advice is that the guidance
should be obtained from the data protection officer or
Caldicott Guardians2 and that:
It is good practice to inform patients where section 60 has been
used to set aside common law confidentiality requirements
and an exemption to the fair processing requirements of the
DPA 1998 has been applied, but there is no requirement to do
so if this would require disproportionate effort.3
Continuing questions about the legal implications of data pro-
cessing also create practical difficulties for the registries. The
present position raises several critical questions that require
clarification :
• For how long should data be retained?
• Is the enforcement of the regulations practical?
• Is the level at which penalties are set for infringement of the
regulations adequate?
• Does the requirement for annual review of the need for reg-
ulatory approval to process patient information create an
unreasonable burden on registries?
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• What is the position of researchers outside the NHS who may
not be properly regarded as “health professionals” within the
safeguard in regulation 7(2) ?
• What is the legality of anonymisation and pseudonymisation
carried out by registry staff ?
• Are the research ethics committees that are required to
approve proposed research, using data processed by cancer
registries, adequately equipped to answer questions on the
complex legal issues that arise in this context ?
• Do the interests of research justify a major departure from
patient autonomy?
• In human rights terms, do utilitarian arguments centred on
the “public good” outweigh the right of the individual
patient to confidentiality ?
• Is there a possibility of a challenge to a registry under human
rights legislation by a patient whose data are processed with-
out explicit consent having been obtained?
• Will patients make requests under Section 7 of the DPA for
details about how their data have been processed and who
has had access to them?
A significant legal concern for cancer registries is that they are
now frequently asked to advise geneticists about the cancer-
risk status of individuals. In Wales alone, it has been reported1
that the number of requests from geneticists to the cancer reg-
istry has risen from around 50 in 1998 to about 700 in 2003.
Section 60(5) of the Health and Social Care Act 2001 states that
regulations may not make provision for requiring the process-
ing of confidential patient information solely or principally for
the purpose of determining the care and treatment to be given
to particular individuals. 
However, it appears that Regulation 2(1)(e) does precisely that.
It permits the provision of information about :
individuals who have suffered from a particular disease or condi-
tion where – (i) that information supports an analysis of the risk
of developing that disease or condition; and (ii) it is required
for the counselling and support of a person who is concerned
about the risk of developing that disease or condition.
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It could be argued that this regulation is ultra vires (beyond the
powers) given to the Secretary of State by Section 60. This
requires urgent review and clarification in the interests both of
patients and of those responsible for the operation of cancer
registries, in the light of human rights considerations. Detailed
discussion of this legal problem is beyond the scope of this
chapter. A consultation on Section 60 is currently in progress
at the behest of the UK Government.
The new statutory provisions in the UK for confidential han-
dling of identifiable health data, for specified purposes and
without consent of the data subject, were intended only as an
“interim measure”, but appear already to have become
entrenched. There is doubt over whether such legislation was
necessary. A comprehensive review is urgently required of the
Data Protection Act 1998 and of Section 60 of the Health and
Social Care Act 2001 and the regulations made under it. 
The UK public deserves to be better informed1 about the way
in which their health data are processed, not only for cancer
information but also in the broader arena of the use of electronic
records and modern communication systems in the NHS. Wide
consultation and public debate will be required on the appro-
priate balance to be struck between personal autonomy and
the confidential handling of identifiable health information
without consent in the public interest.
Consideration should be given to establishing a new statutory
framework within which cancer and other disease registries can
lawfully process patients’ information without their consent,
subject to stringent but workable safeguards that take into
account both the present human rights framework and the
culture of increasing autonomy for patients. The temporary
nature of Section 60 support for data collection and processing,
and the need for annual review of the regulations, do not pro-
vide a stable climate in which to plan the development of disease
registration or medical research involving the confidential use
of identifiable data for research in the public interest. 
Confusion and mistrust created by the current legislative and
regulatory position have had a significant adverse impact on
medical research. We believe that only primary legislation will
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provide a sufficiently durable equilibrium between personal
autonomy, human rights, public health surveillance and medical
research – one that will command widespread public support
in the twenty-first century.
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The national cancer registration system (Extracts from
Department of Health website)
Cancer registries are essential to the implementation of the
NHS Cancer Plan, which aims to improve the quality of care
and survival for cancer patients. Reliable population-based
information on cancer incidence, prevalence and survival rates
is needed and cancer registries are the only available source.
Uses of cancer registries
Cancer registries undertake a range of public health surveillance
and health protection functions. The main functions of cancer
registries are:
• monitoring trends in cancer incidence, prevalence and survival
over time and between different areas and social groups ;
• evaluating the effectiveness of cancer prevention and screen-
ing programmes; for example, population-based data are
required to monitor the effectiveness of the existing national
screening programmes for breast and cervical cancer and to
inform the design of new programmes, such as screening for
colo-rectal and ovarian cancer ; 
• evaluating the quality and outcomes of cancer care by provid-
ing comparative data about treatment patterns and outcomes ; 
• evaluating the impact of environmental and social factors on
cancer risk. For example, cancer registry data are used to
investigate possible cancer risks in relation to power lines,
landfill sites and mobile phones. Cancer registry data are also
used to investigate differences in cancer incidence, survival
and access to treatment between social groups and thus con-
tribute to programmes aimed at reducing inequalities in
health outcomes ; 
• supporting investigations into the causes of cancer ; 
• providing information in support of cancer genetic counselling
services for individuals and families at higher risk of developing
cancer.
To fulfil these objectives, cancer registries need to collate data on
individual patients from multiple sources and over long periods.
These sources include district general hospitals, cancer centres,
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hospices, private hospitals, cancer screening programmes,
other cancer registers, primary care, nursing homes and death
certificates. Data are frequently collected from several sources
within an individual institution (for example, pathology
departments, medical records and radiotherapy databases). 
Registries are asked to link their information with information
from other NHS services, notably to support the evaluation of
the effectiveness of the national breast and cervical cancer
screening programmes. Ensuring such linkages are accurate
again requires checking of personal identifiers. 
Registries are frequently asked by cancer genetic counselling
clinics to confirm cancer diagnoses in family members. The
individuals concerned must first provide informed consent to
the release of their information for this purpose, but in order to
provide such information registries need to have included
these names on their databases. 
Registries also supply names of patients to bona fide researchers
for detailed research projects investigating causes of (or out-
comes from) specific cancers. Such studies must first be
approved by the appropriate multi-centre (or local) research
ethics committees. If patients are approached to provide fur-
ther information (for example, regarding occupation or
lifestyle), this approach will always be via the patient’s general
practitioner or hospital consultant, and participation will
depend on the patient’s fully informed consent. 
Geographical studies (such as studies of cancer risk in people
living near landfill sites) can be undertaken only if a full post-
code is available. A postcode is also required to convert historic
data to existing boundaries of, for example, regions, health
authorities and primary care organisations.
Data release 
All transfers of data to and from cancer registries are strictly
controlled and there have been no breaches of confidentiality
in the more than forty-year history of the national cancer reg-
istration system. Identifiable data releases to third parties are
restricted according to strict data release policies. Publications
from cancer registries only present aggregated data; they never
identify individual patients.
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What do we know as a result of cancer registration?
This is best summarised by listing some examples of what we
know as a result of the work of cancer registries and what we
will not know in future if cancer registration data become
unreliable.
What we know as a result of information obtained from cancer
registration :
• mesothelioma is caused by exposure to asbestos ; 
• skin melanoma rates have been increasing year on year ; 
• lymphoma and oral cancer rates are higher in ethnic minorities ;
• there is wide variation in how cancer is treated around the
country ;
• cancer survival for patients living in poor areas is lower than
for those living in rich areas ; 
• cancer survival is lower in the UK than in Europe for most
cancers ; and
• cancer survival in children has improved dramatically over
the last thirty years. 
What will we not know in future if cancer registration becomes
unreliable?
We may not discover :
• how many cancers occur each year, and which are the most
common ; 
• if cancer occurrence rates in the UK are higher or lower than
in other countries ; 
• if cancer survival rates in the UK have caught up with other
European countries ; 
• if inequalities in cancer treatment or survival between rich
and poor have been abolished ; 
• if cancer screening programmes are effective ; 
• if people living near landfill sites or power lines have an
increased cancer risk; 
• whether some late deaths in childhood-cancer survivors are
related to earlier treatments;
• if the risk of developing certain cancers is elevated in some
occupational groups.
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biomedical research

European law and biomedical
research
by P-eteris Zilgalvis1
The Council of Europe was the first international organisation
to prepare a binding international agreement addressing the
new biomedical technologies. The Convention on Human
Rights and Biomedicine was opened for signature on 4 April
1997 in Oviedo, Spain and thirty-one countries2 have signed to
date. Eighteen member states have ratified and the convention
has come into force for these countries.3 However, the conven-
tion was not the Council of Europe’s first foray into bioethics
or biomedical research, but was preceded by a number of rec-
ommendations in this field and a great deal of debate at inter-
governmental level. The convention has since been followed
by an Additional Protocol on Biomedical Research further
extending the Council’s contribution in this domain.
In this chapter, the work preceding the convention, the con-
vention itself, and the continuing work building on the
achievements of the convention will be discussed, along with
relevant contributions to the field made by the European
Union institutions. 
It is important to note that the instruments of the Council of
Europe and the EU do not cover identical fields. The Council of
Europe is quite distinct from the twenty-five nation European
Union, though all the EU member countries are also members
of the Council of Europe. The obvious difference between the
two institutions is the Council of Europe’s broader member-
ship of forty-five European countries, stretching from one end
of Europe to the other. The Secretary General of the Council of
Europe, Mr Walter Schwimmer, emphasised in his speech on
the role and place of the Council of Europe in the context of
the enlargement of the European Union, at the Paris Press
Club on 3 July 2001, that the problems of bioethics are not lim-
ited to just one part of Europe.4
At the same time, it is necessary to acknowledge that the contri-
butions of European Union institutions are also quite pertinent.
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The Community is empowered to act in this field on the basis
of EC Treaty Articles 152 (public health), Articles 163 to 173
(research, funding of the research framework programme) and
Article 95 (the internal market). Additionally, Article 49 of the
Treaty of European Union (TEU) states that candidate countries
must respect human rights and fundamental freedoms in order
to join the European Union. Direct reference is made in Article
6 of the TEU to the European Convention on Human Rights. 
Not least, as a major funding source for research in Europe
through its Sixth Framework Programme, the European Com-
mission has direct influence on what is considered ethically
acceptable for researchers. In the field of pharmaceutical
research, Directive 2001/20/EC of the European Parliament
and of the Council on the approximation of the laws, regulations
and administrative provisions of the member states relating to
the implementation of good clinical practice in the conduct of
clinical trials on medicinal products for human use was
adopted on 4 April 2001. 
It is important to note that while the Council of Europe’s Con-
vention on Human Rights and Biomedicine covers all types of
biomedical research on human beings, the aforementioned EU
directive on good clinical practice deals only with pharmaceu-
tical research. In regard to medicinal products, it has been
stated that the “European Community has a clearly established
legal competency. The legal basis for Community action is the
principle of the free movement of goods in the EU embodied in
Article 3 of the Treaty on European Union.”1
Another interesting development in the European Union is the
Charter of Fundamental Rights. Its Article 3, paragraph 2
addresses the fields of medicine and biology directly, requiring
free and informed consent and prohibiting eugenic practices,
reproductive cloning and the making of the human body and its
parts as such into a source of financial gain. It is noteworthy that
the explanation of this article found in document Convent 492
states that “ the principles of Article 3 are already included in
the Convention on Human Rights and Biomedicine, adopted
by the Council of Europe.” It also prohibits any discrimination
based on genetic features in its Article 21 (non-discrimination). 
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The legal status of this instrument, though influential, is not
entirely clear at the moment. The charter could be described
as having a declaratory nature in the present scheme of things
in the European Union. However, Mr Romano Prodi, the then
President of the European Commission, did state that “In the
eyes of the European Commission, by proclaiming the Charter
of Fundamental Rights, the European Union institutions have
committed themselves to respecting the Charter in everything
they do and in every policy they promote”.1 Furthermore, it has
been proposed that any future EU constitution could include the
Charter of Fundamental Rights.2 Other commentators have
stated that, in any case, it is the most modern international
instrument addressing human rights and will be a very influential
source for legal argumentation.3
In the field of general data protection, international regulation also
exists, for example the Council of Europe’s Convention for the
Protection of Individuals with regard to Automatic Processing of
Personal Data, Council of Europe Recommendation (97)5 on the
protection of medical data and the directives of the EU related
to data protection, EU Directive 95/46/EC on the protection of
individuals with regard to the processing of personal data and
on the free movement of such data and Directive 96/9 on the
legal protection of databases. However, this area is of sufficient
complexity that it warrants a detailed discussion of its own.
In the sphere of patenting and biotechnology, the relevant EU
legislation is Directive 98/44/CE on the legal protection of
biotechnological inventions, which was adopted on 6 July
1998 after protracted discussions in the European Parliament
and in the member states of the EU. The goal of the directive is
to harmonise national regulations and jurisprudence in EU
member states on patenting in the sphere of biotechnology,
based on the premise that without the safeguard provided by
patents, industry would not be ready to invest in research and
development in Europe. 
The legality of the directive was challenged by the Nether-
lands, with Italy and Norway intervening in opposition. The
European Court of Justice dismissed the Dutch action seeking
annulment of the Community directive on 9 October 2001. Its
165
European law and biomedical research
1.
www.europarl.eu.int/
charter/default_en.htm
accessed on 9 Ju ly
2001.
2.
Assemblée Nationale,
Dé léga t ion  pour
l’Union Européenne,
Compte Rendu No.
149, Réunion du 19
juin 2001, audition de
M. Jacques Delors,
www.assemblee-
nationale.fr/europe,
accessed on 9 Ju ly
2001.
3.
Egils Levits,“Cilve-ktiesı-
bas Eiropas Savienı-bas
t i e s ı-bu  s i s te-ma- ,
Likums un Tiesı-bas,
Vol. 2, No. 11 (15),
November  2000 :
335.
166
judgment in Case C-377/98 took the view that Directive
98/44/CE frames patent law in a sufficiently rigorous way so as
to ensure that human dignity is safeguarded and that the
human body remains unpatentable. 
Article 6.2.c of the aforementioned Directive 98/44/CE is also
of relevance to the use of embryonic stem cells. It states that
uses of embryos for industrial or commercial purposes are
unpatentable if their commercial exploitation is contrary to
public order or morality. 
The background of the Convention on Human Rights and
Biomedicine
The Council of Europe’s Parliamentary Assembly adopted
Recommendation 1100 on the use of human embryos and
foetuses in scientific research in 1989. This was their first rec-
ommendation specifically addressing biomedical research,
though recommendations and resolutions in the field of
bioethics had been adopted by the Assembly as long ago as
1976, and some of them, for example, Recommendation 934
(1982) on genetic engineering, were also relevant to aspects of
biomedical research. 
The Committee of Ministers had also adopted resolutions and
recommendations dealing with bioethical issues as long ago as
1978, but the first recommendation specifically addressing
biomedical research was Recommendation (90)3 concerning
medical research on human beings. This recommendation set
out some of the fundamental principles for biomedical
research on human beings, which were later further developed in
the Convention on Human Rights and Biomedicine and its
Additional Protocol on Biomedical Research. We find there the
principles of the requirement of free, informed, express and
specific consent, and the protection of vulnerable persons and
legally incapacitated persons in this recommendation.
Returning to the Council of Europe’s Convention on Human
Rights and Biomedicine: its roots can be traced to the 17th
Conference of the European Ministers of Justice (Istanbul,
Turkey, 5-7 June 1990), who adopted Resolution No. 3 on
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bioethics. This recommended that the Committee of Ministers
examine the possibility of preparing a framework convention
“setting out common general standards for the protection of
the human person1 in the context of the development of the
biomedical sciences.” The resolution was based on a proposal
by Ms Catherine Lalumiere, Secretary General of the Council
of Europe at that time. 
The Parliamentary Assembly of the Council of Europe recom-
mended in June 1991, in its Recommendation 1160, that the
Committee of Ministers “envisage a framework convention
comprising a main text with general principles and additional
protocols on specific aspects.” The support for the proposal
continued to grow when in September 1991, the Committee of
Ministers instructed the Ad hoc Committee on Bioethics
(CAHBI) to prepare a framework convention setting out com-
mon general standards for the protection of the human person
in the context of the biomedical sciences, and alluded to pro-
tocols to this convention on organ transplants and the use of
substances of human origin, and on biomedical research. 
In July 1994, a first version of the draft convention was opened
for public consultation and was submitted to the Parliamentary
Assembly for an opinion.2 The Steering Committee on
Bioethics (CDBI), which had replaced the CAHBI, took this
opinion and others into account in preparing a final draft. The
CDBI confirmed this draft on 7 June 1996 and submitted it to
the Parliamentary Assembly for an opinion.3 The Committee of
Ministers adopted the convention on 19 November 1996.4
The convention and its protocols are a “system” that can
respond to new (and sometimes threatening) developments in
biomedicine. An example is the preparation of the additional
protocol prohibiting human cloning after the news of Dolly the
sheep’s birth came out. Another example is Article 29 of the
Additional Protocol on Biomedical Research addressing
research in non-member states, which was developed in
response to allegations of exploitation of research subjects
from the developing world, and central and eastern Europe, by
researchers from western Europe.
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tion of the convention,
does not appear in the
convention itself. The
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4.
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For the first time, the convention seeks to establish a common,
minimum level of protection in the field of biomedicine, and
more specifically in the domain of biomedical research,
throughout Europe. In the case of biomedical research, a bal-
ance also needed to be found between the freedom of research,
which brings many benefits to individuals suffering from dis-
eases, and the regulation of research to protect the same or dif-
ferent individuals. Fears may arise that if a type of research is
prohibited in a single country, it will fall behind in the progress
of its research and become dependent on work done elsewhere.1
The development of European standards helps to alleviate
such worries.
The convention gives precedence to the human being over the
sole interest of science or society. The aim of the convention is
to protect human rights and dignity and all its articles must be
interpreted in this light. The main focus of the convention with
regard to biomedical research is specifically this human rights
aspect, unlike other legal instruments in the field, which may
concentrate, for example, to a large extent on the economic
and public health aspects of making new medicines available
more quickly. The interests of society and science are not
neglected, however, and come immediately after those of the
individual. On this basis, it establishes that consent is obliga-
tory for any medical treatment or research and recognises the
right of all individuals to have access to information concern-
ing their health. The text also sets out safeguards protecting
anyone, of any age, who is unable to give consent.
The term “human rights” as used in the title and text of the con-
vention refers to the principles found in the European Convention
for the Protection of Human Rights and Fundamental Freedoms
of 4 November 1950, which guarantees the protection of such
rights. The Convention on Human Rights and Biomedicine not
only shares the same underlying approach, plus many ethical
principles and legal concepts, but also elaborates on some of
the principles found in the earlier Convention. 
Research under the convention
Requirements for any research to be undertaken on human
beings are set out in the convention’s chapter on Scientific
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Research specifically, and in other chapters. The convention
and its Additional Protocol on Biomedical Research apply to all
biomedical research involving interventions on human
beings.1 The general rule for scientific research is set out in
Article 15. It states that scientific research in biomedicine shall
be carried out freely,2 subject to the provisions of the convention
and the other legal provisions ensuring the protection of the
human being. 
The framework principles for all research on human beings are
further enunciated in this relevant chapter. Those principles are:
there must be no alternative of comparable effectiveness to
research on humans; risks to be incurred by the person shall not
be disproportionate to the potential benefits of the research;
the necessary precondition of approval of the research project
by the competent body after a multidisciplinary review of its
ethical acceptability; there must be informed, express, specific
and documented consent. 
There are, of course, situations where persons are not able to give
their consent themselves. They may be small children or be
suffering from senile dementia, to give two examples. The chap-
ter foresees protection in the context of biomedical research
for all such persons not able to consent. The aforementioned
principles listed in the previous paragraph all apply to these
persons as well, with the obvious exception of the proviso on
the person’s consent. The participation of such a person in a
research project may be authorised (specifically and in writing)
by a parent, guardian or other representative or body provided
for by law, subject to the fulfilment of stringent protective con-
ditions. The results of the research must have the potential to
produce real and direct benefits to his or her health; it must be
the case that research of comparable effectiveness cannot be
carried out on individuals capable of giving consent; and there
must be no objection on the part of this person. 
Article 17 also provides, exceptionally and under the protec-
tive conditions prescribed by law, that research which does not
have the potential to produce results of direct benefit to the
health of a person not able to consent to research may be car-
ried out if stringent conditions are fulfilled. In addition to the
169
European law and biomedical research
1.
The protocol states in
its Article 2, that for
the purposes of the
protocol ,  the term
“intervention”
includes a physical
intervention and any
other intervention in
so far as it involves a
risk to the psychologi-
cal health of the per-
son concerned.
2.
The freedom of scien-
tific research is a con-
stitutionally protected
right in some of the
member states; see,
for example, Article
20 of the Swiss Con-
stitution.
170
aforementioned requirements for research on persons not able
to consent, this research must have the aim of contributing,
through significant improvement to the scientific understand-
ing of the individual’s condition, disease or disorder, to the
ultimate attainment of results capable of conferring benefit to
the person concerned or to other persons in the same age cat-
egory or afflicted with the same disease or disorder or having
the same condition. Finally, the research must entail only min-
imal risk and minimal burden for the individual concerned.
Moving to the following chapter, Article 18 of the convention
states that where the law allows research on embryos in vitro, it
shall ensure adequate protection of the embryo and it stipulates
that the creation of human embryos for research purposes is
prohibited. This does not mean that research on supernumer-
ary embryos created for fertilisation purposes is prohibited.
Financial gain from the human body and its parts, as such, is
prohibited by Article 21 of the convention.1 The issue of finan-
cial gain arising from the human body or its parts is addressed
specifically in the context of biomedical research in the Additional
Protocol on Biomedical Research and in the draft instrument
addressing research on archived human biological materials.
A provision that is of particular relevance to research on bio-
logical materials is Article 22 of the convention, covering dis-
posal of a removed part of the human body. It states that when
any part of a human body is removed during the course of an
intervention, it may be stored and used for a purpose other
than that for which it was removed, but only if this is under-
taken in conformity with appropriate information and consent
procedures.
Additional Protocol on Biomedical Research
The convention has been supplemented by an Additional
Protocol on Biomedical Research. The Protocol on Biomedical
Research was approved by the CDBI in June 2003 and adopted
by the Council of Europe’s Committee of Ministers in June 2004.
In addition to this protocol covering interventions on human
beings, the CDBI is preparing an instrument on research on
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archived biological materials, which will address biomedical
research on the personal data included in a research project on
archived biological materials.1
The full range of biomedical research activities involving any
kind of intervention on human beings are covered by the pro-
tocol. For the purposes of the protocol, the term “intervention”
includes both physical interventions and any other interven-
tion posing a psychological risk to the person concerned. 
It is worthwhile noting that both protocols, like the conven-
tion, will apply to both privately funded and publicly funded
research. This departs from the approach taken by the United
States, which has often regulated only federally funded
research, though there are exceptions (research coming under
the authority of the Food and Drugs Administration, for
instance).
In addition to reasserting the principles concerning research
found in the convention, the protocol further elaborates on
them and addresses related issues in detail. The protocol’s Article 7
requires that research be undertaken only if the research project
has been approved by the competent body in conformity with
national law, after independent examination of its scientific
merit, and a multidisciplinary review of its ethical acceptability
by an ethics committee.
Special attention is being paid in the Council of Europe to the
fulfilment of the requirement for a multidisciplinary review of
the ethical acceptability of biomedical research; undertaking a
programme of co-operation in 1997-2004 with its member
countries in central and eastern Europe, called Debra. The
independence of ethics committees is paramount. As Senator
Claude Huriet, who has served as a rapporteur for a Debra
meeting in Vilnius, Lithuania, stated in the French Senate
report on the Protection of Persons Undergoing Biomedical
Research, the independence of the committees is the founda-
tion of their credibility and legitimacy.2
Chapter III of the protocol addresses the question of ethics
committees and opens with Article 9 on independent examina-
tion by an ethics committee. It requires that research projects
be submitted to independent examination in each state in
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which any research activity is to take place. This includes states
from which research subjects are to be recruited for research
physically carried out in another country. Best practice is to also
submit research projects to an ethics committee in every
research location within countries. All research projects within
the scope of this protocol must be submitted for review.
A positive assessment by the ethics committee is not required,
since the role of such bodies or committees in many countries
may be solely advisory. The conclusion of this assessment may
have legal force in some jurisdictions, while in others it serves
to advise the competent body (for example, a regulatory
authority) that will make a binding decision on whether the
research project can commence. The article sets out the purpose
of the multidisciplinary examination after the precondition of
scientific quality has been met. It also states that the assessment
shall draw on an appropriate range of expertise and experience
adequately reflecting professional and lay views.
Chapter IV addresses consent and information. Consent to par-
ticipation in biomedical research is addressed by Article 14. As
noted above, informed consent is a fundamental principle of
the convention, with regard to medical or research interventions.
Consent can be freely withdrawn by the person at any stage of
the research. If the person in question is not able to give consent,
then Chapter V (Protection of persons not able to consent to
research) applies. 
Protection of private life and confidentiality
Chapter VIII of the protocol deals with confidentiality and the
right to information. It provides for the confidentiality of any
information of a personal nature obtained during biomedical
research, the accessibility to research participants of informa-
tion collected on their health, the availability of research
results, the duty of care to research participants concerning
information of relevance to their current or future health, and
protection of information related to the research. 
Research outside Council of Europe member states
Article 29 of chapter VIII addresses research in states that are
not parties to the protocol. The background to the article is
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that it seeks to prevent the possibility of exploitation of poten-
tial research subjects in the developing world by scientists
trying to undertake research that would be prohibited in their
own countries and by the protocol. It sets out the requirement
that sponsors and researchers within the jurisdiction of a party
to the protocol who plan research in a state not party to the
protocol shall ensure that, without prejudice to the conditions
applicable in that state, the research project complies with the
principles on which the provisions of the protocol are based.
Therefore, they cannot go “ethical shopping” and search for
jurisdictions with low or non-existing standards for the protec-
tion of the human being in research.
In conclusion, the Council of Europe has made a substantial
contribution to the protection of human rights in the field of
biomedical research. Its activities continue with the twin aims
of developing norms on specific aspects of this domain and of
ensuring the application of existing norms. 
The Council further seeks to stimulate public debate on these
subjects in the spirit of pluralism and democracy. It is recognised
that there is a need for continued international co-operation in
this field to further clarify and strengthen the protection of
human rights and dignity in the context of biomedical
research on the global level, and the Council of Europe seeks
to actively collaborate with its partners internationally and
nationally to achieve these goals.
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Appendices

Appendix I – Selected websites
American Journal of Bioethics, http ://www.bioethics.net/
Features include Bioethics for Beginners, Bioethics and Genetics,
Bioethics in Other Journals and a Bioethics Forum.
American Society of Bioethics and Humanities,
http ://www.asbh.org/
The American Society for Bioethics and Humanities (ASBH) is a
professional society of more than 1 500 individuals, organisations,
and institutions interested in bioethics and humanities. The
website serves as a source of information for anyone interested
in bioethics.
Bioethics Resources on the Web,
http ://www.nih.gov/sigs/bioethics/
This website contains a broad range of web links, providing
background information and various positions on issues in
bioethics. 
Centre for Bioethics and Health Law, http ://www.uu-cbg.nl/
An independent academic institute at Utrecht University offering
advice and research. It organises courses and provides training
sessions. Topics of particular interest for the Centre for
Bioethics and Health Law (CBG) are ethical and legal aspects of
biotechnology and genetic modification of humans, animals
and plants. Ethical questions in health care are a major field of
interest. 
Clinical Trials, http ://clinicaltrials.gov
Provides regularly updated information about clinical research
in human volunteers. clinicaltrials.gov gives you information
about a trial’s purpose and who may participate. Also responds
to lists of frequently asked questions concerning clinical trials. 
Bioethics division of the Council of Europe,
http ://www.coe.int/T/E/legal_affairs/Legal_cooperation/bioethics/
The major bioethical issues examined from a European point of
view, and the essential legal texts.
European Union,
http ://europa.eu.int/comm/research/biosociety/bioethics/
bioethics_ethics_en.htm
The website contains a list of all national bioethics committees
for all EU member states. 
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Généthique, http ://www.genethique.org/en.htm
The objective of the Généthique Forum is to be a centre for online
discussion and information exchange for scientists, doctors and
politicians  in their quest for an objective reflection in various
scientific domains.
German Reference Centre for Ethics in the Life Sciences,
www.drze.de/links
An extensive list of bioethics links which enables easy access
to a wide range of Internet sites in the area of ethics in the life
sciences.
International Calendar for Bioethics Events,
http ://www2.umdnj.edu/ethicweb/upcome.htm
Regularly updated online calendar for bioethics forums, confer-
ences and debates worldwide. 
Johns Hopkins University Bioethics Institute,
http ://www.hopkinsmedicine.org/bioethics/
The Phoebe R. Berman Bioethics Institute of the Johns Hopkins
University seeks to promote research in bioethics and encourage
moral reflection among a broad range of scholars, professionals,
students, and citizens. The institute serves the entire Johns
Hopkins University and enables students and trainees to
advance their understanding of bioethics in their personal and
professional lives.
Midwest Bioethics Center, http ://www.midbio.org/
An independent practical bioethics centre dedicated to raising
and responding to ethical issues in health and health care.
National Consultative Bioethics Committee,
http ://www.ccne-ethique.org/
To give opinions on ethical problems raised by progress in the
fields of biology, medicine and health, and to publish recom-
mendations on the subject.
The United States National Library of Medicine,
http ://www.nlm.nih.gov/pubs/cbm/hum_exp.html
The NLM compiled a comprehensive bibliography, from 1989
to November 1998, entitled “Ethical issues in research involving
human participants”.
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National Reference Center for Bioethics Literature,
www.georgetown.edu/research/nrcbl/nrc/
The National Reference Center for Bioethics Literature
(NRCBL) is part of the Kennedy Institute of Ethics, Georgetown
University. It is a specialised collection of books, journals, news-
paper articles, legal materials, regulations, codes, government
publications and other relevant documents concerned with
issues in biomedical and professional ethics. The site includes
resources on ethics and human genetics, including a searchable
database of bibliographic references. The site also provides
free access to Bioethicsline, a database of bioethical literature. 
NIH Office of Extramural Research (OER), and the NIH Inter-
Institute Bioethics Interest Group,
http ://www.nih.gov/sigs/bioethics/
The OER provides information on policies and regulations,
resources, guidance for clinical investigators, research
resources, courses and tutorials on bioethical issues in human
studies.
Nuffield Council on Bioethics,
http ://www.nuffieldbioethics.org/home/
An independent body established to consider the ethical issues
arising from developments in medicine and biology. The
Council plays a major role in contributing to policy-making
and stimulating debate in bioethics. 
HHS Office of Human Research Protection,
http ://ohrp.osophs.dhhs.gov/polasur.htm
The OHRP provides a guide and training materials on regulations
and procedures governing research with human subjects ; it
includes a guidance document on financial relationships in
clinical research.
The Stanford University Center for Biomedical Ethics,
http ://scbe.stanford.edu/
The SCBE engages in interdisciplinary research on moral ques-
tions arising from the complex relationships among medicine,
science and society. Its research is committed to exploring and
promoting compassionate approaches to the practice of medicine. 
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Unesco International Bioethics Committee,
http ://portal.Unesco.org/shs/en/ev.php@URL_ID=1879&URL_
DO=DO_TOPIC&URL_SECTION=201.html
The IBC is a body of thirty-six independent experts that follows
progress in the life sciences and provides the only global forum
for in-depth bioethical reflection by exposing the issues at
stake. 
University of Pennsylvania Bioethics Center,
http ://www.bioethics.upenn.edu/
The Center for Bioethics is a leader in bioethics research and its
deployment in the ethical practice of the life sciences and med-
icine. The center is a world-renowned educational and research
enterprise. Includes a useful link to Bioethics for Beginners.
University of Toronto Joint Centre for Bioethics,
http ://www.utoronto.ca/jcb/
The JCB is a partnership between the University of Toronto
and affiliated hospitals. The JCB studies important ethical,
health-related topics through research and clinical activities
and seeks to improve healthcare standards at both national
and international levels. It aims to provide leadership in
bioethics research, education, and clinical activities. 
World Medical Association Ethics Unit,
http ://www.wma.net/e/ethicsunit/index.htm
This website includes information on the Declaration of
Helsinki and other ethical principles involved in health
research.
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Appendix II – Additional protocol
on biomedical research,
Council of Europe
Additional Protocol to the Convention for the Protection of
Human Rights and Dignity of the Human Being with regard to
the Application of Biology and Medicine, on Biomedical
Research
Preamble
The member States of the Council of Europe, the other States
and the European Community signatories to this Additional
Protocol to the Convention for the Protection of Human Rights
and Dignity of the Human Being with regard to the Application
of Biology and Medicine (hereinafter referred to as “the
Convention”),
Considering that the aim of the Council of Europe is the
achievement of greater unity between its members and that
one of the methods by which this aim is pursued is the
maintenance and further realisation of human rights and
fundamental freedoms;
Considering that the aim of the Convention, as defined in
Article 1, is to protect the dignity and identity of all human
beings and guarantee everyone, without discrimination,
respect for their integrity and other rights and fundamental
freedoms with regard to the application of biology and
medicine ;
Considering that progress in medical and biological sciences,
in particular advances obtained through biomedical
research, contributes to saving lives and improving quality
of life;
Conscious of the fact that the advancement of biomedical
science and practice is dependent on knowledge and dis-
covery which necessitates research on human beings;
Stressing that such research is often transdisciplinary and
international;
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Taking into account national and international professional
standards in the field of biomedical research and the previous
work of the Committee of Ministers and the Parliamentary
Assembly of the Council of Europe in this field;
Convinced that biomedical research that is contrary to
human dignity and human rights should never be carried out;
Stressing the paramount concern to be the protection of the
human being participating in research;
Affirming that particular protection shall be given to human
beings who may be vulnerable in the context of research;
Recognising that every person has a right to accept or refuse
to undergo biomedical research and that no one should be
forced to undergo such research;
Resolving to take such measures as are necessary to safeguard
human dignity and the fundamental rights and freedoms of
the individual with regard to biomedical research,
Have agreed as follows:
CHAPTER I
Object and scope
Article 1 – Object and purpose
Parties to this Protocol shall protect the dignity and identity of
all human beings and guarantee everyone, without discrimination,
respect for their integrity and other rights and fundamental
freedoms with regard to any research involving interventions
on human beings in the field of biomedicine.
Article 2 – Scope
1. This Protocol covers the full range of research activities in
the health field involving interventions on human beings.
2. This Protocol does not apply to research on embryos in
vitro. It does apply to research on foetuses and embryos in vivo.
3. For the purposes of this Protocol, the term “intervention”
includes:
i. a physical intervention, and
ii. any other intervention in so far as it involves a risk to the
psychological health of the person concerned.
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CHAPTER II
General provisions
Article 3 – Primacy of the human being
The interests and welfare of the human being participating in
research shall prevail over the sole interest of society or science.
Article 4 – General rule
Research shall be carried out freely, subject to the provisions
of this Protocol and the other legal provisions ensuring the
protection of the human being.
Article 5 – Absence of alternatives
Research on human beings may only be undertaken if there is
no alternative of comparable effectiveness.
Article 6 – Risks and benefits
1. Research shall not involve risks and burdens to the human
being disproportionate to its potential benefits.
2. In addition, where the research does not have the potential to
produce results of direct benefit to the health of the research
participant, such research may only be undertaken if the
research entails no more than acceptable risk and acceptable
burden for the research participant. This shall be without prej-
udice to the provision contained in Article 15 paragraph 2, sub-
paragraph ii for the protection of persons not able to consent to
research.
Article 7 – Approval
Research may only be undertaken if the research project has
been approved by the competent body after independent
examination of its scientific merit, including assessment of the
importance of the aim of research, and multidisciplinary
review of its ethical acceptability.
Article 8 – Scientific quality
Any research must be scientifically justified, meet generally
accepted criteria of scientific quality and be carried out in
accordance with relevant professional obligations and standards
under the supervision of an appropriately qualified researcher.
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CHAPTER III
Ethics committee
Article 9 – Independent examination by an ethics committee
1. Every research project shall be submitted for independent
examination of its ethical acceptability to an ethics committee.
Such projects shall be submitted to independent examination
in each State in which any research activity is to take place.
2. The purpose of the multidisciplinary examination of the
ethical acceptability of the research project shall be to protect
the dignity, rights, safety and well-being of research participants.
The assessment of the ethical acceptability shall draw on an
appropriate range of expertise and experience adequately
reflecting professional and lay views.
3. The ethics committee shall produce an opinion containing
reasons for its conclusion.
Article 10 – Independence of the ethics committee
1. Parties to this Protocol shall take measures to assure the
independence of the ethics committee. That body shall not be
subject to undue external influences.
2. Members of the ethics committee shall declare all circum-
stances that might lead to a conflict of interest. Should such
conflicts arise, those involved shall not participate in that
review.
Article 11 – Information for the ethics committee
1. All information which is necessary for the ethical assessment
of the research project shall be given in written form to the
ethics committee.
2. In particular, information on items contained in the appendix
to this Protocol shall be provided, in so far as it is relevant for
the research project. The appendix may be amended by the
Committee set up by Article 32 of the Convention by a two-
thirds majority of the votes cast.
Article 12 – Undue influence
The ethics committee must be satisfied that no undue influ-
ence, including that of a financial nature, will be exerted on
persons to participate in research. In this respect, particular
attention must be given to vulnerable or dependent persons.
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CHAPTER IV
Information and consent
Article 13 – Information for research participants
1. The persons being asked to participate in a research project
shall be given adequate information in a comprehensible form.
This information shall be documented.
2. The information shall cover the purpose, the overall plan
and the possible risks and benefits of the research project, and
include the opinion of the ethics committee. Before being
asked to consent to participate in a research project, the persons
concerned shall be specifically informed, according to the
nature and purpose of the research:
i. of the nature, extent and duration of the procedures
involved, in particular, details of any burden imposed by
the research project;
ii. of available preventive, diagnostic and therapeutic proce-
dures;
iii. of the arrangements for responding to adverse events or
the concerns of research participants;
iv. of arrangements to ensure respect for private life and
ensure the confidentiality of personal data;
v. of arrangements for access to information relevant to the
participant arising from the research and to its overall
results;
vi. of the arrangements for fair compensation in the case of
damage;
vii. of any foreseen potential further uses, including commercial
uses, of the research results, data or biological materials;
viii. of the source of funding of the research project.
3. In addition, the persons being asked to participate in a research
project shall be informed of the rights and safeguards prescribed
by law for their protection, and specifically of their right to
refuse consent or to withdraw consent at any time without
being subject to any form of discrimination, in particular
regarding the right to medical care.
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Article 14 – Consent
1. No research on a person may be carried out, subject to the
provisions of both Chapter V and Article 19, without the
informed, free, express, specific and documented consent of
the person. Such consent may be freely withdrawn by the per-
son at any phase of the research.
2. Refusal to give consent or the withdrawal of consent to par-
ticipation in research shall not lead to any form of discrimina-
tion against the person concerned, in particular regarding the
right to medical care.
3. Where the capacity of the person to give informed consent
is in doubt, arrangements shall be in place to verify whether or
not the person has such capacity.
CHAPTER V
Protection of persons not able to consent to research
Article 15 – Protection of persons not able to consent to research
1. Research on a person without the capacity to consent to
research may be undertaken only if all the following specific
conditions are met:
i. the results of the research have the potential to produce real
and direct benefit to his or her health;
ii. research of comparable effectiveness cannot be carried out
on individuals capable of giving consent;
iii. the person undergoing research has been informed of his
or her rights and the safeguards prescribed by law for his or
her protection, unless this person is not in a state to receive
the information;
iv. the necessary authorisation has been given specifically and
in writing by the legal representative or an authority, per-
son or body provided for by law, and after having received
the information required by Article 16, taking into account
the person’s previously expressed wishes or objections. An
adult not able to consent shall as far as possible take part in
the authorisation procedure. The opinion of a minor shall
be taken into consideration as an increasingly determining
factor in proportion to age and degree of maturity;
v. the person concerned does not object.
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2. Exceptionally and under the protective conditions prescribed
by law, where the research has not the potential to produce
results of direct benefit to the health of the person concerned,
such research may be authorised subject to the conditions laid
down in paragraph 1, sub-paragraphs ii, iii, iv, and v above, and
to the following additional conditions:
i. the research has the aim of contributing, through significant
improvement in the scientific understanding of the individ-
ual’s condition, disease or disorder, to the ultimate attainment
of results capable of conferring benefit to the person concerned
or to other persons in the same age category or afflicted with
the same disease or disorder or having the same condition;
ii. the research entails only minimal risk and minimal burden
for the individual concerned; and any consideration of
additional potential benefits of the research shall not be
used to justify an increased level of risk or burden.
3. Objection to participation, refusal to give authorisation or
the withdrawal of authorisation to participate in research shall
not lead to any form of discrimination against the person
concerned, in particular regarding the right to medical care.
Article 16 – Information prior to authorisation
1. Those being asked to authorise participation of a person in
a research project shall be given adequate information in a
comprehensible form. This information shall be documented.
2. The information shall cover the purpose, the overall plan
and the possible risks and benefits of the research project, and
include the opinion of the ethics committee. They shall further
be informed of the rights and safeguards prescribed by law for
the protection of those not able to consent to research and
specifically of the right to refuse or to withdraw authorisation
at any time, without the person concerned being subject to
any form of discrimination, in particular regarding the right to
medical care. They shall be specifically informed according to
the nature and purpose of the research of the items of infor-
mation listed in Article 13.
3. The information shall also be provided to the individual
concerned, unless this person is not in a state to receive the
information.
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Article 17 – Research with minimal risk and minimal burden
1. For the purposes of this Protocol it is deemed that the
research bears a minimal risk if, having regard to the nature
and scale of the intervention, it is to be expected that it will
result, at the most, in a very slight and temporary negative
impact on the health of the person concerned.
2. It is deemed that it bears a minimal burden if it is to be
expected that the discomfort will be, at the most, temporary and
very slight for the person concerned. In assessing the burden for
an individual, a person enjoying the special confidence of the
person concerned shall assess the burden where appropriate.
CHAPTER VI
Specific situations
Article 18 – Research during pregnancy or breastfeeding
1. Research on a pregnant woman which does not have the
potential to produce results of direct benefit to her health, or to
that of her embryo, foetus or child after birth, may only be
undertaken if the following additional conditions are met:
i. the research has the aim of contributing to the ultimate
attainment of results capable of conferring benefit to other
women in relation to reproduction or to other embryos,
foetuses or children;
ii. research of comparable effectiveness cannot be carried out
on women who are not pregnant;
iii. the research entails only minimal risk and minimal burden.
2. Where research is undertaken on a breastfeeding woman,
particular care shall be taken to avoid any adverse impact on
the health of the child.
Article 19 – Research on persons in emergency clinical situations
1. The law shall determine whether, and under which protective
additional conditions, research in emergency situations may
take place when:
i. a person is not in a state to give consent, and 
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ii. because of the urgency of the situation, it is impossible to
obtain in a sufficiently timely manner, authorisation from
his or her representative or an authority or a person or
body which would in the absence of an emergency situation
be called upon to give authorisation.
2. The law shall include the following specific conditions:
i. research of comparable effectiveness cannot be carried out
on persons in non-emergency situations;
ii. the research project may only be undertaken if it has been
approved specifically for emergency situations by the com-
petent body;
iii. any relevant previously expressed objections of the person
known to the researcher shall be respected;
iv. where the research has not the potential to produce results
of direct benefit to the health of the person concerned, it
has the aim of contributing, through significant improve-
ment in the scientific understanding of the individual’s
condition, disease or disorder, to the ultimate attainment of
results capable of conferring benefit to the person concerned
or to other persons in the same category or afflicted with
the same disease or disorder or having the same condition,
and entails only minimal risk and minimal burden.
3. Persons participating in the emergency research project or,
if applicable, their representatives shall be provided with all
the relevant information concerning their participation in the
research project as soon as possible. Consent or authorisation
for continued participation shall be requested as soon as rea-
sonably possible.
Article 20 – Research on persons deprived of liberty
Where the law allows research on persons deprived of liberty,
such persons may participate in a research project in which the
results do not have the potential to produce direct benefit to
their health only if the following additional conditions are met:
i. research of comparable effectiveness cannot be carried out
without the participation of persons deprived of liberty;
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ii. the research has the aim of contributing to the ultimate
attainment of results capable of conferring benefit to persons
deprived of liberty;
iii. the research entails only minimal risk and minimal burden.
CHAPTER VII
Safety and supervision
Article 21 – Minimisation of risk and burden
1. All reasonable measures shall be taken to ensure safety and
to minimise risk and burden for the research participants.
2. Research may only be carried out under the supervision of a
clinical professional who possesses the necessary qualifications
and experience.
Article 22 – Assessment of health status
1. The researcher shall take all necessary steps to assess the
state of health of human beings prior to their inclusion in
research, to ensure that those at increased risk in relation to
participation in a specific project be excluded.
2. Where research is undertaken on persons in the reproductive
stage of their lives, particular consideration shall be given to
the possible adverse impact on a current or future pregnancy
and the health of an embryo, foetus or child.
Article 23 – Non-interference with necessary clinical interventions
1. Research shall not delay nor deprive participants of medically
necessary preventive, diagnostic or therapeutic procedures.
2. In research associated with prevention, diagnosis or treatment,
participants assigned to control groups shall be assured of
proven methods of prevention, diagnosis or treatment.
3. The use of placebo is permissible where there are no methods
of proven effectiveness, or where withdrawal or withholding of
such methods does not present an unacceptable risk or burden.
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Article 24 – New developments
1. Parties to this Protocol shall take measures to ensure that
the research project is re-examined if this is justified in the
light of scientific developments or events arising in the course
of the research.
2. The purpose of the re-examination is to establish whether:
i. the research needs to be discontinued or if changes to the
research project are necessary for the research to continue;
ii. research participants, or if applicable their representatives,
need to be informed of the developments or events;
iii. additional consent or authorisation for participation is
required.
3. Any new information relevant to their participation shall be
conveyed to the research participants, or, if applicable, to their
representatives, in a timely manner.
4. The competent body shall be informed of the reasons for any
premature termination of a research project.
CHAPTER VIII
Confidentiality and right to information
Article 25 – Confidentiality
1. Any information of a personal nature collected during bio-
medical research shall be considered as confidential and
treated according to the rules relating to the protection of pri-
vate life.
2. The law shall protect against inappropriate disclosure of any
other information related to a research project that has been
submitted to an ethics committee in compliance with this Pro-
tocol.
Article 26 – Right to information
1. Research participants shall be entitled to know any infor-
mation collected on their health in conformity with the provi-
sions of Article 10 of the Convention.
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2. Other personal information collected for a research project
will be accessible to them in conformity with the law on the pro-
tection of individuals with regard to processing of personal data.
Article 27 – Duty of care
If research gives rise to information of relevance to the current
or future health or quality of life of research participants, this
information must be offered to them. That shall be done
within a framework of health care or counselling. In commu-
nication of such information, due care must be taken in order
to protect confidentiality and to respect any wish of a partici-
pant not to receive such information.
Article 28 – Availability of results
1. On completion of the research, a report or summary shall be
submitted to the ethics committee or the competent body.
2. The conclusions of the research shall be made available to
participants in reasonable time, on request.
3. The researcher shall take appropriate measures to make
public the results of research in reasonable time.
CHAPTER IX
Research in States not parties to this Protocol
Article 29 – Research in States not parties to this Protocol
Sponsors or researchers within the jurisdiction of a Party to
this Protocol that plan to undertake or direct a research project
in a State not party to this Protocol shall ensure that, without
prejudice to the provisions applicable in that State, the
research project complies with the principles on which the
provisions of this Protocol are based. Where necessary, the
Party shall take appropriate measures to that end.
CHAPTER X
Infringement of the provisions of the Protocol
Article 30 – Infringement of the rights or principles
The Parties shall provide appropriate judicial protection to pre-
vent or to put a stop to an unlawful infringement of the rights
or principles set forth in this Protocol at short notice.
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Article 31 – Compensation for damage
The person who has suffered damage as a result of participation
in research shall be entitled to fair compensation according to
the conditions and procedures prescribed by law.
Article 32 – Sanctions
Parties shall provide for appropriate sanctions to be applied in
the event of infringement of the provisions contained in this
Protocol.
CHAPTER XI
Relation between this Protocol and other provisions and
re-examination of the Protocol
Article 33 – Relation between this Protocol and the Convention
As between the Parties, the provisions of Articles 1 to 32 of
this Protocol shall be regarded as additional articles to the
Convention, and all the provisions of the Convention shall
apply accordingly.
Article 34 – Wider protection
None of the provisions of this Protocol shall be interpreted as
limiting or otherwise affecting the possibility for a Party to
grant research participants a wider measure of protection than
is stipulated in this Protocol.
Article 35 – Re-examination of the Protocol
In order to monitor scientific developments, the present Protocol
shall be examined within the Committee referred to in Article
32 of the Convention no later than five years from the entry
into force of this Protocol and thereafter at such intervals as
the Committee may determine.
CHAPTER XII
Final clauses
Article 36 – Signature and ratification
This Protocol shall be open for signature by Signatories to the
Convention. It is subject to ratification, acceptance or approval.
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A Signatory may not ratify, accept or approve this Protocol
unless it has previously or simultaneously ratified, accepted or
approved the Convention. Instruments of ratification, accep-
tance or approval shall be deposited with the Secretary General
of the Council of Europe.
Article 37 – Entry into force
1. This Protocol shall enter into force on the first day of the
month following the expiration of a period of three months
after the date on which five States, including at least four member
States of the Council of Europe, have expressed their consent
to be bound by the Protocol in accordance with the provisions
of Article 36.
2. In respect of any State which subsequently expresses its
consent to be bound by it, the Protocol shall enter into force
on the first day of the month following the expiration of a
period of three months after the date of the deposit of the
instrument of ratification, acceptance or approval.
Article 38 – Accession
1. After the entry into force of this Protocol, any State which has
acceded to the Convention may also accede to this Protocol.
2. Accession shall be effected by the deposit with the Secretary
General of the Council of Europe of an instrument of accession
which shall take effect on the first day of the month following
the expiration of a period of three months after the date of its
deposit.
Article 39 – Denunciation
1. Any Party may at any time denounce this Protocol by means
of a notification addressed to the Secretary General of the
Council of Europe.
2. Such denunciation shall become effective on the first day of
the month following the expiration of a period of three months
after the date of receipt of such notification by the Secretary
General.
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Article 40 – Notifications
The Secretary General of the Council of Europe shall notify the
member States of the Council of Europe, the European Com-
munity, any Signatory, any Party and any other State which
has been invited to accede to the Protocol of:
a. any signature;
b. the deposit of any instrument of ratification, acceptance,
approval or accession;
c. any date of entry into force of this Protocol in accordance
with Articles 37 and 38;
d. any other act, notification or communication relating to
this Protocol.
In witness whereof the undersigned, being duly authorised
thereto, have signed this Protocol.
Done at Strasbourg, this ................, in English and in French,
both texts being equally authentic, in a single copy which shall
be deposited in the archives of the Council of Europe. The
Secretary General of the Council of Europe shall transmit
certified copies to each member State of the Council of Europe,
to the non-member States which have participated in the
elaboration of this Protocol, to any State invited to accede to
the Convention and to the European Community.
Appendix to the Additional Protocol on Biomedical Research
Information to be given to the ethics committee
Information on the following items shall be provided to the
ethics committee, in so far as it is relevant for the research
project:
Description of the project
i. the name of the principal researcher, qualifications and
experience of researchers and, where appropriate, the clin-
ically responsible person, and funding arrangements;
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ii. the aim and justification for the research based on the
latest state of scientific knowledge;
iii. methods and procedures envisaged, including statistical
and other analytical techniques;
iv. a comprehensive summary of the research project in lay
language;
v. a statement of previous and concurrent submissions of the
research project for assessment or approval and the out-
come of those submissions;
Participants, consent and information
vi. justification for involving human beings in the research
project;
vii. the criteria for inclusion or exclusion of the categories of
persons for participation in the research project and how
those persons are to be selected and recruited;
viii. reasons for the use or the absence of control groups;
ix. a description of the nature and degree of foreseeable risks
that may be incurred through participating in research;
x. the nature, extent and duration of the interventions to be
carried out on the research participants, and details of any
burden imposed by the research project;
xi. arrangements to monitor, evaluate and react to contingencies
that may have consequences for the present or future
health of research participants;
xii. the timing and details of information for those persons
who would participate in the research project and the
means proposed for provision of this information;
xiii. documentation intended to be used to seek consent or, in
the case of persons not able to consent, authorisation for
participation in the research project;
xiv. arrangements to ensure respect for the private life of those
persons who would participate in research and ensure the
confidentiality of personal data;
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xv. arrangements foreseen for information which may be
generated and be relevant to the present or future health
of those persons who would participate in research and
their family members;
Other information
xvi. details of all payments and rewards to be made in the con-
text of the research project;
xvii. details of all circumstances that might lead to conflicts of
interest that may affect the independent judgement of the
researchers;
xviii.details of any foreseen potential further uses, including
commercial uses, of the research results, data or biological
materials;
xix. details of all other ethical issues, as perceived by the
researcher;
xx. details of any insurance or indemnity to cover damage
arising in the context of the research project.
The ethics committee may request additional information
necessary for evaluation of the research project.
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Appendix III – World Medical
Association’s Declaration of Helsinki 1
Ethical Principles for Medical Research Involving Human
Subjects
Adopted by the 18th WMA General Assembly, Helsinki, Finland,
June 1964, and amended by the 29th WMA General Assembly,
Tokyo, Japan, October 1975; 35th WMA General Assembly,
Venice, Italy, October 1983; 41st WMA General Assembly,
Hong Kong, September 1989; 48th WMA General Assembly,
Somerset West, Republic of South Africa, October 1996; and
the 52nd WMA General Assembly, Edinburgh, Scotland, October
2000. Note of Clarification on Paragraph 29 added by the
WMA General Assembly, Washington 2002.
A – Introduction 
1. The World Medical Association has developed the Declaration
of Helsinki as a statement of ethical principles to provide guidance
to physicians and other participants in medical research
involving human subjects. Medical research involving human
subjects includes research on identifiable human material or
identifiable data.
2. It is the duty of the physician to promote and safeguard the
health of the people. The physician’s knowledge and conscience
are dedicated to the fulfilment of this duty.
3. The Declaration of Geneva of the World Medical Association
binds the physician with the words, “The health of my patient
will be my first consideration,” and the International Code of
Medical Ethics declares that “A physician shall act only in the
patient’s interest when providing medical care which might
have the effect of weakening the physical and mental condition
of the patient”.
4. Medical progress is based on research which ultimately must
rest in part on experimentation involving human subjects.
5. In medical research on human subjects, considerations
related to the well-being of the human subject should take prece-
dence over the interests of science and society.
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(Edinburgh, Scotland).
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Washington 2002.
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6. The primary purpose of medical research involving human
subjects is to improve prophylactic, diagnostic and therapeutic
procedures and the understanding of the aetiology and patho-
genesis of disease. Even the best proven prophylactic, diagnostic
and therapeutic methods must continuously be challenged
through research for their effectiveness, efficiency, accessibility
and quality. 
7. In current medical practice and in medical research, most
prophylactic, diagnostic and therapeutic procedures involve
risks and burdens. 
8. Medical research is subject to ethical standards that pro-
mote respect for all human beings and protect their health and
rights. Some research populations are vulnerable and need
special protection. The particular needs of the economically
and medically disadvantaged must be recognised. Special
attention is also required for those who cannot give or refuse
consent for themselves, for those who may be subject to giving
consent under duress, for those who will not benefit personally
from the research and for those for whom the research is com-
bined with care. 
9. Research Investigators should be aware of the ethical, legal
and regulatory requirements for research on human subjects
in their own countries as well as applicable international
requirements. No national ethical, legal or regulatory requirement
should be allowed to reduce or eliminate any of the protections
for human subjects set forth in this Declaration.
B – BASIC PRINCIPLES FOR ALL MEDICAL RESEARCH
10. It is the duty of the physician in medical research to protect
the life, health, privacy and dignity of the human subject.
11. Medical research involving human subjects must conform
to generally accepted scientific principles, be based on a thor-
ough knowledge of the scientific literature, other relevant
sources of information, and on adequate laboratory and, where
appropriate, animal experimentation.
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12. Appropriate caution must be exercised in the conduct of
research which may affect the environment, and the welfare of
animals used for research must be respected.
13. The design and performance of each experimental procedure
involving human subjects should be clearly formulated in an
experimental protocol. This protocol should be submitted for
consideration, comment, guidance – and, where appropriate,
approval – to a specially appointed ethical review committee,
which must be independent of the investigator, the sponsor or
any other kind of undue influence. This independent commit-
tee should be in conformity with the laws and regulations of
the country in which the research experiment is performed.
The committee has the right to monitor ongoing trials. The
researcher has the obligation to provide monitoring information
to the committee, especially any serious adverse events. The
researcher should also submit to the committee, for review,
information regarding funding, sponsors, institutional affiliations,
other potential conflicts of interest and incentives for subjects. 
14. The research protocol should always contain a statement
of the ethical considerations involved and should indicate that
there is compliance with the principles enunciated in this
Declaration.
15. Medical research involving human subjects should be
conducted only by scientifically qualified persons and under
the supervision of a clinically competent medical person. The
responsibility for the human subject must always rest with a
medically qualified person and never rest on the subject of the
research, even though the subject has given consent.
16. Every medical research project involving human subjects
should be preceded by careful assessment of predictable risks
and burdens in comparison with foreseeable benefits to the
subject or to others. This does not preclude the participation of
healthy volunteers in medical research. The design of all studies
should be publicly available.
17. Physicians should abstain from engaging in research pro-
jects involving human subjects unless they are confident that
the risks involved have been adequately assessed and can be
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satisfactorily managed. Physicians should cease any investiga-
tion if the risks are found to outweigh the potential benefits or
if there is conclusive proof of positive and beneficial results.
18. Medical research involving human subjects should only
be conducted if the importance of the objective outweighs the
inherent risks and burdens to the subject. This is especially
important when the human subjects are healthy volunteers.
19. Medical research is only justified if there is a reasonable
likelihood that the populations in which the research is carried
out stand to benefit from the results of the research.
20. The subjects must be volunteers and informed participants
in the research project.
21. The right of research subjects to safeguard their integrity
must always be respected. Every precaution should be taken to
respect the privacy of the subject, the confidentiality of the
patient’s information and to minimise the impact of the study
on the subject’s physical and mental integrity and on the per-
sonality of the subject.
22. In any research on human beings, each potential subject
must be adequately informed of the aims, methods, sources of
funding, any possible conflicts of interest, institutional affilia-
tions of the researcher, the anticipated benefits and potential
risks of the study and the discomfort it may entail. The subject
should be informed of the right to abstain from participation in
the study or to withdraw consent to participate at any time
without reprisal. After ensuring that the subject has understood
the information, the physician should then obtain the subjects
freely-given informed consent, preferably in writing. If the consent
cannot be obtained in writing, the non-written consent must
be formally documented and witnessed.
23. When obtaining informed consent for the research project
the physician should be particularly cautious if the subject is
in a dependent relationship with the physician or may consent
under duress. In that case the informed consent should be
obtained by a well-informed physician who is not engaged in
the investigation and who is completely independent of this
relationship.
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24. For a research subject who is legally incompetent, physi-
cally or mentally incapable of giving consent or is a legally
incompetent minor, the investigator must obtain informed
consent from the legally authorised representative in accor-
dance with applicable law. These groups should not be
included in research unless the research is necessary to promote
the health of the population represented and this research
cannot instead be performed on legally competent persons.
25. When a subject deemed legally incompetent, such as a
minor child, is able to give assent to decisions about participa-
tion in research, the investigator must obtain that assent in
addition to the consent of the legally authorised representative.
26. Research on individuals from whom it is not possible to
obtain consent, including proxy or advance consent, should be
done only if the physical/mental condition that prevents
obtaining informed consent is a necessary characteristic of the
research population. The specific reasons for involving
research subjects with a condition that renders them unable to
give informed consent should be stated in the experimental
protocol for consideration and approval of the review committee.
The protocol should state that consent to remain in the research
should be obtained as soon as possible from the individual or
a legally authorised surrogate.
27. Both authors and publishers have ethical obligations. In
publication of the results of research, the investigators are
obliged to preserve the accuracy of the results. Negative as
well as positive results should be published or be otherwise
publicly available. Sources of funding, institutional affiliations
and any possible conflicts of interest should be declared in the
publication. Reports of experimentation not in accordance
with the principles laid down in this Declaration should not be
accepted for publication.
C – ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH
COMBINED WITH MEDICAL CARE
28. The physician may combine medical research with medical
care, only to the extent that the research is justified by its
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potential prophylactic, diagnostic or therapeutic value. When
medical research is combined with medical care, additional
standards apply to protect the patients who are research subjects.
29. The benefits, risks, burdens and effectiveness of a new
method should be tested against those of the best current pro-
phylactic, diagnostic and therapeutic methods. This does not
exclude the use of placebo, or no treatment, in studies where
no proven prophylactic, diagnostic or therapeutic method
exists. (See footnote earlier)
30. At the conclusion of the study, every patient entered into the
study should be assured of access to the best proven prophylac-
tic, diagnostic and therapeutic methods identified by the study.
31. The physician should fully inform the patient which
aspects of the care are related to the research. The refusal of a
patient to participate in a study must never interfere with the
patient–physician relationship.
32. In the treatment of a patient, where proven prophylactic,
diagnostic and therapeutic methods do not exist or have been
ineffective, the physician, with informed consent from the
patient, must be free to use unproven or new prophylactic,
diagnostic and therapeutic measures, if in the physician’s
judgement it offers hope of saving life, re-establishing health
or alleviating suffering. Where possible, these measures should
be made the object of research, designed to evaluate their
safety and efficacy. In all cases, new information should be
recorded and, where appropriate, published. The other relevant
guidelines of this Declaration should be followed. 
Footnote : Note of clarification on paragraph 29 of the WMA
Declaration of Helsinki
The WMA hereby reaffirms its position that extreme care must
be taken in making use of a placebo-controlled trial and that in
general this methodology should only be used in the absence
of existing proven therapy. However, a placebo-controlled trial
may be ethically acceptable, even if proven therapy is avail-
able, under the following circumstances :
– Where for compelling and scientifically sound methodological
reasons its use is necessary to determine the efficacy or
safety of a prophylactic, diagnostic or therapeutic method ; or 
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– Where a prophylactic, diagnostic or therapeutic method is
being investigated for a minor condition and the patients who
receive placebo will not be subject to any additional risk of
serious or irreversible harm. 
All other provisions of the Declaration of Helsinki must be
adhered to, especially the need for appropriate ethical and
scientific review.
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